<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="//cdn.jsdelivr.net/npm/mathjax@2.7.5/MathJax.js?config=TeX-AMS-MML_SVG.js"></script><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/SBCSh_3xRKChiMqC9EeqAAj0gxhW_7gGOjXmbjc6BWIirDCLYAffWf5n0dcytrpfn1rjy9UABURsbSie0FfZkg=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"antibodies;hiv-infections;predictive-markers","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-022-01953-6"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Peter B. Gilbert","Yunda Huang","Allan C. deCamp","Shelly Karuna","Yuanyuan Zhang","Craig A. Magaret","Elena E. Giorgi","Bette Korber","Paul T. Edlefsen","Raabya Rossenkhan","Michal Juraska","Erika Rudnicki","Nidhi Kochar","Ying Huang","Lindsay N. Carpp","Dan H. Barouch","Nonhlanhla N. Mkhize","Tandile Hermanus","Prudence Kgagudi","Valerie Bekker","Haajira Kaldine","Rutendo E. Mapengo","Amanda Eaton","Elize Domin","Carley West","Wenhong Feng","Haili Tang","Kelly E. Seaton","Jack Heptinstall","Caroline Brackett","Kelvin Chiong","Georgia D. Tomaras","Philip Andrew","Bryan T. Mayer","Daniel B. Reeves","Magdalena E. Sobieszczyk","Nigel Garrett","Jorge Sanchez","Cynthia Gay","Joseph Makhema","Carolyn Williamson","James I. Mullins","John Hural","Myron S. Cohen","Lawrence Corey","David C. Montefiori","Lynn Morris"],"publishedAt":1661126400,"publishedAtString":"2022-08-22","title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Antibodies,HIV infections,Predictive markers"},"journal":{"pcode":"nm","title":"nature medicine","volume":"28","issue":"9","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script><script id="js-position4" data-test="math-js" async="" src="/static/js/math-es6-bundle-23597ae350.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","description":"The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker—which quantifies the neutralization potency of antibodies in an individual’s serum against an HIV-1 isolate—can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80 of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80 >200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80 biomarker as a surrogate endpoint for evaluation of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines. By integrating the serum concentration of a broadly neutralizing antibody (bNAb) with its in vitro 80% inhibitory concentration, the PT80 biomarker may be used to guide target levels of bNAbs for effective prevention of HIV-1 acquisition.","datePublished":"2022-08-22T00:00:00Z","dateModified":"2022-10-03T00:00:00Z","pageStart":"1924","pageEnd":"1932","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-022-01953-6","keywords":["Antibodies","HIV infections","Predictive markers","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig5_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig6_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"28","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Peter B. Gilbert","url":"http://orcid.org/0000-0002-2662-9427","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Washington","address":{"name":"Department of Biostatistics, University of Washington, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"pgilbert@fredhutch.org","@type":"Person"},{"name":"Yunda Huang","url":"http://orcid.org/0000-0003-1546-6172","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Washington","address":{"name":"Department of Global Health, University of Washington, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Allan C. deCamp","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Shelly Karuna","url":"http://orcid.org/0000-0001-5946-9733","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Yuanyuan Zhang","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Craig A. Magaret","url":"http://orcid.org/0000-0002-5056-2664","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Elena E. Giorgi","affiliation":[{"name":"Los Alamos National Laboratory","address":{"name":"Los Alamos National Laboratory, Los Alamos, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Bette Korber","url":"http://orcid.org/0000-0002-2026-5757","affiliation":[{"name":"Los Alamos National Laboratory","address":{"name":"Los Alamos National Laboratory, Los Alamos, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Paul T. Edlefsen","url":"http://orcid.org/0000-0002-8393-8103","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Raabya Rossenkhan","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Michal Juraska","url":"http://orcid.org/0000-0002-0920-2915","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Erika Rudnicki","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nidhi Kochar","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ying Huang","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lindsay N. Carpp","url":"http://orcid.org/0000-0003-0333-5925","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Dan H. Barouch","url":"http://orcid.org/0000-0001-5127-4659","affiliation":[{"name":"Beth Israel Deaconess Medical Center","address":{"name":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard","address":{"name":"Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nonhlanhla N. Mkhize","affiliation":[{"name":"National Health Laboratory Service","address":{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of the Witwatersrand","address":{"name":"Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Tandile Hermanus","affiliation":[{"name":"National Health Laboratory Service","address":{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of the Witwatersrand","address":{"name":"Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Prudence Kgagudi","affiliation":[{"name":"National Health Laboratory Service","address":{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of the Witwatersrand","address":{"name":"Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Valerie Bekker","affiliation":[{"name":"National Health Laboratory Service","address":{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of the Witwatersrand","address":{"name":"Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"Duke University Departments of Surgery, Immunology, Molecular Genetics and Microbiology","address":{"name":"Duke Center for Human Systems Immunology, Duke University Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Haajira Kaldine","affiliation":[{"name":"National Health Laboratory Service","address":{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of the Witwatersrand","address":{"name":"Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rutendo E. Mapengo","affiliation":[{"name":"National Health Laboratory Service","address":{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of the Witwatersrand","address":{"name":"Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Amanda Eaton","url":"http://orcid.org/0000-0003-3064-2947","affiliation":[{"name":"Duke University Medical Center","address":{"name":"Department of Surgery, Duke University Medical Center, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Elize Domin","affiliation":[{"name":"Duke University Medical Center","address":{"name":"Department of Surgery, Duke University Medical Center, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Carley West","affiliation":[{"name":"Duke University Medical Center","address":{"name":"Department of Surgery, Duke University Medical Center, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Wenhong Feng","affiliation":[{"name":"Duke University Medical Center","address":{"name":"Department of Surgery, Duke University Medical Center, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Haili Tang","affiliation":[{"name":"Duke University Medical Center","address":{"name":"Department of Surgery, Duke University Medical Center, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Kelly E. Seaton","url":"http://orcid.org/0000-0002-2009-3270","affiliation":[{"name":"Duke Center for Human Systems Immunology","address":{"name":"Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jack Heptinstall","affiliation":[{"name":"Duke Center for Human Systems Immunology","address":{"name":"Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Caroline Brackett","affiliation":[{"name":"Duke Center for Human Systems Immunology","address":{"name":"Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Kelvin Chiong","affiliation":[{"name":"Duke Center for Human Systems Immunology","address":{"name":"Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Georgia D. Tomaras","affiliation":[{"name":"Duke Center for Human Systems Immunology","address":{"name":"Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Philip Andrew","affiliation":[{"name":"Family Health International","address":{"name":"Family Health International, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Bryan T. Mayer","url":"http://orcid.org/0000-0003-2258-5276","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Daniel B. Reeves","url":"http://orcid.org/0000-0001-5684-9538","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Magdalena E. Sobieszczyk","affiliation":[{"name":"Columbia University Irving Medical Center","address":{"name":"Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nigel Garrett","url":"http://orcid.org/0000-0002-4530-234X","affiliation":[{"name":"University of KwaZulu-Natal","address":{"name":"Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of KwaZulu-Natal","address":{"name":"Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jorge Sanchez","affiliation":[{"name":"Universidad Nacional Mayor de San Marcos","address":{"name":"Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Cynthia Gay","affiliation":[{"name":"The University of North Carolina at Chapel Hill","address":{"name":"Division of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Joseph Makhema","affiliation":[{"name":"Botswana-Harvard AIDS Initiative Partnership for HIV Research and Education","address":{"name":"Botswana-Harvard AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana","@type":"PostalAddress"},"@type":"Organization"},{"name":"Beth Israel Deaconess Medical Center","address":{"name":"Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Carolyn Williamson","url":"http://orcid.org/0000-0003-0125-1226","affiliation":[{"name":"University of Cape Town","address":{"name":"Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"James I. Mullins","affiliation":[{"name":"University of Washington","address":{"name":"Department of Global Health, University of Washington, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Washington","address":{"name":"Department of Microbiology, University of Washington, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Washington","address":{"name":"Department of Medicine, University of Washington, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"John Hural","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Myron S. Cohen","affiliation":[{"name":"The University of North Carolina at Chapel Hill","address":{"name":"Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lawrence Corey","url":"http://orcid.org/0000-0002-2179-2436","affiliation":[{"name":"Fred Hutchinson Cancer Center","address":{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Washington","address":{"name":"Department of Medicine, University of Washington, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Washington","address":{"name":"Department of Laboratory Medicine, University of Washington, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"David C. Montefiori","url":"http://orcid.org/0000-0003-0856-6319","affiliation":[{"name":"Duke University Medical Center","address":{"name":"Department of Surgery, Duke University Medical Center, Durham, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lynn Morris","url":"http://orcid.org/0000-0003-3961-7828","affiliation":[{"name":"National Health Laboratory Service","address":{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of the Witwatersrand","address":{"name":"Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of KwaZulu-Natal","address":{"name":"Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-022-01953-6">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition">
    <meta name="dc.source" content="Nature Medicine 2022 28:9">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2022-08-22">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2022 The Author(s)">
    <meta name="dc.rights" content="2022 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker—which quantifies the neutralization potency of antibodies in an individual’s serum against an HIV-1 isolate—can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80 of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80 &amp;gt;200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80 biomarker as a surrogate endpoint for evaluation of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines. By integrating the serum concentration of a broadly neutralizing antibody (bNAb) with its in vitro 80% inhibitory concentration, the PT80 biomarker may be used to guide target levels of bNAbs for effective prevention of HIV-1 acquisition.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2022-08-22">
    <meta name="prism.volume" content="28">
    <meta name="prism.number" content="9">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1924">
    <meta name="prism.endingPage" content="1932">
    <meta name="prism.copyright" content="2022 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-022-01953-6">
    <meta name="prism.doi" content="doi:10.1038/s41591-022-01953-6">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-022-01953-6.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-022-01953-6">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition">
    <meta name="citation_volume" content="28">
    <meta name="citation_issue" content="9">
    <meta name="citation_publication_date" content="2022/09">
    <meta name="citation_online_date" content="2022/08/22">
    <meta name="citation_firstpage" content="1924">
    <meta name="citation_lastpage" content="1932">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-022-01953-6">
    <meta name="DOI" content="10.1038/s41591-022-01953-6">
    <meta name="size" content="210229">
    <meta name="citation_doi" content="10.1038/s41591-022-01953-6">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-022-01953-6&amp;api_key=">
    <meta name="description" content="The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker—which quantifies the neutralization potency of antibodies in an individual’s serum against an HIV-1 isolate—can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80 of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80 &amp;gt;200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80 biomarker as a surrogate endpoint for evaluation of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines. By integrating the serum concentration of a broadly neutralizing antibody (bNAb) with its in vitro 80% inhibitory concentration, the PT80 biomarker may be used to guide target levels of bNAbs for effective prevention of HIV-1 acquisition.">
    <meta name="dc.creator" content="Gilbert, Peter B.">
    <meta name="dc.creator" content="Huang, Yunda">
    <meta name="dc.creator" content="deCamp, Allan C.">
    <meta name="dc.creator" content="Karuna, Shelly">
    <meta name="dc.creator" content="Zhang, Yuanyuan">
    <meta name="dc.creator" content="Magaret, Craig A.">
    <meta name="dc.creator" content="Giorgi, Elena E.">
    <meta name="dc.creator" content="Korber, Bette">
    <meta name="dc.creator" content="Edlefsen, Paul T.">
    <meta name="dc.creator" content="Rossenkhan, Raabya">
    <meta name="dc.creator" content="Juraska, Michal">
    <meta name="dc.creator" content="Rudnicki, Erika">
    <meta name="dc.creator" content="Kochar, Nidhi">
    <meta name="dc.creator" content="Huang, Ying">
    <meta name="dc.creator" content="Carpp, Lindsay N.">
    <meta name="dc.creator" content="Barouch, Dan H.">
    <meta name="dc.creator" content="Mkhize, Nonhlanhla N.">
    <meta name="dc.creator" content="Hermanus, Tandile">
    <meta name="dc.creator" content="Kgagudi, Prudence">
    <meta name="dc.creator" content="Bekker, Valerie">
    <meta name="dc.creator" content="Kaldine, Haajira">
    <meta name="dc.creator" content="Mapengo, Rutendo E.">
    <meta name="dc.creator" content="Eaton, Amanda">
    <meta name="dc.creator" content="Domin, Elize">
    <meta name="dc.creator" content="West, Carley">
    <meta name="dc.creator" content="Feng, Wenhong">
    <meta name="dc.creator" content="Tang, Haili">
    <meta name="dc.creator" content="Seaton, Kelly E.">
    <meta name="dc.creator" content="Heptinstall, Jack">
    <meta name="dc.creator" content="Brackett, Caroline">
    <meta name="dc.creator" content="Chiong, Kelvin">
    <meta name="dc.creator" content="Tomaras, Georgia D.">
    <meta name="dc.creator" content="Andrew, Philip">
    <meta name="dc.creator" content="Mayer, Bryan T.">
    <meta name="dc.creator" content="Reeves, Daniel B.">
    <meta name="dc.creator" content="Sobieszczyk, Magdalena E.">
    <meta name="dc.creator" content="Garrett, Nigel">
    <meta name="dc.creator" content="Sanchez, Jorge">
    <meta name="dc.creator" content="Gay, Cynthia">
    <meta name="dc.creator" content="Makhema, Joseph">
    <meta name="dc.creator" content="Williamson, Carolyn">
    <meta name="dc.creator" content="Mullins, James I.">
    <meta name="dc.creator" content="Hural, John">
    <meta name="dc.creator" content="Cohen, Myron S.">
    <meta name="dc.creator" content="Corey, Lawrence">
    <meta name="dc.creator" content="Montefiori, David C.">
    <meta name="dc.creator" content="Morris, Lynn">
    <meta name="dc.subject" content="Antibodies">
    <meta name="dc.subject" content="HIV infections">
    <meta name="dc.subject" content="Predictive markers">
    <meta name="citation_reference" content="citation_journal_title=Clin. Vaccin. Immunol.; citation_title=Correlates of protection induced by vaccination; citation_author=SA Plotkin; citation_volume=17; citation_publication_date=2010; citation_pages=1055-1065; citation_doi=10.1128/CVI.00131-10; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=The complex challenges of HIV vaccine development require renewed and expanded global commitment; citation_author=LG Bekker; citation_volume=395; citation_publication_date=2020; citation_pages=384-388; citation_doi=10.1016/S0140-6736(19)32682-0; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=Clin. Infect. Dis.; citation_title=Nomenclature for immune correlates of protection after vaccination; citation_author=SA Plotkin, PB Gilbert; citation_volume=54; citation_publication_date=2012; citation_pages=1615-1617; citation_doi=10.1093/cid/cis238; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=Cell Host Microbe; citation_title=A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge; citation_author=A Pegu; citation_volume=26; citation_publication_date=2019; citation_pages=336-346; citation_doi=10.1016/j.chom.2019.08.014; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=Vaccine-induced protection from homologous Tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers; citation_author=MG Pauthner; citation_volume=50; citation_publication_date=2019; citation_pages=241-252; citation_doi=10.1016/j.immuni.2018.11.011; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition; citation_author=L Corey; citation_volume=384; citation_publication_date=2021; citation_pages=1003-1014; citation_doi=10.1056/NEJMoa2031738; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=PLoS Pathog.; citation_title=Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection; citation_author=K Wagh; citation_volume=12; citation_publication_date=2016; citation_pages=e1005520; citation_doi=10.1371/journal.ppat.1005520; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=PLoS Pathog.; citation_title=Potential of conventional &amp; bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C &amp; D infections; citation_author=K Wagh; citation_volume=14; citation_publication_date=2018; citation_pages=e1006860; citation_doi=10.1371/journal.ppat.1006860; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=PLoS Comput. Biol.; citation_title=Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials; citation_author=DB Reeves; citation_volume=16; citation_publication_date=2020; citation_pages=e1007626; citation_doi=10.1371/journal.pcbi.1007626; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=PLoS Comput. Biol.; citation_title=Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention; citation_author=BT Mayer; citation_volume=18; citation_publication_date=2022; citation_pages=e1010003; citation_doi=10.1371/journal.pcbi.1010003; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=J. Acquir Immune Defic. Syndr.; citation_title=Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01; citation_author=Y Huang; citation_volume=83; citation_publication_date=2020; citation_pages=434-439; citation_doi=10.1097/QAI.0000000000002272; citation_id=CR11">
    <meta name="citation_reference" content="Huang, Y. et al. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Hum. Vaccines Immunother. 
                  https://doi.org/10.1080/21645515.2021.1908030
                  
                 (2021).">
    <meta name="citation_reference" content="citation_journal_title=BMC Bioinformatics; citation_title=Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model; citation_author=EE Giorgi; citation_volume=11; citation_publication_date=2010; citation_pages=532; citation_doi=10.1186/1471-2105-11-532; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=BMC Infect. Dis.; citation_title=Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool; citation_author=E Grebe; citation_volume=19; citation_publication_date=2019; citation_doi=10.1186/s12879-019-4543-9; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Stat. Med.; citation_title=Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials; citation_author=PB Gilbert, Y Zhang, E Rudnicki, Y Huang; citation_volume=38; citation_publication_date=2019; citation_pages=4503-4518; citation_doi=10.1002/sim.8310; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=Annu. Rev. Med.; citation_title=Broadly neutralizing antibodies for HIV prevention; citation_author=ST Karuna, L Corey; citation_volume=71; citation_publication_date=2020; citation_pages=329-346; citation_doi=10.1146/annurev-med-110118-045506; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Annu. Rev. Immunol.; citation_title=Vaccines and broadly neutralizing antibodies for HIV-1 prevention; citation_author=KE Stephenson, K Wagh, B Korber, DH Barouch; citation_volume=38; citation_publication_date=2020; citation_pages=673-703; citation_doi=10.1146/annurev-immunol-080219-023629; citation_id=CR17">
    <meta name="citation_reference" content="Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022).">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial; citation_author=KE Stephenson; citation_volume=27; citation_publication_date=2021; citation_pages=1718-1724; citation_doi=10.1038/s41591-021-01509-0; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=PLoS Med.; citation_title=Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults; citation_author=MR Gaudinski; citation_volume=15; citation_publication_date=2018; citation_pages=e1002493; citation_doi=10.1371/journal.pmed.1002493; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study; citation_author=YZ Cohen; citation_volume=14; citation_publication_date=2019; citation_pages=e0219142; citation_doi=10.1371/journal.pone.0219142; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Duration of humoral immunity to common viral and vaccine antigens; citation_author=IJ Amanna, NE Carlson, MK Slifka; citation_volume=357; citation_publication_date=2007; citation_pages=1903-1915; citation_doi=10.1056/NEJMoa066092; citation_id=CR22">
    <meta name="citation_reference" content="Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection; citation_author=DS Khoury; citation_volume=27; citation_publication_date=2021; citation_pages=1205-1211; citation_doi=10.1038/s41591-021-01377-8; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Vaccine; citation_title=Evidence for antibody as a protective correlate for COVID-19 vaccines; citation_author=KA Earle; citation_volume=39; citation_publication_date=2021; citation_pages=4423-4428; citation_doi=10.1016/j.vaccine.2021.05.063; citation_id=CR25">
    <meta name="citation_reference" content="Fong, Y. et al. Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. 10.1101/2022.04.06.22272763 Preprint at 
                  https://doi.org/10.1101/2022.04.06.22272763
                  
                 (2022).">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age; citation_author=EB Walter; citation_volume=386; citation_publication_date=2022; citation_pages=35-46; citation_doi=10.1056/NEJMoa2116298; citation_id=CR27">
    <meta name="citation_reference" content="Emergency Use Authorization for Vaccines to Prevent COVID-19 (US Food and Drug Administration, 2022); 
                  https://www.fda.gov/media/142749/download
                  
                ">
    <meta name="citation_reference" content="Plotkin, S. A. &amp; Gilbert, P. in Plotkin’s Vaccines 7th edn (eds Plotkin, S. A. et al.) 35–40 (Elsevier, 2018).">
    <meta name="citation_reference" content="Astronomo, R. D. et al. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. J. Clin. Invest. 
                  https://doi.org/10.1172/JCI146975
                  
                 (2021).">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Amping up HIV antibodies; citation_author=DR Burton; citation_volume=372; citation_publication_date=2021; citation_pages=1397-1398; citation_doi=10.1126/science.abf5376; citation_id=CR31">
    <meta name="citation_reference" content="Carroll, R. J., Ruppert, D., Stefanski, L. A. &amp; Crainiceanu, C. M. Measurement Error in Nonlinear Models (Chapman and Hall/CRC, 2006).">
    <meta name="citation_reference" content="citation_journal_title=Biometrics; citation_title=A concordance correlation coefficient to evaluate reproducibility; citation_author=LI Lin; citation_volume=45; citation_publication_date=1989; citation_pages=255-268; citation_doi=10.2307/2532051; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=Methods Mol. Biol.; citation_title=Measuring HIV neutralization in a luciferase reporter gene assay; citation_author=DC Montefiori; citation_volume=485; citation_publication_date=2009; citation_pages=395-405; citation_doi=10.1007/978-1-59745-170-3_26; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=J. Virol.; citation_title=Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies; citation_author=M Li; citation_volume=79; citation_publication_date=2005; citation_pages=10108-10125; citation_doi=10.1128/JVI.79.16.10108-10125.2005; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=J. Immunol. Methods; citation_title=Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1; citation_author=M Sarzotti-Kelsoe; citation_volume=409; citation_publication_date=2014; citation_pages=131-146; citation_doi=10.1016/j.jim.2013.11.022; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=J. Virol.; citation_title=Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia; citation_author=GD Tomaras; citation_volume=82; citation_publication_date=2008; citation_pages=12449-12463; citation_doi=10.1128/JVI.01708-08; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Immune-correlates analysis of an HIV-1 vaccine efficacy trial; citation_author=BF Haynes; citation_volume=366; citation_publication_date=2012; citation_pages=1275-1286; citation_doi=10.1056/NEJMoa1113425; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=PLoS Med.; citation_title=Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial; citation_author=KH Mayer; citation_volume=14; citation_publication_date=2017; citation_pages=e1002435; citation_doi=10.1371/journal.pmed.1002435; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=EBioMedicine; citation_title=Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee; citation_author=NI Nicely; citation_volume=2; citation_publication_date=2015; citation_pages=713-722; citation_doi=10.1016/j.ebiom.2015.06.016; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=J. Virol.; citation_title=HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities; citation_author=J Pollara; citation_volume=88; citation_publication_date=2014; citation_pages=7715-7726; citation_doi=10.1128/JVI.00156-14; citation_id=CR41">
    <meta name="citation_reference" content="Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis. 
                  https://doi.org/10.1515/scid-2016-0001
                  
                 (2017).">
    <meta name="citation_reference" content="citation_journal_title=EBioMedicine; citation_title=Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials; citation_author=Y Huang; citation_volume=64; citation_publication_date=2021; citation_pages=103203; citation_doi=10.1016/j.ebiom.2020.103203; citation_id=CR43">
    <meta name="citation_reference" content="citation_journal_title=MAbs; citation_title=Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults; citation_author=Y Huang; citation_volume=9; citation_publication_date=2017; citation_pages=792-800; citation_doi=10.1080/19420862.2017.1311435; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=Biometrika; citation_title=On fitting Cox’s proportional hazards models to survey data; citation_author=DY Lin; citation_volume=87; citation_publication_date=2000; citation_pages=37-47; citation_doi=10.1093/biomet/87.1.37; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=AIDS; citation_title=A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results; citation_author=CD Pilcher; citation_volume=33; citation_publication_date=2019; citation_pages=1231-1240; citation_doi=10.1097/QAD.0000000000002190; citation_id=CR46">
    <meta name="citation_author" content="Gilbert, Peter B.">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author_institution" content="Department of Biostatistics, University of Washington, Seattle, USA">
    <meta name="citation_author" content="Huang, Yunda">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author_institution" content="Department of Global Health, University of Washington, Seattle, USA">
    <meta name="citation_author" content="deCamp, Allan C.">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Karuna, Shelly">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Zhang, Yuanyuan">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Magaret, Craig A.">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Giorgi, Elena E.">
    <meta name="citation_author_institution" content="Los Alamos National Laboratory, Los Alamos, USA">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Korber, Bette">
    <meta name="citation_author_institution" content="Los Alamos National Laboratory, Los Alamos, USA">
    <meta name="citation_author" content="Edlefsen, Paul T.">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Rossenkhan, Raabya">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Juraska, Michal">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Rudnicki, Erika">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Kochar, Nidhi">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Huang, Ying">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Carpp, Lindsay N.">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Barouch, Dan H.">
    <meta name="citation_author_institution" content="Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, USA">
    <meta name="citation_author_institution" content="Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, USA">
    <meta name="citation_author" content="Mkhize, Nonhlanhla N.">
    <meta name="citation_author_institution" content="National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa">
    <meta name="citation_author" content="Hermanus, Tandile">
    <meta name="citation_author_institution" content="National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa">
    <meta name="citation_author" content="Kgagudi, Prudence">
    <meta name="citation_author_institution" content="National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa">
    <meta name="citation_author" content="Bekker, Valerie">
    <meta name="citation_author_institution" content="National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Duke Center for Human Systems Immunology, Duke University Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Durham, USA">
    <meta name="citation_author" content="Kaldine, Haajira">
    <meta name="citation_author_institution" content="National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa">
    <meta name="citation_author" content="Mapengo, Rutendo E.">
    <meta name="citation_author_institution" content="National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa">
    <meta name="citation_author" content="Eaton, Amanda">
    <meta name="citation_author_institution" content="Department of Surgery, Duke University Medical Center, Durham, USA">
    <meta name="citation_author" content="Domin, Elize">
    <meta name="citation_author_institution" content="Department of Surgery, Duke University Medical Center, Durham, USA">
    <meta name="citation_author" content="West, Carley">
    <meta name="citation_author_institution" content="Department of Surgery, Duke University Medical Center, Durham, USA">
    <meta name="citation_author" content="Feng, Wenhong">
    <meta name="citation_author_institution" content="Department of Surgery, Duke University Medical Center, Durham, USA">
    <meta name="citation_author" content="Tang, Haili">
    <meta name="citation_author_institution" content="Department of Surgery, Duke University Medical Center, Durham, USA">
    <meta name="citation_author" content="Seaton, Kelly E.">
    <meta name="citation_author_institution" content="Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA">
    <meta name="citation_author" content="Heptinstall, Jack">
    <meta name="citation_author_institution" content="Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA">
    <meta name="citation_author" content="Brackett, Caroline">
    <meta name="citation_author_institution" content="Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA">
    <meta name="citation_author" content="Chiong, Kelvin">
    <meta name="citation_author_institution" content="Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA">
    <meta name="citation_author" content="Tomaras, Georgia D.">
    <meta name="citation_author_institution" content="Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, USA">
    <meta name="citation_author" content="Andrew, Philip">
    <meta name="citation_author_institution" content="Family Health International, Durham, USA">
    <meta name="citation_author" content="Mayer, Bryan T.">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Reeves, Daniel B.">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Sobieszczyk, Magdalena E.">
    <meta name="citation_author_institution" content="Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA">
    <meta name="citation_author" content="Garrett, Nigel">
    <meta name="citation_author_institution" content="Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa">
    <meta name="citation_author_institution" content="Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa">
    <meta name="citation_author" content="Sanchez, Jorge">
    <meta name="citation_author_institution" content="Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru">
    <meta name="citation_author" content="Gay, Cynthia">
    <meta name="citation_author_institution" content="Division of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, USA">
    <meta name="citation_author" content="Makhema, Joseph">
    <meta name="citation_author_institution" content="Botswana-Harvard AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana">
    <meta name="citation_author_institution" content="Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, USA">
    <meta name="citation_author" content="Williamson, Carolyn">
    <meta name="citation_author_institution" content="Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa">
    <meta name="citation_author" content="Mullins, James I.">
    <meta name="citation_author_institution" content="Department of Global Health, University of Washington, Seattle, USA">
    <meta name="citation_author_institution" content="Department of Microbiology, University of Washington, Seattle, USA">
    <meta name="citation_author_institution" content="Department of Medicine, University of Washington, Seattle, USA">
    <meta name="citation_author" content="Hural, John">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author" content="Cohen, Myron S.">
    <meta name="citation_author_institution" content="Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, USA">
    <meta name="citation_author" content="Corey, Lawrence">
    <meta name="citation_author_institution" content="Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA">
    <meta name="citation_author_institution" content="Department of Medicine, University of Washington, Seattle, USA">
    <meta name="citation_author_institution" content="Department of Laboratory Medicine, University of Washington, Seattle, USA">
    <meta name="citation_author" content="Montefiori, David C.">
    <meta name="citation_author_institution" content="Department of Surgery, Duke University Medical Center, Durham, USA">
    <meta name="citation_author" content="Morris, Lynn">
    <meta name="citation_author_institution" content="National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa">
    <meta name="citation_author_institution" content="Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition">
    <meta name="twitter:description" content="Nature Medicine - By integrating the serum concentration of a broadly neutralizing antibody (bNAb) with its in vitro 80% inhibitory concentration, the PT80 biomarker may be used to guide target...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-022-01953-6">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition - Nature Medicine">
    <meta property="og:description" content="By integrating the serum concentration of a broadly neutralizing antibody (bNAb) with its in vitro 80% inhibitory concentration, the PT80 biomarker may be used to guide target levels of bNAbs for effective prevention of HIV-1 acquisition.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 2px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 2px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: 1em}
.MathJax_MenuRadioCheck.RTL {right: 1em; left: auto}
.MathJax_MenuLabel {padding: 2px 2em 4px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #CCCCCC; margin: 4px 1px 0px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: Highlight; color: HighlightText}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style><style type="text/css">.MJX_Assistive_MathML {position: absolute!important; top: 0; left: 0; clip: rect(1px, 1px, 1px, 1px); padding: 1px 0 0 0!important; border: 0!important; height: 1px!important; width: 1px!important; overflow: hidden!important; display: block!important; -webkit-touch-callout: none; -webkit-user-select: none; -khtml-user-select: none; -moz-user-select: none; -ms-user-select: none; user-select: none}
.MJX_Assistive_MathML.MJX_Assistive_MathML_Block {width: 100%!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MJXp-script {font-size: .8em}
.MJXp-right {-webkit-transform-origin: right; -moz-transform-origin: right; -ms-transform-origin: right; -o-transform-origin: right; transform-origin: right}
.MJXp-bold {font-weight: bold}
.MJXp-italic {font-style: italic}
.MJXp-scr {font-family: MathJax_Script,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-frak {font-family: MathJax_Fraktur,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-sf {font-family: MathJax_SansSerif,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-cal {font-family: MathJax_Caligraphic,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-mono {font-family: MathJax_Typewriter,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-largeop {font-size: 150%}
.MJXp-largeop.MJXp-int {vertical-align: -.2em}
.MJXp-math {display: inline-block; line-height: 1.2; text-indent: 0; font-family: 'Times New Roman',Times,STIXGeneral,serif; white-space: nowrap; border-collapse: collapse}
.MJXp-display {display: block; text-align: center; margin: 1em 0}
.MJXp-math span {display: inline-block}
.MJXp-box {display: block!important; text-align: center}
.MJXp-box:after {content: " "}
.MJXp-rule {display: block!important; margin-top: .1em}
.MJXp-char {display: block!important}
.MJXp-mo {margin: 0 .15em}
.MJXp-mfrac {margin: 0 .125em; vertical-align: .25em}
.MJXp-denom {display: inline-table!important; width: 100%}
.MJXp-denom > * {display: table-row!important}
.MJXp-surd {vertical-align: top}
.MJXp-surd > * {display: block!important}
.MJXp-script-box > *  {display: table!important; height: 50%}
.MJXp-script-box > * > * {display: table-cell!important; vertical-align: top}
.MJXp-script-box > *:last-child > * {vertical-align: bottom}
.MJXp-script-box > * > * > * {display: block!important}
.MJXp-mphantom {visibility: hidden}
.MJXp-munderover, .MJXp-munder {display: inline-table!important}
.MJXp-over {display: inline-block!important; text-align: center}
.MJXp-over > * {display: block!important}
.MJXp-munderover > *, .MJXp-munder > * {display: table-row!important}
.MJXp-mtable {vertical-align: .25em; margin: 0 .125em}
.MJXp-mtable > * {display: inline-table!important; vertical-align: middle}
.MJXp-mtr {display: table-row!important}
.MJXp-mtd {display: table-cell!important; text-align: center; padding: .5em 0 0 .5em}
.MJXp-mtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-mlabeledtr {display: table-row!important}
.MJXp-mlabeledtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mlabeledtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-merror {background-color: #FFFF88; color: #CC0000; border: 1px solid #CC0000; padding: 1px 3px; font-style: normal; font-size: 90%}
.MJXp-scale0 {-webkit-transform: scaleX(.0); -moz-transform: scaleX(.0); -ms-transform: scaleX(.0); -o-transform: scaleX(.0); transform: scaleX(.0)}
.MJXp-scale1 {-webkit-transform: scaleX(.1); -moz-transform: scaleX(.1); -ms-transform: scaleX(.1); -o-transform: scaleX(.1); transform: scaleX(.1)}
.MJXp-scale2 {-webkit-transform: scaleX(.2); -moz-transform: scaleX(.2); -ms-transform: scaleX(.2); -o-transform: scaleX(.2); transform: scaleX(.2)}
.MJXp-scale3 {-webkit-transform: scaleX(.3); -moz-transform: scaleX(.3); -ms-transform: scaleX(.3); -o-transform: scaleX(.3); transform: scaleX(.3)}
.MJXp-scale4 {-webkit-transform: scaleX(.4); -moz-transform: scaleX(.4); -ms-transform: scaleX(.4); -o-transform: scaleX(.4); transform: scaleX(.4)}
.MJXp-scale5 {-webkit-transform: scaleX(.5); -moz-transform: scaleX(.5); -ms-transform: scaleX(.5); -o-transform: scaleX(.5); transform: scaleX(.5)}
.MJXp-scale6 {-webkit-transform: scaleX(.6); -moz-transform: scaleX(.6); -ms-transform: scaleX(.6); -o-transform: scaleX(.6); transform: scaleX(.6)}
.MJXp-scale7 {-webkit-transform: scaleX(.7); -moz-transform: scaleX(.7); -ms-transform: scaleX(.7); -o-transform: scaleX(.7); transform: scaleX(.7)}
.MJXp-scale8 {-webkit-transform: scaleX(.8); -moz-transform: scaleX(.8); -ms-transform: scaleX(.8); -o-transform: scaleX(.8); transform: scaleX(.8)}
.MJXp-scale9 {-webkit-transform: scaleX(.9); -moz-transform: scaleX(.9); -ms-transform: scaleX(.9); -o-transform: scaleX(.9); transform: scaleX(.9)}
.MathJax_PHTML .noError {vertical-align: ; font-size: 90%; text-align: left; color: black; padding: 1px 3px; border: 1px solid}
</style></head>
<body class="article-page"><div id="MathJax_Message" style="display: none;"></div><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-022-01953-6;doi=10.1038/s41591-022-01953-6;subjmeta=1291,1901,2152,2153,2423,250,255,308,53,631,692;kwrd=Antibodies,HIV+infections,Predictive+markers">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=850395742&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01953-6%26doi%3D10.1038/s41591-022-01953-6%26subjmeta%3D1291,1901,2152,2153,2423,250,255,308,53,631,692%26kwrd%3DAntibodies,HIV+infections,Predictive+markers">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=850395742&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01953-6%26doi%3D10.1038/s41591-022-01953-6%26subjmeta%3D1291,1901,2152,2153,2423,250,255,308,53,631,692%26kwrd%3DAntibodies,HIV+infections,Predictive+markers"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-022-01953-6"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01953-6.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01953-6.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2022-08-22">22 August 2022</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition</h1>
                    <ul class="c-article-author-list c-article-author-list--long js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Peter_B_-Gilbert-Aff1-Aff2" data-author-popup="auth-Peter_B_-Gilbert-Aff1-Aff2" data-author-search="Gilbert, Peter B." data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="1_47">Peter B. Gilbert<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2662-9427"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2662-9427</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Yunda-Huang-Aff1-Aff3" data-author-popup="auth-Yunda-Huang-Aff1-Aff3" data-author-search="Huang, Yunda" data-track-context="researcher popup with no profile" data-track-index="2_47">Yunda Huang</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-1546-6172"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1546-6172</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff3" tabindex="-1">3</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Allan_C_-deCamp-Aff1" data-author-popup="auth-Allan_C_-deCamp-Aff1" data-author-search="deCamp, Allan C." data-track-context="researcher popup with no profile" data-track-index="3_47">Allan C. deCamp</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Shelly-Karuna-Aff1" data-author-popup="auth-Shelly-Karuna-Aff1" data-author-search="Karuna, Shelly" data-track-context="researcher popup with no profile" data-track-index="4_47">Shelly Karuna</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-5946-9733"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-5946-9733</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Yuanyuan-Zhang-Aff1" data-author-popup="auth-Yuanyuan-Zhang-Aff1" data-author-search="Zhang, Yuanyuan" data-track-context="researcher popup with no profile" data-track-index="5_47">Yuanyuan Zhang</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Craig_A_-Magaret-Aff1" data-author-popup="auth-Craig_A_-Magaret-Aff1" data-author-search="Magaret, Craig A." data-track-context="researcher popup with no profile" data-track-index="6_47">Craig A. Magaret</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-5056-2664"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-5056-2664</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Elena_E_-Giorgi-Aff4-Aff24" data-author-popup="auth-Elena_E_-Giorgi-Aff4-Aff24" data-author-search="Giorgi, Elena E." data-track-context="researcher popup with no profile" data-track-index="7_47">Elena E. Giorgi</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup><sup class="u-js-hide">&nbsp;<a href="#nAff24" tabindex="-1">nAff24</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Bette-Korber-Aff4" data-author-popup="auth-Bette-Korber-Aff4" data-author-search="Korber, Bette" data-track-context="researcher popup with no profile" data-track-index="8_47">Bette Korber</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2026-5757"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2026-5757</a></span><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Paul_T_-Edlefsen-Aff1" data-author-popup="auth-Paul_T_-Edlefsen-Aff1" data-author-search="Edlefsen, Paul T." data-track-context="researcher popup with no profile" data-track-index="9_47">Paul T. Edlefsen</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-8393-8103"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8393-8103</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Raabya-Rossenkhan-Aff1" data-author-popup="auth-Raabya-Rossenkhan-Aff1" data-author-search="Rossenkhan, Raabya" data-track-context="researcher popup with no profile" data-track-index="10_47">Raabya Rossenkhan</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Michal-Juraska-Aff1" data-author-popup="auth-Michal-Juraska-Aff1" data-author-search="Juraska, Michal" data-track-context="researcher popup with no profile" data-track-index="11_47">Michal Juraska</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-0920-2915"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-0920-2915</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Erika-Rudnicki-Aff1" data-author-popup="auth-Erika-Rudnicki-Aff1" data-author-search="Rudnicki, Erika" data-track-context="researcher popup with no profile" data-track-index="12_47">Erika Rudnicki</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Nidhi-Kochar-Aff1" data-author-popup="auth-Nidhi-Kochar-Aff1" data-author-search="Kochar, Nidhi" data-track-context="researcher popup with no profile" data-track-index="13_47">Nidhi Kochar</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ying-Huang-Aff1" data-author-popup="auth-Ying-Huang-Aff1" data-author-search="Huang, Ying" data-track-context="researcher popup with no profile" data-track-index="14_47">Ying Huang</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lindsay_N_-Carpp-Aff1" data-author-popup="auth-Lindsay_N_-Carpp-Aff1" data-author-search="Carpp, Lindsay N." data-track-context="researcher popup with no profile" data-track-index="15_47">Lindsay N. Carpp</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0333-5925"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0333-5925</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Dan_H_-Barouch-Aff5-Aff6" data-author-popup="auth-Dan_H_-Barouch-Aff5-Aff6" data-author-search="Barouch, Dan H." data-track-context="researcher popup with no profile" data-track-index="16_47">Dan H. Barouch</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-5127-4659"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-5127-4659</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Nonhlanhla_N_-Mkhize-Aff7-Aff8" data-author-popup="auth-Nonhlanhla_N_-Mkhize-Aff7-Aff8" data-author-search="Mkhize, Nonhlanhla N." data-track-context="researcher popup with no profile" data-track-index="17_47">Nonhlanhla N. Mkhize</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a>,<a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Tandile-Hermanus-Aff7-Aff8" data-author-popup="auth-Tandile-Hermanus-Aff7-Aff8" data-author-search="Hermanus, Tandile" data-track-context="researcher popup with no profile" data-track-index="18_47">Tandile Hermanus</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a>,<a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Prudence-Kgagudi-Aff7-Aff8" data-author-popup="auth-Prudence-Kgagudi-Aff7-Aff8" data-author-search="Kgagudi, Prudence" data-track-context="researcher popup with no profile" data-track-index="19_47">Prudence Kgagudi</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a>,<a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Valerie-Bekker-Aff7-Aff8-Aff25" data-author-popup="auth-Valerie-Bekker-Aff7-Aff8-Aff25" data-author-search="Bekker, Valerie" data-track-context="researcher popup with no profile" data-track-index="20_47">Valerie Bekker</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a>,<a href="#Aff8" tabindex="-1">8</a></sup><sup class="u-js-hide">&nbsp;<a href="#nAff25" tabindex="-1">nAff25</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Haajira-Kaldine-Aff7-Aff8" data-author-popup="auth-Haajira-Kaldine-Aff7-Aff8" data-author-search="Kaldine, Haajira" data-track-context="researcher popup with no profile" data-track-index="21_47">Haajira Kaldine</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a>,<a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rutendo_E_-Mapengo-Aff7-Aff8" data-author-popup="auth-Rutendo_E_-Mapengo-Aff7-Aff8" data-author-search="Mapengo, Rutendo E." data-track-context="researcher popup with no profile" data-track-index="22_47">Rutendo E. Mapengo</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a>,<a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Amanda-Eaton-Aff9" data-author-popup="auth-Amanda-Eaton-Aff9" data-author-search="Eaton, Amanda" data-track-context="researcher popup with no profile" data-track-index="23_47">Amanda Eaton</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3064-2947"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3064-2947</a></span><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Elize-Domin-Aff9" data-author-popup="auth-Elize-Domin-Aff9" data-author-search="Domin, Elize" data-track-context="researcher popup with no profile" data-track-index="24_47">Elize Domin</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Carley-West-Aff9" data-author-popup="auth-Carley-West-Aff9" data-author-search="West, Carley" data-track-context="researcher popup with no profile" data-track-index="25_47">Carley West</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Wenhong-Feng-Aff9" data-author-popup="auth-Wenhong-Feng-Aff9" data-author-search="Feng, Wenhong" data-track-context="researcher popup with no profile" data-track-index="26_47">Wenhong Feng</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Haili-Tang-Aff9" data-author-popup="auth-Haili-Tang-Aff9" data-author-search="Tang, Haili" data-track-context="researcher popup with no profile" data-track-index="27_47">Haili Tang</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Kelly_E_-Seaton-Aff10" data-author-popup="auth-Kelly_E_-Seaton-Aff10" data-author-search="Seaton, Kelly E." data-track-context="researcher popup with no profile" data-track-index="28_47">Kelly E. Seaton</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2009-3270"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2009-3270</a></span><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jack-Heptinstall-Aff10" data-author-popup="auth-Jack-Heptinstall-Aff10" data-author-search="Heptinstall, Jack" data-track-context="researcher popup with no profile" data-track-index="29_47">Jack Heptinstall</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Caroline-Brackett-Aff10" data-author-popup="auth-Caroline-Brackett-Aff10" data-author-search="Brackett, Caroline" data-track-context="researcher popup with no profile" data-track-index="30_47">Caroline Brackett</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Kelvin-Chiong-Aff10" data-author-popup="auth-Kelvin-Chiong-Aff10" data-author-search="Chiong, Kelvin" data-track-context="researcher popup with no profile" data-track-index="31_47">Kelvin Chiong</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Georgia_D_-Tomaras-Aff10" data-author-popup="auth-Georgia_D_-Tomaras-Aff10" data-author-search="Tomaras, Georgia D." data-track-context="researcher popup with no profile" data-track-index="32_47">Georgia D. Tomaras</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Philip-Andrew-Aff11" data-author-popup="auth-Philip-Andrew-Aff11" data-author-search="Andrew, Philip" data-track-context="researcher popup with no profile" data-track-index="33_47">Philip Andrew</a><sup class="u-js-hide"><a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Bryan_T_-Mayer-Aff1" data-author-popup="auth-Bryan_T_-Mayer-Aff1" data-author-search="Mayer, Bryan T." data-track-context="researcher popup with no profile" data-track-index="34_47">Bryan T. Mayer</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-2258-5276"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-2258-5276</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Daniel_B_-Reeves-Aff1" data-author-popup="auth-Daniel_B_-Reeves-Aff1" data-author-search="Reeves, Daniel B." data-track-context="researcher popup with no profile" data-track-index="35_47">Daniel B. Reeves</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-5684-9538"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-5684-9538</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Magdalena_E_-Sobieszczyk-Aff12" data-author-popup="auth-Magdalena_E_-Sobieszczyk-Aff12" data-author-search="Sobieszczyk, Magdalena E." data-track-context="researcher popup with no profile" data-track-index="36_47">Magdalena E. Sobieszczyk</a><sup class="u-js-hide"><a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Nigel-Garrett-Aff13-Aff14" data-author-popup="auth-Nigel-Garrett-Aff13-Aff14" data-author-search="Garrett, Nigel" data-track-context="researcher popup with no profile" data-track-index="37_47">Nigel Garrett</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-4530-234X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-4530-234X</a></span><sup class="u-js-hide"><a href="#Aff13" tabindex="-1">13</a>,<a href="#Aff14" tabindex="-1">14</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jorge-Sanchez-Aff15" data-author-popup="auth-Jorge-Sanchez-Aff15" data-author-search="Sanchez, Jorge" data-track-context="researcher popup with no profile" data-track-index="38_47">Jorge Sanchez</a><sup class="u-js-hide"><a href="#Aff15" tabindex="-1">15</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Cynthia-Gay-Aff16" data-author-popup="auth-Cynthia-Gay-Aff16" data-author-search="Gay, Cynthia" data-track-context="researcher popup with no profile" data-track-index="39_47">Cynthia Gay</a><sup class="u-js-hide"><a href="#Aff16" tabindex="-1">16</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Joseph-Makhema-Aff17-Aff18" data-author-popup="auth-Joseph-Makhema-Aff17-Aff18" data-author-search="Makhema, Joseph" data-track-context="researcher popup with no profile" data-track-index="40_47">Joseph Makhema</a><sup class="u-js-hide"><a href="#Aff17" tabindex="-1">17</a>,<a href="#Aff18" tabindex="-1">18</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Carolyn-Williamson-Aff19" data-author-popup="auth-Carolyn-Williamson-Aff19" data-author-search="Williamson, Carolyn" data-track-context="researcher popup with no profile" data-track-index="41_47">Carolyn Williamson</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0125-1226"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0125-1226</a></span><sup class="u-js-hide"><a href="#Aff19" tabindex="-1">19</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-James_I_-Mullins-Aff3-Aff20-Aff21" data-author-popup="auth-James_I_-Mullins-Aff3-Aff20-Aff21" data-author-search="Mullins, James I." data-track-context="researcher popup with no profile" data-track-index="42_47">James I. Mullins</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a>,<a href="#Aff20" tabindex="-1">20</a>,<a href="#Aff21" tabindex="-1">21</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-John-Hural-Aff1" data-author-popup="auth-John-Hural-Aff1" data-author-search="Hural, John" data-track-context="researcher popup with no profile" data-track-index="43_47">John Hural</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Myron_S_-Cohen-Aff22" data-author-popup="auth-Myron_S_-Cohen-Aff22" data-author-search="Cohen, Myron S." data-track-context="researcher popup with no profile" data-track-index="44_47">Myron S. Cohen</a><sup class="u-js-hide"><a href="#Aff22" tabindex="-1">22</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lawrence-Corey-Aff1-Aff21-Aff23" data-author-popup="auth-Lawrence-Corey-Aff1-Aff21-Aff23" data-author-search="Corey, Lawrence" data-track-context="researcher popup with no profile" data-track-index="45_47">Lawrence Corey</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2179-2436"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2179-2436</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff21" tabindex="-1">21</a>,<a href="#Aff23" tabindex="-1">23</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-David_C_-Montefiori-Aff9" data-author-popup="auth-David_C_-Montefiori-Aff9" data-author-search="Montefiori, David C." data-track-context="researcher popup with no profile" data-track-index="46_47">David C. Montefiori</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0856-6319"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0856-6319</a></span><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 47 authors for this article" title="Show all 47 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lynn-Morris-Aff7-Aff8-Aff13" data-author-popup="auth-Lynn-Morris-Aff7-Aff8-Aff13" data-author-search="Morris, Lynn" data-track-context="researcher popup with no profile" data-track-index="47_47">Lynn Morris</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3961-7828"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3961-7828</a></span><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a>,<a href="#Aff8" tabindex="-1">8</a>,<a href="#Aff13" tabindex="-1">13</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;28</b>,&nbsp;<span class="u-visually-hidden">pages </span>1924–1932 (<span data-test="article-publication-year">2022</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">11k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">63 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">45 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-022-01953-6/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            <p class="u-mt-0">This article has been <a href="#change-history">updated</a></p>
        </div>
    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT<sub>80</sub>) biomarker—which quantifies the neutralization potency of antibodies in an individual’s serum against an HIV-1 isolate—can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT<sub>80</sub> of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT<sub>80</sub> &gt;200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT<sub>80</sub> biomarker as a surrogate endpoint for evaluation of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-023-43384-y/MediaObjects/41467_2023_43384_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-023-43384-y?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41467-023-43384-y">High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">14 December 2023</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41586-024-08500-y/MediaObjects/41586_2024_8500_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41586-024-08500-y?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41586-024-08500-y">Antibody prophylaxis may mask subclinical SIV infections in macaques
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">05 February 2025</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-023-02582-3/MediaObjects/41591_2023_2582_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-023-02582-3?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41591-023-02582-3">Dynamics and durability of HIV-1 neutralization are determined by viral replication
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">13 November 2023</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749510732,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>Most licensed antiviral vaccines prevent infection or disease primarily through eliciting antibodies that block acquisition or replication and, for several of these vaccines, neutralizing antibody (nAb) titer was established as a correlate of protection or surrogate endpoint<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055–1065 (2010)." href="/articles/s41591-022-01953-6#ref-CR1" id="ref-link-section-d54774234e1472">1</a></sup>. A successful HIV vaccine will also probably need to generate bnAbs. Global efforts to meet the formidable scientific challenge of developing such an HIV vaccine<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Bekker, L. G. et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet 395, 384–388 (2020)." href="/articles/s41591-022-01953-6#ref-CR2" id="ref-link-section-d54774234e1476">2</a></sup> would benefit greatly from a validated nAb titer correlate of protection<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055–1065 (2010)." href="/articles/s41591-022-01953-6#ref-CR1" id="ref-link-section-d54774234e1480">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Plotkin, S. A. &amp; Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615–1617 (2012)." href="/articles/s41591-022-01953-6#ref-CR3" id="ref-link-section-d54774234e1483">3</a></sup>. The nonhuman primate (NHP) SHIV (simian-HIV) challenge model laid groundwork for this validation by showing that serum nAb titer is a correlate of protection from SHIV acquisition, in a meta-analysis of NHPs administered a single bnAb<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336–346 (2019)." href="/articles/s41591-022-01953-6#ref-CR4" id="ref-link-section-d54774234e1487">4</a></sup>, and also in NHPs immunized with recombinant native-like HIV-1 Envelope trimers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Pauthner, M. G. et al. Vaccine-induced protection from homologous Tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers. Immunity 50, 241–252 (2019)." href="/articles/s41591-022-01953-6#ref-CR5" id="ref-link-section-d54774234e1491">5</a></sup>.</p><p>The Antibody Mediated Prevention (AMP) trials (<a href="https://clinicaltrials.gov/ct2/show/NCT02716675">NCT02716675</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT02568215">NCT02568215</a>) of the intraveneously (IV) administered CD4 binding site (CD4bs)-targeting bnAb VRC01 assessed HIV-1 prevention efficacy (PE), defined as the percentage reduction (VRC01 versus placebo) in the risk of HIV-1 acquisition over 80 weeks<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e1512">6</a></sup>. Neutralization sieve analysis showed that PE is strongly dependent on the neutralization sensitivity of an HIV-1 isolate to VRC01, measured as in vitro 80 or 50% inhibitory concentration (IC<sub>80</sub> or IC<sub>50</sub>, respectively). In particular, statistical tests showed that PE is significantly greater against viruses with lower IC<sub>80</sub> or lower IC<sub>50</sub>, and the result was replicated across each of the individual AMP trials in two distinct cohorts. In HVTN 704/HPTN 085 (704/085), which enrolled 2,699 transgender individuals and men who have sex with men in Brazil, Peru and the United States, PE was 73.0% (95% confidence interval (CI) 27.6–89.9%) against viruses with IC<sub>80</sub> &lt; 1 µg ml<sup>–1</sup>. Moreover, in HVTN 703/HPTN 081 (703/081), which enrolled 1,924 heterosexual women in Botswana, Kenya, Malawi, Mozambique, South Africa, Tanzania and Zimbabwe, PE was 78.6% (95% CI 17.3–94.4%) against viruses with IC<sub>80</sub> &lt; 1 µg ml<sup>–1</sup>. In each trial, PE was near zero for viruses with IC<sub>80</sub> &gt; 1 µg ml<sup>–1</sup>.</p><p>The parameter IC<sub>80</sub> is a neutralization property of a given antibody clinical lot against a given HIV-1 pseudovirus in vitro. In the absence of a validated nAb titer correlate of protection, summary measures (for example, geometric mean) of a bnAb IC<sub>80</sub> against each pseudovirus in a panel likely to reflect circulating HIV-1s have been used to predict bnAb prevention potential. For example, geometric mean IC<sub>80</sub> and the percentage of viruses neutralized at a specific IC<sub>80</sub> cutoff (that is, neutralization breadth in vitro) against a panel of representative HIV-1 pseudoviruses have been used to help identify the most promising bnAbs, multispecific bnAbs and bnAb combinations to advance into clinical trials for their potential to achieve high prevention efficacy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection. PLoS Pathog. 12, e1005520 (2016)." href="/articles/s41591-022-01953-6#ref-CR7" id="ref-link-section-d54774234e1549">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Wagh, K. et al. Potential of conventional &amp; bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C &amp; D infections. PLoS Pathog. 14, e1006860 (2018)." href="/articles/s41591-022-01953-6#ref-CR8" id="ref-link-section-d54774234e1552">8</a></sup>. However, because IC<sub>80</sub> contains no information about the concentration of bnAb in an individual’s sera it is therefore not sufficient to quantify the ability of that individual’s blood to neutralize an exposing virus at a given time because antibody concentration changes over time after administration. Logically, both time-varying bnAb concentration and bnAb potency/breadth, as quantified by distributions of IC<sub>80</sub>, might be required to estimate prevention efficacy. Certain mathematical combinations of these quantities (for example, refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Reeves, D. B. et al. Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. PLoS Comput. Biol. 16, e1007626 (2020)." href="/articles/s41591-022-01953-6#ref-CR9" id="ref-link-section-d54774234e1561">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Comput. Biol. 18, e1010003 (2022)." href="/articles/s41591-022-01953-6#ref-CR10" id="ref-link-section-d54774234e1564">10</a></sup>) have been assumed to be correlates of prevention efficacy in previous modeling studies.</p><p>In this work, we analyzed a nAb titer biomarker that integrates IC<sub>80</sub> with serum bnAb concentration, PT<sub>80</sub>, of a VRC01 recipient’s serum at a given time to a given reference virus as a correlate of VRC01 prevention efficacy in the AMP trials. Figure <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig1">1</a> depicts how the PT<sub>80</sub> biomarker is calculated using serum bnAb concentration and IC<sub>80</sub>, where the PT<sub>80</sub> of a bnAb against an exposing virus population (rather than a single reference virus) can be determined using the geometric mean of the IC<sub>80</sub> values of bnAb against each exposing virus. The results support the premise that the PT<sub>80</sub> biomarker can be used to predict HIV-1 PE of bnAb regimens, and hence advance this biomarker as a correlate of protection for evaluation of bnAb regimens and as a tool for guiding research on candidate bnAb-inducing vaccines.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Visual representation of how two independent pieces of information (serum bnAb concentration at a given time point and neutralization sensitivity of a target virus to the bnAb (IC80)) are used to calculate the PT80 biomarker."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Visual representation of how two independent pieces of information (serum bnAb concentration at a given time point and neutralization sensitivity of a target virus to the bnAb (IC<sub>80</sub>)) are used to calculate the PT<sub>80</sub> biomarker.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="600"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>a</b>, Formula for calculation of PT<sub>80</sub> for a bnAb against a target virus. IC<sub>80</sub> for a clinical lot bnAb product against a target virus, as determined by the TZM-bl target cell assay, is the bnAb concentration needed for 80% reduction in RLU compared with target virus control wells after subtraction of background RLU. Based on the PT<sub>80</sub> biomarker, increasing bnAb serum concentration and increasing target virus sensitivity (that is, decreasing IC<sub>80</sub>) have an equal impact on increasing PT<sub>80</sub> and hence improvement in potential prevention efficacy. <b>b</b>, Example calculations showing how PT<sub>80</sub> against a target virus differs for three different bnAbs sharing the same IC<sub>80</sub> against the target virus yet are present at different serum concentrations. A similar result would be obtained (differing PT<sub>80</sub> values) if the same bnAb was present at three different serum concentrations. <b>c</b>, Adaptation of the formula shown in <b>a</b> to a scenario where average PT<sub>80</sub> is calculated against a population of exposing viruses. <b>d</b>, Example calculations of average PT<sub>80</sub> over a follow-up period against an exposing virus population for three different bnAbs. The yellow bnAb has characteristics of VRC01 observed in the AMP trials (average serum concentration over VRC01 recipients and over 80 weeks of follow-up 20 µg ml<sup>–1</sup>, average IC<sub>80</sub> of exposing viruses 4.0 µg ml<sup>–1</sup>, which is calculated as the weighted average of the three IC<sub>80</sub>s: for example, (0.5 µg ml<sup>–1</sup>) × 0.30 + (2.0 µg ml<sup>–1</sup>) × 0.15 + (6.5 µg ml<sup>–1</sup>) × 0.55 = 4.0 µg ml<sup>–1</sup>). If IC<sub>80</sub> is used for comparison of the yellow and blue bnAbs, the results indicate that the blue bnAb is twofold better than the yellow in regard to its potential prevention efficacy, whereas if PT<sub>80</sub> is used for comparison the blue bnAb is fivefold better than the yellow. The PT<sub>80</sub> biomarker is superior on account of its enhanced measurement of neutralization potency against anticipated exposing viruses.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Cohorts used for each analysis</h3><p>Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">1</a> provides information on the types of cohorts that were used for each analysis.</p><h3 class="c-article__sub-heading" id="Sec4">Serum neutralization ID<sub>80</sub> titer is well estimated by PT<sub>80</sub>
                        </h3><p>The failure of IC<sub>80</sub> as a self-sufficient correlate was observed in the AMP trials, in that no PE was observed against sensitive viruses (IC<sub>80</sub> &lt; 1 μg ml<sup>–1</sup>) after antibody levels had decayed to becoming undetectable (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">2</a>). Therefore, we assessed serum neutralization titer as a correlate. We previously reported that, in VRC01 recipients in the HVTN 104 trial (healthy, uninfected participants at low risk of HIV-1 acquisition) and in VRC01 recipients in the AMP trials who remained HIV-1 negative through at least the week 88 visit, the experimentally measured serum ID<sub>80</sub> titer of VRC01 against a given virus was well estimated by PT<sub>80</sub>, defined as an individual’s VRC01 serum concentration divided by the IC<sub>80</sub> of the VRC01 drug product against the same virus (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. J. Acquir Immune Defic. Syndr. 83, 434–439 (2020)." href="/articles/s41591-022-01953-6#ref-CR11" id="ref-link-section-d54774234e1718">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Huang, Y. et al. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Hum. Vaccines Immunother. 
                  https://doi.org/10.1080/21645515.2021.1908030
                  
                 (2021)." href="/articles/s41591-022-01953-6#ref-CR12" id="ref-link-section-d54774234e1721">12</a></sup>, respectively) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig1">1</a>). In VRC01-recipient cases in the AMP trials (that is, participants with confirmed acquisition of HIV-1 infection after enrollment and by the week 80 visit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e1728">6</a></sup>), a similar result was observed in sera obtained at the study visit (and, for a subset, from the last two study visits) immediately before the first positive HIV-1 RNA PCR test, when assayed against autologous isolates (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig2">2</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Agreement between predicted versus experimental serum neutralization ID80 titer."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Agreement between predicted versus experimental serum neutralization ID<sub>80</sub> titer.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/2" rel="nofollow"><picture><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="594"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>Sera from samples from the last visit (and for a subset from the last two visits) and before the first positive HIV-1 RNA PCR test were assayed against autologous isolates from 64 VRC01 recipients who acquired HIV-1 infection (cases) (90 isolates, 164 titers). PT<sub>80</sub> values are plotted against experimental ID<sub>80</sub> for each sample and each isolate (Lin’s concordance correlation coefficient<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45, 255–268 (1989)." href="/articles/s41591-022-01953-6#ref-CR33" id="ref-link-section-d54774234e1755">33</a></sup> = 0.90 (95% CI 0.56–0.98)). PT<sub>80</sub> was calculated as popPK model-predicted concentration divided by IC<sub>80</sub>. Nine of 164 experimental ID<sub>80</sub> titers were below the limit of detection at PT<sub>80</sub> &gt; 10 (range 10.6–25.1). One of 164 experimental ID<sub>80</sub> titers was at or above the limit of detection at PT<sub>80</sub> &lt; 10 (8.7). Dashed horizontal and vertical lines at a PT<sub>80</sub> = 10 show the experimental ID<sub>80</sub> limit of detection; concordance of predicted versus experimental values above versus below 10 was 154/164 (94%). Sera with PT<sub>80</sub> &lt; 1.0 were not experimentally tested, as this would have required concentration of sera.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec5">PT<sub>80</sub> associated with VRC01 prevention efficacy</h3><p>To define the level of VRC01 serum neutralization that correlates with reduced HIV-1 acquisition in AMP, we first used the median VRC01 serum concentration (calculated as the median observed VRC01 concentration at all mid-infusion visits across all noncases in the case-control samples) and the IC<sub>80</sub> of the acquired virus to estimate how VRC01 PE varied with PT<sub>80</sub> against the autologous virus. Achieving 50, 75 and 90% PE required PT<sub>80</sub> values of 32, 82 and 194, respectively; these titers were higher than those needed to achieve the same level of protection in the NHP high-dose challenge model<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336–346 (2019)." href="/articles/s41591-022-01953-6#ref-CR4" id="ref-link-section-d54774234e1804">4</a></sup> (8, 32 and 83, respectively) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig3">3</a>). These protection-by-PT<sub>80</sub> curves looked similar in two different sensitivity analyses of the NHP challenge model data, where bnAb and/or SHIV challenge virus data with outlying protection curves were excluded (figure 2 of ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336–346 (2019)." href="/articles/s41591-022-01953-6#ref-CR4" id="ref-link-section-d54774234e1814">4</a></sup>; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig7">1</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Estimated PE by PT80 to the autologous acquired virus in AMP trials and in NHP studies."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Estimated PE by PT<sub>80</sub> to the autologous acquired virus in AMP trials and in NHP studies.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="733"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, Estimated PE by PT<sub>80</sub> to the acquired virus in AMP (black solid line) compared with the protection curve in three different sets of NHP (blue, mustard and green lines). <b>b</b>, PT<sub>80</sub> values associated with 50, 75 and 90% PE for AMP trials and each of the three sets of NHP. PT<sub>80</sub> values &lt;2 were set to 1. Set A: <i>n</i> = 274 NHPs that received a single bnAb followed by SHIV challenge, bnAb titer data from all neutralization assays<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336–346 (2019)." href="/articles/s41591-022-01953-6#ref-CR4" id="ref-link-section-d54774234e1851">4</a></sup>; set B: only the NHPs in set A that received a CD4 binding site-targeting bnAb, excluding all that were challenged with SF162P3 and including only bnAb titer data from the TZM-bl target cell assay; and set C: all NHPs in set A but excluding those that received a membrane-proximal external region-targeting bnAb and all those challenged with SF162P3, and including only bnAb titer data from the TZM-bl target cell assay. The dashed horizontal lines are drawn at the y-axis values of 50, 75 and 90. These lines indicate the various curves that intersect a level of prevention efficacy of 50%, 75% or 90%.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec6">Population-level PT<sub>80</sub> correlate of protection</h3><p>The above estimates, which use a representative VRC01 serum concentration (median), are imprecise given that individual VRC01 concentrations at HIV-1 acquisition differ from this representative concentration. Supporting an alternative approach, the even spread of estimated infection dates across infusion intervals in placebo recipients (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig8">2</a>) suggested that HIV-1 exposures occurred approximately uniformly over time. When population pharmacokinetics (popPK) modeling—which incorporates data from all individuals in a given cohort to study PK at the population level—was used to estimate daily VRC01 concentrations, PT<sub>80</sub> values were markedly higher against sensitive versus resistant placebo recipient-acquired viruses (taken to be representative of strains circulating in the trial settings): median over days and viruses (interquartile range) PT<sub>80</sub> was 41.3 (16.3–112.0) against IC<sub>80</sub> &lt; 1 µg ml<sup>–1</sup> virus, 9.6 (4.1–23.7) against IC<sub>80</sub> 1–3 µg ml<sup>–1</sup> virus and 1.3 (0.3–4.3) against IC<sub>80</sub> &gt; 3 µg ml<sup>–1</sup> virus (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig4">4</a>). Notably, for virus sensitivity categories 1–3 and &gt;3 µg ml<sup>–1</sup>, many PT<sub>80</sub> values fell below the limit of detection of the TZM-bl target cell neutralization assay (titer = 10) and, in the &gt;3 µg ml<sup>–1</sup> category, nearly half the PT<sub>80</sub> values were &lt;1.0 (although PT<sub>80</sub> values &lt;1.0 can be predicted, they were not experimentally tested, which would require concentration of serum).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Distributions of VRC01 serum PT80 against viruses acquired by placebo recipients, within each virus neutralization IC80 sensitivity category."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Distributions of VRC01 serum PT<sub>80</sub> against viruses acquired by placebo recipients, within each virus neutralization IC<sub>80</sub> sensitivity category.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="492"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p>Approach 2 of Huang et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. J. Acquir Immune Defic. Syndr. 83, 434–439 (2020)." href="/articles/s41591-022-01953-6#ref-CR11" id="ref-link-section-d54774234e1925">11</a></sup> was used to calculate PT<sub>80</sub> against a given virus, by dividing the popPK model-predicted VRC01 serum concentration by the IC<sub>80</sub> of the VRC01 drug product against the virus. The distributions are for PT<sub>80</sub> values of the 82 noncases in the case-control cohort calculated each day over the 80-week follow-up against each of the viruses (<i>n</i> = 19 IC<sub>80</sub> &lt; 1 µg ml<sup>–1</sup>; <i>n</i> = 10 IC<sub>80</sub> 1–3 µg ml<sup>–1</sup>; <i>n</i> = 35 IC<sub>80</sub> &gt; 3 µg ml<sup>–1</sup>) acquired by placebo recipients. On the <i>y</i> axis, each filled black dot is a point estimate of PE against viruses in the specified sensitivity category and vertical lines are 95% CI estimates as previously reported<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e1961">6</a></sup>. The arrow indicates a value (−108.7) below the <i>y</i>-axis lower limit. On the <i>x</i> axis, each filled black dot is the median PT<sub>80</sub> against viruses acquired by placebo recipients within each virus neutralization IC<sub>80</sub> sensitivity category; horizontal rectangles extend through the interquartile range, and on each side of the boxplot is a kernel density estimation of the distribution shape of PT<sub>80</sub>.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec7">Low PT<sub>80</sub> values against autologous virus at HIV-1 acquisition</h3><p>If serum VRC01 neutralization titer is a true correlate of prevention efficacy, then PT<sub>80</sub> values of VRC01-recipient noncases (their individual-specific median PT<sub>80</sub> values over follow-up) against viruses acquired by placebo recipients must therefore be higher than those of VRC01-recipient cases at acquisition against autologous viruses (assuming that exposures to HIV-1 occur approximately uniformly over time). Noncases are defined as participants who completed the week 88 visit without HIV-1 infection diagnosis. We found that, indeed, autologous PT<sub>80</sub> values were higher in VRC01-recipient noncases, with a geometric mean of 4.3 (95% CI 4.0–4.7) compared with a geometric mean of 1.5 (95% CI 0.9–2.4) in VRC01-recipient cases, a ratio of 2.9 (95% CI 1.8–4.8, <i>P</i> &lt; 0.001); similar results were obtained for individual dose arms (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig5">5</a> and <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01953-6#Sec11">Methods</a>). In these calculations, each individual’s HIV-1 acquisition date was derived by a Bayesian procedure that combines an estimate obtained by fitting a Poisson distribution to the <i>gag–pol–nef</i> sequences from the first RNA PCR-positive time points<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Giorgi, E. E. et al. Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model. BMC Bioinformatics 11, 532 (2010)." href="/articles/s41591-022-01953-6#ref-CR13" id="ref-link-section-d54774234e2017">13</a></sup> with information from the HIV diagnostic assays that were applied to 4-weekly samples<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Grebe, E. et al. Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. BMC Infect. Dis. 19, 894 (2019)." href="/articles/s41591-022-01953-6#ref-CR14" id="ref-link-section-d54774234e2021">14</a></sup> (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01953-6#Sec11">Methods</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="PT80 values to autologous acquired viruses at HIV-1 acquisition among VRC01 arm cases, and to placebo recipient-acquired viruses among VRC01 arm noncases."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: PT<sub>80</sub> values to autologous acquired viruses at HIV-1 acquisition among VRC01 arm cases, and to placebo recipient-acquired viruses among VRC01 arm noncases.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="1212"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p><b>a</b>, Violin plots for VRC01-recipient cases versus noncases, where approach 2 of Huang et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. J. Acquir Immune Defic. Syndr. 83, 434–439 (2020)." href="/articles/s41591-022-01953-6#ref-CR11" id="ref-link-section-d54774234e2045">11</a></sup> was used to calculate PT<sub>80</sub> at a given time point against a given virus. For each VRC01-recipient case, PT<sub>80</sub> at the estimated date of HIV-1 acquisition (red dots) was calculated as the estimated VRC01 concentration at acquisition divided by the VRC01 drug product IC<sub>80</sub> against the autologous virus. For each of the 82 sampled VRC01-recipient noncases, PT<sub>80</sub> at each day of follow-up against each placebo recipient-acquired virus was calculated as the estimated VRC01 concentration divided by VRC01 drug product IC<sub>80</sub> against the virus (blue dots). The lower bound, horizontal line and upper bound of the vertical rectangular boxplots show the 25th, 50th and 75th percentiles, respectively. On each side of the boxplot is a kernel density estimation of the distribution shape of PT<sub>80</sub>. <b>b</b>, By VRC01 dose arm and across dose arms pooled: geometric mean PT<sub>80</sub> at HIV-1 acquisition in VRC01-recipient cases against the autologous acquired virus, geometric mean PT<sub>80</sub> in VRC01-recipient noncases (their individual-specific medians over follow-up) to placebo recipient-acquired viruses, and their ratio. Error bars represent 95% CIs.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec8">VRC01 serum concentration is a correlate of risk</h3><p>We next assessed VRC01 serum concentration as a correlate of risk of instantaneous HIV-1 acquisition using a Cox model<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Gilbert, P. B., Zhang, Y., Rudnicki, E. &amp; Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. Stat. Med. 38, 4503–4518 (2019)." href="/articles/s41591-022-01953-6#ref-CR15" id="ref-link-section-d54774234e2085">15</a></sup>, including all VRC01-recipient cases and randomly sampled noncases. The estimated hazard ratio of HIV-1 acquisition per tenfold increase in date-of-acquisition serum VRC01 concentration was 0.53 (95% CI 0.31–0.92, <i>P</i> = 0.02). The fact that the AMP trials randomized VRC01 at two doses provided the opportunity to confirm that this correlate of risk result was consistent with the observed dose effect on HIV-1 acquisition. Affirmatively, the 30 mg kg<sup>–1</sup> arm had 23% improved efficacy compared with the 10 mg kg<sup>–1</sup> arm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2096">6</a></sup> (calculation shown in <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01953-6#Sec11">Methods</a>) and the 30 mg kg<sup>–1</sup> arm had 2.4-fold higher median mid-infusion visit serum VRC01 concentration than the 10 mg kg<sup>–1</sup> arm, where the correlate of risk result yielded 25% risk reduction per 2.4-fold increase in concentration.</p><h3 class="c-article__sub-heading" id="Sec9">Prediction of prevention efficacy of a triple-bnAb regimen</h3><p>Various bnAb combinations and bispecific Abs, enabling consecutive targeting of different epitopes, are in clinical development for HIV-1 prevention<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Karuna, S. T. &amp; Corey, L. Broadly neutralizing antibodies for HIV prevention. Annu. Rev. Med. 71, 329–346 (2020)." href="/articles/s41591-022-01953-6#ref-CR16" id="ref-link-section-d54774234e2116">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Stephenson, K. E., Wagh, K., Korber, B. &amp; Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673–703 (2020)." href="/articles/s41591-022-01953-6#ref-CR17" id="ref-link-section-d54774234e2119">17</a></sup>. Predicted potency-breadth curves have suggested that a triple combination consisting of one CD4bs-targeting bnAb, one V2 glycan-targeting bnAb and one V3 glycan-targeting bnAb would have the best neutralization coverage against a panel of clade C viruses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection. PLoS Pathog. 12, e1005520 (2016)." href="/articles/s41591-022-01953-6#ref-CR7" id="ref-link-section-d54774234e2123">7</a></sup>. One such combination, VRC07-523LS (CD4bs), PGT121 (V3 glycan) and PGDM1400 (V2 glycan), has been predicted to have 99% neutralization breadth (IC<sub>80</sub> &lt; 10 μg ml<sup>–1</sup>) and a geometric mean IC<sub>80</sub> of 0.09 μg ml<sup>–1</sup> against a diverse panel of viruses, compared with 76% neutralization breadth and a geometric mean IC<sub>80</sub> of 2.64 μg ml<sup>–1</sup> for VRC01 alone<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Stephenson, K. E., Wagh, K., Korber, B. &amp; Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673–703 (2020)." href="/articles/s41591-022-01953-6#ref-CR17" id="ref-link-section-d54774234e2140">17</a></sup>. (LS refers to a Fc-modified version to extend half-life.) This specific triple-bnAb combination is in development for potential efficacy testing and has been safely administered to adults without HIV in a recent phase 1 study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022)." href="/articles/s41591-022-01953-6#ref-CR18" id="ref-link-section-d54774234e2144">18</a></sup>. We therefore decided to apply PT<sub>80</sub> to predict PE of 20 or 40 mg kg<sup>–1</sup> each of PGT121.414.LS, PGDM1400LS and VRC07-523LS delivered together IV. Using available serum concentration data<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022)." href="/articles/s41591-022-01953-6#ref-CR18" id="ref-link-section-d54774234e2153">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718–1724 (2021)." href="/articles/s41591-022-01953-6#ref-CR19" id="ref-link-section-d54774234e2156">19</a></sup>, steady-state serum concentrations of each bnAb over 16 weeks were simulated based on popPK modeling (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01953-6#Sec11">Methods</a>). Because data from the LS forms of PGT121 and PGDM1400 are not yet available, the predictions considered a possible increase of 2.5-fold in elimination half-life conferred by the LS mutation, with 2.5-fold being a conservative assumption based on the previously reported fourfold increase<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018)." href="/articles/s41591-022-01953-6#ref-CR20" id="ref-link-section-d54774234e2163">20</a></sup>. Our results suggest that PT<sub>80</sub> &gt; 200 of a bnAb regimen to a given exposing virus would provide 90% or higher efficacy to block HIV-1 acquisition with that virus. We applied this threshold (PT<sub>80</sub> &gt; 200) in our definition of neutralization coverage. Neutralization coverage by at least one bnAb in the regimen, averaged over time for a 16-weekly regimen, and to the 47 viruses (all subtype C) acquired by 29 placebo recipients from 703/081 was 71%; neutralization coverage averaged over time and to the 70 viruses (90% subtype B) acquired by 35 placebo recipients from 704/085 was 73% (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig6">6a,b</a>). In contrast, neutralization coverage of VRC01 (at 30 mg kg<sup>–1</sup>) averaged over time and to the 703/081 or 704/085 viruses was 8%.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-6" data-title="Neutralization coverage, geometric mean PT80 and PT80-predicted prevention efficacy over time against viruses circulating in each of the AMP trials for the bnAb regimen, delivered IV every 16 weeks and evaluated in study cohorts of the same size as in the AMP trials."><figure><figcaption><b id="Fig6" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 6: Neutralization coverage, geometric mean PT<sub>80</sub> and PT<sub>80</sub>-predicted prevention efficacy over time against viruses circulating in each of the AMP trials for the bnAb regimen, delivered IV every 16 weeks and evaluated in study cohorts of the same size as in the AMP trials.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/6" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig6_HTML.png?as=webp"><img aria-describedby="Fig6" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig6_HTML.png" alt="figure 6" loading="lazy" width="685" height="1080"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-6-desc"><p><b>a</b>,<b>b</b>, Neutralization coverage (defined by PT<sub>80</sub> &gt; 200) (averaged to viruses). <b>c</b>,<b>d</b>, geometric mean PT<sub>80</sub>. <b>e</b>,<b>f</b>, PT<sub>80</sub>-predicted prevention efficacy. <b>a</b>–<b>d</b>, PGT121LS + PGDM1400LS + VRC07-523LS, 20 + 20 + 20 mg kg<sup>–1</sup>. <b>e</b>,<b>f</b>, PGT121LS + PGDM1400LS + VRC07-523LS, 40 +40 + 40 mg kg<sup>–1</sup>.<b>a</b>,<b>c</b>,<b>e</b>, HVTN 703/HPTN 081. <b>b</b>,<b>d</b>,<b>f</b>, HVTN 704/HPTN 085. <b>a</b>,<b>b</b>, Tables below each plot provide neutralization coverage averaged to viruses and averaged over the given time frame. Virus exposure was considered covered by 1-, 2- or 3-active bnAbs if the coverage threshold (PT<sub>80</sub> &gt; 200) was achieved by at least one, at least two or all three bnAbs, respectively. All predictions were made under the scenario that PGT121LS and PGDM1400LS have 2.5-fold higher half-lives than PGT121 and PGDM1400, based on modeling of the observed serum concentration data of PGT121 and PGDM1400 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022)." href="/articles/s41591-022-01953-6#ref-CR18" id="ref-link-section-d54774234e2263">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718–1724 (2021)." href="/articles/s41591-022-01953-6#ref-CR19" id="ref-link-section-d54774234e2266">19</a></sup>). For each bnAb regimen, geometric mean PT<sub>80</sub> at each time point was calculated as the geometric mean of predicted serum concentration across bnAb recipients at each time point during steady state (simulated based on popPK modeling of each bnAb as described in <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01953-6#Sec11">Methods</a>), divided by the geometric mean of bnAb drug product IC<sub>80</sub> across viruses circulating in the designated AMP trial. The PT<sub>80</sub> of the triple-bnAb regimen was calculated using the Bliss–Hill interaction model of individual bnAb PT<sub>80</sub> titers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Comput. Biol. 18, e1010003 (2022)." href="/articles/s41591-022-01953-6#ref-CR10" id="ref-link-section-d54774234e2282">10</a></sup>. The viruses circulating in each trial were: <b>a</b>,<b>c</b>,<b>e</b>, <i>m</i> = 47 viruses acquired by <i>n</i> = 29 703/081 (sub-Saharan Africa) placebo recipients; <b>b</b>,<b>d</b>,<b>f</b>, <i>m</i> = 70 viruses acquired by <i>n</i> = 35 704/085 (Americas + Switzerland) placebo recipients. <b>e</b>,<b>f</b>, Solid line, median; shaded area, 95% prediction interval.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01953-6/figures/6" data-track-dest="link:Figure6 Full size image" aria-label="Full size image figure 6" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>We then applied the relationship between PT<sub>80</sub> and PE (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig3">3</a> and <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01953-6#Sec11">Methods</a>) in our prediction of PE. Predicted prevention efficacy of the triple-bnAb regimen at 20 mg kg<sup>–1</sup> each, administered every 16 weeks, was 91% (95% CI: 86%, 94%) against the 47 clade C viruses and 92% (95% CI: 87%, 96%) against the 70 predominantly clade B viruses (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig6">6e,f</a>). For the triple-bnAb regimen at 40 mg kg<sup>–1</sup> each, the predicted prevention efficacy was 95% (95% CI: 92%, 97%) and 96% (95% CI: 92%, 98%), respectively. Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig9">3</a> shows analogous 24-week plots for the LS bnAb versions, indicating about 87% predicted efficacy. As internal validation, the predicted prevention efficacy of the VRC01 30 mg kg<sup>–1</sup> regimen used in AMP was 26 and 32% against the clade C viruses and the predominantly clade B viruses, respectively, which matches closely the observed prevention efficacy of 27 and 31% (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2356">6</a></sup>). Had the AMP VRC01 regimen been increased to 40 mg kg<sup>–1</sup> dosing and administered twice as frequently for 80 weeks, predicted prevention efficacy would have been 43% (34%, 51%) against the clade C viruses and 56% (44%, 67%) against the predominantly clade B viruses. Had VRC07-523LS (rather than VRC01) been administered at 40 mg kg<sup>–1</sup> every 16 weeks, predicted prevention efficacy would have been 79% (68%, 86%) against the clade C viruses and 89% (79%, 94%) against the predominantly clade B viruses. This modeling suggests that combination bnAb regimens are needed for high prevention efficacy.</p><p>The same analyses were performed for predicted serum neutralization 50% inhibitory dilution titer (PT<sub>50</sub>) defined in the analogous way, using IC<sub>50</sub> rather than IC<sub>80</sub>; the results and conclusions were similar (Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig10">4</a>–<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig15">9</a>).</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec10-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec10">Discussion</h2><div class="c-article-section__content" id="Sec10-content"><p>This study advances the PT<sub>80</sub> biomarker as a probable surrogate endpoint for HIV-1 acquisition. By estimation of which serum bnAb titers will be protective for humans in the prevention of HIV-1 acquisition, regardless of clade, sex or route of infection, these findings address the critical need to establish targets for future preclinical and clinical expectations, for both passive instillation of bnAb combinations and active administration of any candidate HIV-1 vaccine. Notably, the neutralization titers suggested by data from the AMP trials are necessary for high PE (approximately 200 for 90% prevention efficacy, similar to that reported in NHP<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336–346 (2019)." href="/articles/s41591-022-01953-6#ref-CR4" id="ref-link-section-d54774234e2390">4</a></sup>) should be achievable. Crucial for meeting this goal will be the use of bnAb combinations, some of which are now advancing to clinical testing (for example, PGDM1400LS + PGT121.414LS + VRC07-523LS), which have been engineered to have increased half-lives (LS versions) and improved in vitro neutralization. The PT<sub>80</sub> correlate can be used for systematic comparison and down-selection of candidate bnAb combinations in development<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Cohen, Y. Z. et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study. PLoS ONE 14, e0219142 (2019)." href="/articles/s41591-022-01953-6#ref-CR21" id="ref-link-section-d54774234e2396">21</a></sup>. We estimate through modeling that the PGDM1400LS + PGT121.414LS + VRC07-523LS combination will provide levels of HIV prevention efficacy that greatly exceed those of VRC01, from 29 to 90% (that is, 7.3-fold higher efficacy). Subcutaneous administration, and the possibility of more frequent dosing, could also help maintain higher bnAb titers.</p><p>Modeling of vaccine prophylaxis versus passive infusion prophylaxis requires different considerations, because a candidate bnAb-inducing vaccine would induce a polyclonal bnAb response. Despite this difference, the approach to prediction of prevention efficacy based on serum neutralization titers against anticipated exposing viruses over time is applicable to both prevention modalities. For example, for candidate bnAb-inducing vaccines, the primary immunogenicity endpoint of a vaccine study could be the magnitude–breadth of directly measured serum ID<sub>80</sub> titers against a panel of viruses representing the antigenic distribution of strains circulating in a given geographic region/population of interest, averaged over a given follow-up period. Combining these magnitude–breadth data with antibody decay longitudinal mixed-effects models (for example, those in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Amanna, I. J., Carlson, N. E. &amp; Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007)." href="/articles/s41591-022-01953-6#ref-CR22" id="ref-link-section-d54774234e2405">22</a></sup>) would allow prediction of vaccine efficacy during the follow-up period. However, for passive antibody prophylaxis PT<sub>80</sub> would be used because the ability to accurately model bnAb concentrations over time pharmacokinetically enables effective use of this biomarker that is much easier to use than ID<sub>80</sub>.</p><p>Another key future potential application of the PT<sub>80</sub> correlate is in provisional and traditional approval decisions for bnAb combination regimens (and, later, potentially bnAb-inducing vaccines). The framework is also broadly applicable—for example, rapid adaptation of the pseudovirus-based HIV-1 neutralization assay to COVID-19 vaccine studies helped provide evidence for establishing a neutralizing antibody surrogate endpoint for COVID-19 vaccines<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022)." href="#ref-CR23" id="ref-link-section-d54774234e2418">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021)." href="#ref-CR24" id="ref-link-section-d54774234e2418_1">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021)." href="#ref-CR25" id="ref-link-section-d54774234e2418_2">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Fong, Y. et al. Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. 10.1101/2022.04.06.22272763 Preprint at 
                  https://doi.org/10.1101/2022.04.06.22272763
                  
                 (2022)." href="/articles/s41591-022-01953-6#ref-CR26" id="ref-link-section-d54774234e2421">26</a></sup>—with applications including a noninferiority, neutralization-based endpoint approach to support vaccine emergency use authorization or approval<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N. Engl. J. Med. 386, 35–46 (2022)." href="/articles/s41591-022-01953-6#ref-CR27" id="ref-link-section-d54774234e2425">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Emergency Use Authorization for Vaccines to Prevent COVID-19 (US Food and Drug Administration, 2022); 
                  https://www.fda.gov/media/142749/download
                  
                " href="/articles/s41591-022-01953-6#ref-CR28" id="ref-link-section-d54774234e2428">28</a></sup>. Moreover, our findings<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022)." href="/articles/s41591-022-01953-6#ref-CR23" id="ref-link-section-d54774234e2432">23</a></sup> are informing policy decisions (for example, on boosters) and will potentially aid design of future trials, including those of pan-coronavirus vaccines. The near-simultaneous validation of a pseudovirus-based neutralization assay for these two different pathogens (HIV-1 and SARS-CoV-2) is an exciting step forward in biomarker science, and we anticipate that our PT<sub>80</sub> correlate described here will have similar utility in the HIV prevention field.</p><p>It is important to note that immune markers can be useful as correlates of protection (that is, reliably predictive of prevention efficacy) even if they are not a mechanistic correlate of protection (defined in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Plotkin, S. A. &amp; Gilbert, P. in Plotkin’s Vaccines 7th edn (eds Plotkin, S. A. et al.) 35–40 (Elsevier, 2018)." href="/articles/s41591-022-01953-6#ref-CR29" id="ref-link-section-d54774234e2441">29</a></sup> as "the immune response that is responsible for protection"). For example, there are several approved vaccines for which a nonmechanistic correlate of protection is accepted as a surrogate endpoint for regulatory decisions<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Plotkin, S. A. &amp; Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615–1617 (2012)." href="/articles/s41591-022-01953-6#ref-CR3" id="ref-link-section-d54774234e2445">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Plotkin, S. A. &amp; Gilbert, P. in Plotkin’s Vaccines 7th edn (eds Plotkin, S. A. et al.) 35–40 (Elsevier, 2018)." href="/articles/s41591-022-01953-6#ref-CR29" id="ref-link-section-d54774234e2448">29</a></sup>. It is advantageous to use a serum marker as the correlate of protection for ease of use (for example, avoidance of invasive mucosal sampling). However, in general, for a biomarker like PT<sub>80</sub>—that is, one that statistically correlates with protection yet is measured in serum and is thus less likely to be a mechanistic correlate of protection for a sexually transmitted infection (HIV) compared with another biomarker such as PT<sub>80</sub> in mucosal tissues—it is important to study its correlation with the more mechanistic biomarker. For IV administered VRC01, strong positive associations have been reported between serum versus rectal mucosal levels<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Astronomo, R. D. et al. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. J. Clin. Invest. 
                  https://doi.org/10.1172/JCI146975
                  
                 (2021)." href="/articles/s41591-022-01953-6#ref-CR30" id="ref-link-section-d54774234e2456">30</a></sup> whereas further work with larger sample sizes may be needed to better understand the extent of correlation between serum versus vaginal mucosal levels. Further research is also needed to characterize neutralization activity in serum versus tissues of virus entry among mAb recipients.</p><p>The correlations of PT<sub>80</sub> (or PT<sub>50</sub>) with prevention efficacy in the AMP trials versus the NHP model are similar<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Burton, D. R. Amping up HIV antibodies. Science 372, 1397–1398 (2021)." href="/articles/s41591-022-01953-6#ref-CR31" id="ref-link-section-d54774234e2468">31</a></sup>, with the caveat that we estimated/modeled population-level PE as a function of PT<sub>80</sub> in the AMP trials whereas the NHP challenge models estimated/modeled per-challenge-level PE (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig3">3</a>). There has been concern that the high-dose rectal challenge NHP model, which is designed to infect all animals after one exposure, may overestimate the required titer needed to protect humans from sexual exposure to HIV, who demonstrate low per-exposure risk for infection (around 0.4–1.0%); even low-titer, repeat-dose NHP challenge models infect up to 30% of animals per challenge. However, our results suggest that the NHP model did not yield a biased overestimate. Moreover, our results caution that low-dose NHP challenge models could overestimate prevention efficacy. Nevertheless, studies of vaccinated NHP showed that protection against autologous virus requires high titers of tier 2 polyclonal neutralizing antibodies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Pauthner, M. G. et al. Vaccine-induced protection from homologous Tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers. Immunity 50, 241–252 (2019)." href="/articles/s41591-022-01953-6#ref-CR5" id="ref-link-section-d54774234e2478">5</a></sup>. This is in line with the AMP trial indicating that high titers of bnAbs are apparently required for protection. Collectively, these findings pose a major challenge to the development of HIV-1 vaccines expected to depend on stimulation of bnAb formation, and highlight a need to increase vaccine-elicited bnAb levels and improve their durability.</p><p>Two analyses of the AMP trial data—a neutralization sieve analysis and a correlate of risk analysis—mutually support the PT<sub>80</sub> biomarker as a correlate of protection and as a key biomarker for modeling predicted bnAb prevention efficacy. Neutralization sieve analysis showed that prevention efficacy decreased with increasing virus IC<sub>80</sub>, because estimated PE was 4.5-fold higher against viruses tenfold more sensitive to VRC01 neutralization (81.6% against viruses with IC<sub>80</sub> = 0.2 µg ml<sup>–1</sup> versus 16.5% against viruses with IC<sub>80</sub> = 2 µg ml<sup>–1</sup>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2498">6</a></sup>. Correlate of risk analysis estimated that HIV-1 acquisition risk of VRC01 recipients was 2.1-fold lower for every tenfold increase in VRC01 serum concentration at exposure. Our model of PE based on the PT<sub>80</sub> biomarker posits that a change in either VRC01 concentration against an exposing virus, or IC<sub>80</sub> of the exposing virus, translates to the same impact on PE—for example, increasing concentration tenfold or decreasing IC<sub>80</sub> tenfold would alter PE by the same amount. The fact that the ‘IC<sub>80</sub> effect’ of 4.5 exceeded the ‘concentration effect’ of 2.1 suggests deviation from this model. However, this result is expected if in fact the model holds, because there is uncertainty in the estimation of HIV-1 acquisition dates. The uncertainty in the actual date of infection biased the estimate of the concentration effect toward 1.0, which is so-called biasing-towards-the-null caused by random/unsystematic measurement error (for example, ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Carroll, R. J., Ruppert, D., Stefanski, L. A. &amp; Crainiceanu, C. M. Measurement Error in Nonlinear Models (Chapman and Hall/CRC, 2006)." href="/articles/s41591-022-01953-6#ref-CR32" id="ref-link-section-d54774234e2511">32</a></sup> in the statistics literature), indicating that 2.1 is an underestimate. In contrast, neutralization sieve analysis did not use estimated infection dates and thus is not subject to this attenuating bias. Therefore, the results are consistent with our model for prediction of bnAb regimen PE, which posits that PE can be improved equally by increasing either bnAb concentration or neutralization sensitivity. Note that the AMP trials did not use an LS-modified bnAb; estimations of concentrations at the true acquisition dates would be more accurate for an LS bnAb, because these have a prolonged elimination phase with serum concentrations decaying slowly.</p><p>Both IC<sub>80</sub> and VRC01 concentration varied markedly in AMP: the IC<sub>80</sub> of acquired viruses ranged from 0.07 to &gt;10 µg ml<sup>–1</sup> (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2524">6</a></sup>); the lowest observed VRC01 serum concentration was &lt;0.07 µg ml<sup>–1</sup> (the assay’s lower limit of quantification) and the highest observed concentration in the AMP trials was 278 µg ml<sup>–1</sup> (5 days post-infusion 2, 30 mg kg<sup>–1</sup> arm). This dynamic range is key for discerning correlates. However, one limitation of our analysis is that the challenges of infection timing estimation constrain the ability of the concentration correlates analysis to fully leverage concentration variability. In contrast, the fact that neutralization sieve analysis does not rely upon infection time estimation (and accounts for the full range of IC<sub>80</sub> values) renders it more sensitive for characterization of correlates than concentration correlates analysis.</p><p>A further limitation of this correlates study in regard to making progress toward validation of the PT<sub>80</sub> biomarker is that we restricted to the VRC01 antibody. Our prediction modeling of prevention efficacy for antibody regimens involving other antibodies besides VRC01 (some of which are in different epitope classes than CD4bs antibodies) assumes transportability of the PT<sub>80</sub> biomarker correlate learned from VRC01 to the PT<sub>80</sub> biomarker for other antibodies and antibody combinations. More specifically, our prevention efficacy modeling exercise assumes that the mathematical relationship of per-exposure prevention efficacy with the PT<sub>80</sub> biomarker level would be the same for other antibodies or antibody combinations. Transportability assumptions may be more credible within an epitope class than across different epitope classes.</p><p>Another limitation is that AMP studied PE and correlates for the outcome of HIV-1 diagnosis, not for infection of a single cell, which is not fully observable. Virus features (IC<sub>80</sub>, genotypes) were measured from the first available HIV RNA-positive detection in plasma. Open questions include: were viruses present in hidden compartments before detectability along with delayed seroconversion? What were their features? Did the presence of VRC01 result in subclinical acquisition of HIV?</p><p>Cumulatively, our results demonstrate the utility of the pseudovirus-based neutralization assay in infectious disease research more generally, and advance the PT<sub>80</sub> biomarker toward use as a correlate of protection for future HIV-1 bnAb combination trials or bnAb-inducing vaccine trials.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec11-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec11">Methods</h2><div class="c-article-section__content" id="Sec11-content"><h3 class="c-article__sub-heading" id="Sec12">Ethical compliance</h3><p>All work described here complied with all relevant ethical regulations. This work was approved by the Duke University Health System Institutional Review Board (Duke University) through protocol no. Pro00093087. For the National Institute for Communicable Diseases (NICD), the work was approved by the University of the Witwatersrand Human Research Ethics Committee through protocol no. M201105. All participants in the AMP trials provided written informed consent<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2570">6</a></sup>. Participants were compensated to cover relevant trial participation costs for each completed study visit.</p><h3 class="c-article__sub-heading" id="Sec13">TZM-bl target cell neutralization assay</h3><p>The TZM-bl target cell assay<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395–405 (2009)." href="/articles/s41591-022-01953-6#ref-CR34" id="ref-link-section-d54774234e2582">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125 (2005)." href="/articles/s41591-022-01953-6#ref-CR35" id="ref-link-section-d54774234e2585">35</a></sup>, which is optimized and validated<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131–146 (2014)." href="/articles/s41591-022-01953-6#ref-CR36" id="ref-link-section-d54774234e2589">36</a></sup>, was used to assess in vitro sensitivity to VRC01 (in VRC01-recipient serum samples) of HIV-1 Env-pseudotyped viruses (for brevity, we refer to HIV-1 Env-pseudotyped viruses as ‘viruses’ in the main text). Full details on pseudovirus stock preparation, the TZM-bl assay and calculation of serum neutralization titers are reported in the appendix of ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2593">6</a></sup>. A brief summary also follows below.</p><p>Using RNA samples from AMP participants who had acquired HIV-1 infection, the genomic region of the acquired HIV-1 isolate coding for the complete Env glycoprotein was sequenced and an <i>env–rev</i> cassette plasmid was synthesized by Genewiz. For production of HIV-1 Env-pseudotyped virus, 293 T/17 cells (American Type Culture Collection, no. CRL-11268) were cotransfected with <i>env</i> plasmids and an <i>env</i>-defective backbone vector (pSG3delEnv). TZM-bl target cell neutralization assays were performed in two laboratories using a common standard operating procedure. Assays for HVTN 703/HPTN 081 were performed at NICD in Johannesburg, South Africa; assays for HVTN 704/HPTN 085 were performed at Duke University. Assay equivalency has been established between NICD and Duke. Neutralization was measured as a function of reduction in luciferase reporter gene expression (due to the presence of serum VRC01) after a single round of HIV-1 Env-pseudotyped virus infection of TZM-bl target cells (obtained from National Institutes of Health (NIH) AIDS Research and Reference Reagent Program no. ARP-8129). Before assay, serum samples were heat inactivated at 56 °C for 30 min. Autologous sera were assayed against each HIV-1 Env-pseudotyped virus at a starting dilution of 1:10 using eight three-fold serial dilutions. Neutralization titers are expressed as the reciprocal dilution of serum from a VRC01 recipient at which relative luminescence units (RLU) were reduced by either 50% (ID<sub>50</sub>) or 80% (ID<sub>80</sub>) relative to virus control wells after subtraction of background RLU in cell control wells. The VRC01 drug product was used as a positive control; heat inactivation did not affect neutralization activity of the VRC01 drug product when spiked into a normal human serum sample. Data collection was performed with the Victor X Light luminometer (PerkinElmer 2030 software, instrument program v.4.00.5) at Duke up to 11 November 2020. After this date, the Glomax Navigator System luminometer was used for data collection using Glomax Navigator software (v.3.2.3, firmware v.4.92.0). At NICD, the PerkinElmer Victor X luminometer was used for data collection with PerkinElmer 2030 software (v.4).</p><p>Additional assays were performed on the VRC01 drug product (Leidos Biomedical Research, Inc./VRC-HIVMAB060-00-AB, lot no. 16-524). Neutralization titers are expressed as the concentration of the VRC01 drug product at which RLU were reduced by either 50% (IC<sub>50</sub>) or 80% (IC<sub>80</sub>) relative to virus control wells after subtraction of background RLU in cell control wells. The VRC01 drug product was assayed against each HIV-1 Env-pseudotyped virus three times, at starting concentrations of 100 and 5 μg ml<sup>–1</sup>, using eight three-fold serial dilutions. HIV-1 PVO.4 Env-pseudotyped virus was included in each assay as a positive control. VRC01 drug product stock concentrations were prepared at Duke and sent to NICD, and thus the two laboratories worked with identical material.</p><h3 class="c-article__sub-heading" id="Sec14">Binding antibody multiplex assay</h3><p>Serum VRC01 IgG levels were measured on a Bio-Plex instrument (Bio-Rad) using a qualified assay that was subsequently validated using the same conditions. The assay was designed to measure infused VRC01 by its ability to bind anti-idiotype antibody captured on fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1 Luminex assay<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449–12463 (2008)." href="#ref-CR37" id="ref-link-section-d54774234e2630">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012)." href="#ref-CR38" id="ref-link-section-d54774234e2630_1">38</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Mayer, K. H. et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial. PLoS Med. 14, e1002435 (2017)." href="/articles/s41591-022-01953-6#ref-CR39" id="ref-link-section-d54774234e2633">39</a></sup>. Bio-Plex software (Bio-Plex Manager, v.6.1) provides two readouts: a background-subtracted median fluorescent intensity (MFI), where background refers to a plate level control (that is, a blank well containing antigen-conjugated beads run on each plate) and a concentration based on a standard curve run on the same assay plate, using a five-parameter logistic (5PL) curve fit. Each sample was run in duplicate.</p><p>Clinical-grade VRC01 was titrated to create a standard curve that was used to determine the concentrations of the diluted samples. The negative controls were CH58 (Duke Protein Production Facility<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Nicely, N. I. et al. Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine 2, 713–722 (2015)." href="/articles/s41591-022-01953-6#ref-CR40" id="ref-link-section-d54774234e2640">40</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Pollara, J. et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88, 7715–7726 (2014)." href="/articles/s41591-022-01953-6#ref-CR41" id="ref-link-section-d54774234e2643">41</a></sup>) and blank beads. Samples with VRC01 concentrations &lt;0.01 μg ml<sup>–1</sup> at a dilution of 1:100 were truncated at 0.01 μg ml<sup>–1</sup> for plotting purposes. Serum samples were tested at multiple dilution factors to ensure that MFI fell within the linear range of the standard curve. Reported VRC01 serum concentration was programmatically selected as the sample dilution factor where the in-well concentration was closest to the EC<sub>50</sub> of the 5PL standard curve run on the same assay plate. All samples that tested above the upper limit of quantitation at the minimum required screening dilution were successfully titrated to fall within the linear range of the assay, to provide a reportable concentration. All samples tested with serum concentrations above the lower limit of quantitation (LLOQ) were successfully titrated to provided a reportable value. All samples with concentration values below LLOQ were repeated for confirmation. The programmatically selected concentration was confirmed across other sample-matched linear range concentration values by meeting preset 70–130% agreement criteria; the same recovery threshold applied to the standard curve and spiked controls with known concentrations.</p><h3 class="c-article__sub-heading" id="Sec15">Two-phase case-control sampling design for measurement of VRC01 serum concentrations</h3><p>All VRC01 recipient primary endpoint cases (HIV-1 diagnosis by the week 80 visit; same definition as in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2661">6</a></sup>) were sampled for measurement of VRC01 serum concentrations at all blood storage visits through to HIV-1 diagnosis. Among VRC01 recipients completing the week 88 visit without HIV-1 infection diagnosis (noncases), a stratified sample of participants was selected into a subcohort for measurement of VRC01 concentrations at all blood storage visits (baseline, every 4 weeks through to week 80, 5 days post second infusion, week 88). All sampled noncases were not likely to have used pre-exposure prophylaxis, defined for 704/085 by self-report and testing of Tenofovir drug levels from all available dried blood spot samples that were stored at all visits, and for 703/081 by self-report. The sampling was restricted to noncases that did not permanently discontinue infusions. A total of 82 noncases, approximately 50% from each trial, were sampled for concentration measurements by sampling strata defined by randomized VRC01 dose arm cross-classified by geographic region, as described in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">3</a>.</p><h3 class="c-article__sub-heading" id="Sec16">Statistics and reproducibility</h3><p>In the AMP trials, participants were randomly assigned to treatment arm as described in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e2677">6</a></sup>. Sample sizes of the two AMP trials were predetermined using a one-sided 0.025-level Wald test for comparison of log-transformed one minus cumulative incidences of HIV-1 acquisition between pooled VRC01 groups versus the control group, as described in the protocol and in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis. 
                  https://doi.org/10.1515/scid-2016-0001
                  
                 (2017)." href="/articles/s41591-022-01953-6#ref-CR42" id="ref-link-section-d54774234e2681">42</a></sup> Power calculations for the case-control study are described in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis. 
                  https://doi.org/10.1515/scid-2016-0001
                  
                 (2017)." href="/articles/s41591-022-01953-6#ref-CR42" id="ref-link-section-d54774234e2685">42</a></sup> and further studied in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Gilbert, P. B., Zhang, Y., Rudnicki, E. &amp; Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. Stat. Med. 38, 4503–4518 (2019)." href="/articles/s41591-022-01953-6#ref-CR15" id="ref-link-section-d54774234e2689">15</a></sup>.</p><p>This study utilized two sets of TZM-bl target cell HIV-1 neutralization assay results. One set was generated with a clinical lot of VRC01 and a second with autologous serum samples. Assays with the clinical lot of VRC01 were performed three times, where each time the samples were tested in duplicate wells. The three titer values were averaged on the log-transformed scale. Assays with autologous serum samples were performed once using duplicate wells. VRC01 drug product was used as a positive control in each assay run. The assay has been formally validated for accuracy, sensitivity, specificity, precision, linearity, range and robustness. For in vitro neutralization measurements (IC<sub>50</sub> or IC<sub>80</sub>), duplicate values for wells that scored at least 40% neutralization must have agreed within 30% to have passed quality control. Laboratory staff conducting the TZM-bl target cell assays were blinded to group allocation during data collection and analysis.</p><p>The binding antibody multiplex assay (BAMA) was qualified, and validation experiments using the same assay conditions were complete at the time the AMP study was performed. Additionally, qualified BAMA-derived serum VRC01 concentrations demonstrated excellent concordance with true VRC01 concentration in a blinded, HIV-1 seronegative, serum-spiked quality control reference panel (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">1</a>). Several criteria were used to determine whether data from an assay were acceptable and could be statistically analyzed. The standard curve EC<sub>50</sub> and MFI values were tracked against historical data in Levey–Jennings, and points with MFI &gt; 100 must have had a percentage coefficient of variation &lt;20% between replicates. Any sample without at least two observed concentrations in agreement with each other, or with baseline MFI &gt; 1,000, was repeated to obtain an accurate measurement.</p><p>Point estimates of HIV-1 infection time (calendar date) were calculated by blinded analysts for each participant, using the median of the Bayesian posterior distribution. For BAMA measurements, nonlinear mixed-effects models were used to analyze individual-level concentrations over time, based on data up to the visit before the last HIV-negative visit for cases and on data from all available visits for noncases, including data from six noncase participants who were purposefully sampled on the last visit before week 88, to keep the laboratory blinded to the case-control status of the samples (because all noncases would have had the full course of time points until week 88).</p><h3 class="c-article__sub-heading" id="Sec17">Statistical analyses</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec18">popPK modeling for estimation of VRC01 serum time–concentration curves</h4><p>All PK analyses considered VRC01 serum concentrations measured by BAMA at post-infusion time points, with concentration values subtracted from that observed at the baseline pre-infusion visit of the same participant. The assay LLOQ is 0.07 μg ml<sup>–1</sup>, and values less than LLOQ were replaced by LLOQ2 before baseline subtraction. Nonlinear mixed-effects models were used to analyze these individual-level concentrations over time, based on data up to the visit before the last HIV-negative visit for cases and on data from all available visits for noncases, including data from six noncase participants who were purposefully sampled at the last visit before week 88, to keep the laboratory blinded to the case-control status of the samples (because all noncases would have had the full course of time points until week 88).</p><p>VRC01 PK following IV infusion, with a more rapid decline in the distribution phase and slower decline in the elimination phase, was described by a two-compartment disposition model with first-order elimination from the central compartment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Huang, Y. et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine 64, 103203 (2021)." href="/articles/s41591-022-01953-6#ref-CR43" id="ref-link-section-d54774234e2728">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Huang, Y. et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs 9, 792–800 (2017)." href="/articles/s41591-022-01953-6#ref-CR44" id="ref-link-section-d54774234e2731">44</a></sup>. The PK model was parametrized in terms of CL, <i>V</i><sub>c</sub>, <i>Q</i> and <i>V</i><sub>p</sub>, denoting clearance from the central compartment (l d<sup>–1</sup>), volume of the central compartment (l), intercompartmental distribution clearance (l d<sup>–1</sup>) and volume of the peripheral compartment (l), respectively. An exponential between-individual random effect for CL, <i>V</i><sub>c</sub>, <i>Q</i> and <i>V</i><sub>p</sub>, as well as an exponential interinfusion-interval random effect (that is, interoccasion variability) for CL and <i>V</i><sub>p</sub>, were considered based on patterns observed in the data. In the final popPK model, trial (HVTN 704/HPTN 085 or HVTN 703/HPTN 081) and body weight were included as a predictor of <i>V</i><sub>p</sub> and CL, respectively. Further details are described in ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Huang, Y. et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine 64, 103203 (2021)." href="/articles/s41591-022-01953-6#ref-CR43" id="ref-link-section-d54774234e2771">43</a></sup> and references therein. Each VRC01 recipient’s concentrations on a daily grid, including at the estimated time of infection for cases, were estimated from the final popPK model. The point-wise 95% prediction interval of each daily grid concentration was computed as the 2.5th and 97.5th percentiles of the estimated concentrations of &gt;1,000 parametric bootstrap samples, generated via resampling of the random effects and residual errors from the final popPK model of the observed concentrations. Based on each bootstrap sample of the concentration data at the observed time points, the popPK model was refit and daily grid concentrations were estimated for each bootstrap dataset.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec19">Serum neutralization titer associated with VRC01 prevention efficacy</h4><p>Because knowing the exact day of HIV-1 acquisition (and hence VRC01 concentration on the day of acquisition) is unattainable in a clinical trial setting, for Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig3">3</a> PT<sub>80</sub> was calculated as the median observed VRC01 concentration at all mid-infusion visits across all noncases in case-control samples (19.6 µg ml<sup>–1</sup> measured by BAMA), divided by the IC<sub>80</sub> of the VRC01 drug product against the acquired virus (<i>n</i> = 162 HIV-1 cases) in both VRC01 and placebo arms from the AMP trials. The median concentration was computed based on the <i>n</i> = 82 noncase VRC01 recipients sampled for PK modeling from both dose arms and both trials. Note that the neutralization sieve analysis for Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig3">3</a> could not use individual-specific concentration estimates because the sieve method is designed to assess only how PE is dependent on a virus feature (for example, IC<sub>80</sub>), not on a feature that depends on both host and virus. The analysis was performed similarly for Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig11">5</a>, except that PT<sub>50</sub> and IC<sub>50</sub> were used in place of PT<sub>80</sub> and IC<sub>80</sub>, respectively.</p><p>The NHP estimated protection curves in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig3">3</a> were calculated from logistic regression using day-of-challenge PT<sub>80</sub> from meta-analysis of each of the datasets described in the figure (and similarly in Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig11">5</a> using day-of-challenge PT<sub>50</sub>).</p><p>In Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig4">4</a>, PT<sub>80</sub> was calculated as the estimated serum concentration for each of the 82 noncases in the case-control sample at each day of follow-up, divided by the IC<sub>80</sub> of the VRC01 drug product against the viruses acquired by placebo recipients (<i>n</i> = 19 IC<sub>80</sub> &lt; 1 µg ml<sup>–1</sup>; <i>n</i> = 10 IC<sub>80</sub> 1–3 µg ml<sup>–1</sup>; <i>n</i> = 35 IC<sub>80</sub> &gt; 3 µg ml<sup>–1</sup>). These serum concentrations in daily grid over the trial follow-up period (from day 1 to week 80 visit) were estimated based on popPK modeling of observed VRC01 concentrations for each of the 82 VRC01 recipient noncases sampled for PK modeling. Analyses were performed similarly for Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig12">6</a>, except that PT<sub>50</sub> and IC<sub>50</sub> were used in place of PT<sub>80</sub> and IC<sub>80</sub>, respectively.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec20">VRC01 serum concentration correlates analysis</h4><p>The population for analysis included all AMP participants from either trial assigned to one of the two VRC01 dose arms. A Cox model with enrollment as the time origin was used to assess the association of VRC01 serum concentration (included as a time-dependent covariate on a daily grid) with the instantaneous hazard of HIV-1 acquisition, which uses empirical inverse probability sampling weights to accommodate the case-control sampling design<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Gilbert, P. B., Zhang, Y., Rudnicki, E. &amp; Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. Stat. Med. 38, 4503–4518 (2019)." href="/articles/s41591-022-01953-6#ref-CR15" id="ref-link-section-d54774234e2881">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Lin, D. Y. On fitting Cox’s proportional hazards models to survey data. Biometrika 87, 37–47 (2000)." href="/articles/s41591-022-01953-6#ref-CR45" id="ref-link-section-d54774234e2884">45</a></sup>. Regression calibration was used to account for measurement error in estimated daily grid VRC01 concentration from the popPK model. Two covariates, trial (HVTN 704/HPTN 085 or HVTN 703/HPTN 081) and dose group (10 or 30 mg kg<sup>–1</sup>), were adjusted for in the Cox model. A nonparametric bootstrap procedure was used to estimate standard error and compute 95% CIs for the hazard ratio of HIV-1 infection per tenfold increment in the current value of VRC01 concentration. The bootstrap-based percentiles on a grid of coverage levels were inverted to compute a two-sided <i>P</i> value for whether VRC01 concentration correlated with the instantaneous hazard of HIV-1 acquisition.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec21">Calculations to support the premise that the VRC01 serum concentration correlate of risk result is consistent with the observed VRC01 dose effect on HIV-1 acquisition</h4><p>The 30 mg kg<sup>–1</sup> arm had 23% improved efficacy compared with the 10 mg kg<sup>–1</sup> arm, calculated as follows:</p><div id="Equa" class="c-article-equation"><div class="c-article-equation__content"><span class="mathjax-tex">$${{{\mathrm{PE}}}}\,{{{\mathrm{of}}}}\,29\% \,{{{\mathrm{and}}}}\,8\% \,(23\% = \left( {1-\left( {1 - 0.29} \right)/\left( {1 - 0.08} \right)} \right) \times 100\% ).$$</span></div></div><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec22">PT<sub>80</sub> against autologous acquired virus analysis</h4><p>The ‘marker method’ of Gilbert et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Gilbert, P. B., Zhang, Y., Rudnicki, E. &amp; Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. Stat. Med. 38, 4503–4518 (2019)." href="/articles/s41591-022-01953-6#ref-CR15" id="ref-link-section-d54774234e3024">15</a></sup> was applied to assess whether PT<sub>80</sub> against the autologous acquired virus at acquisition tended to be low compared with PT<sub>80</sub> against placebo viruses, assuming that exposures had occurred uniformly over the 80-week follow-up period. The results are shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig5">5b</a>. For each VRC01 case, the PT<sub>80</sub> against their autologous acquired virus at acquisition was calculated in three steps: (1) estimation of the time–concentration curve for each case from a popPK model<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Huang, Y. et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine 64, 103203 (2021)." href="/articles/s41591-022-01953-6#ref-CR43" id="ref-link-section-d54774234e3038">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Huang, Y. et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs 9, 792–800 (2017)." href="/articles/s41591-022-01953-6#ref-CR44" id="ref-link-section-d54774234e3041">44</a></sup> over a daily grid spanning all possible dates of HIV acquisition; (2) averaging of (log-transformed) daily concentrations weighted by the Bayesian posterior distribution of daily probabilities of HIV acquisition over the entire grid; and (3) dividing this aggregated concentration in step 2 by the IC<sub>80</sub> of the VRC01 drug product against their acquired virus (Huang et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. J. Acquir Immune Defic. Syndr. 83, 434–439 (2020)." href="/articles/s41591-022-01953-6#ref-CR11" id="ref-link-section-d54774234e3047">11</a></sup>, approach 2). For each VRC01 recipient noncase, we calculated their median estimated VRC01 serum concentration over follow-up (estimated on a daily grid from day 1 to the week 80 visit from the PK model), which represents the most typical VRC01 concentration that would occur at the time of HIV-1 exposure. We then divided this median VRC01 serum concentration by the geometric mean VRC01 IC<sub>80</sub> of the viruses acquired by placebo recipients in the AMP trial, which is a typical value of PT<sub>80</sub> against a given exposing virus assuming that HIV-1 exposure follows a uniform distribution over the trial follow-up period (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig8">2</a>).</p><p>The geometric mean PT<sub>80</sub> values among cases and the geometric mean of those typical PT<sub>80</sub> values among noncases were calculated with the standard errors estimated by the bootstrap procedure described earlier for daily grid serum concentrations. From these estimates, Wald-based 95% CIs were computed; bootstrap-based percentiles on a grid of coverage levels were inverted to compute a two-sided <i>P</i> value. The analysis was performed for the AMP trials pooled, for the two VRC01 dose arms pooled and for each individual VRC01 dose arm.</p><p>Analyses were performed similarly for Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig13">7</a>, except that PT<sub>50</sub> and IC<sub>50</sub> were used in place of PT<sub>80</sub> and IC<sub>80</sub>, respectively.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec23">Neutralization coverage of combination bnAbs</h4><p>In Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig6">6a–d</a>, steady state of a repeated bnAb administration regimen is considered to be reached when the rate of bnAb input is equal to the rate of bnAb elimination and consequently serum concentration–time levels remain the same over continuing cycles. For each single bnAb, a virus exposure was considered neutralized (covered) if PT<sub>80</sub> (calculated as PK modeled concentration divided by virus IC<sub>80</sub>) exceeded 200. In Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig14">8</a>, this threshold was defined as when PT<sub>50</sub> (calculated as PK modeled concentration divided by virus IC<sub>50</sub>) exceeded 600. Coverage was computed assuming that exposures to HIV-1 follow a uniform distribution over the 16- or 24-week period post-infusion that is considered.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec24">Predicted prevention efficacy of combination bnAbs</h4><p>The prediction of PE for the triple-bnAb combination, PGDM1400LS + PGT121LS + VRC07-523LS, was carried out in four steps. First, serum concentration of each single bnAb over time (16 or 24 weeks in steady state) was predicted based on the popPK model of each single bnAb assuming an extended half-life of the LS-version bnAb over the parental form as described earlier. Second, the corresponding PT<sub>50</sub> and PT<sub>80</sub> values of each bnAb against either the panel of viruses acquired by 703/081 placebo recipients or the panel of viruses acquired by 704/085 recipients were calculated using the predicted serum concentration obtained in step 1 divided by the IC<sub>50</sub> and IC<sub>80</sub>, respectively, of each virus. Third, the PT<sub>50</sub> and PT<sub>80</sub> values of the combination bnAb regimen against each virus were calculated assuming a Bliss–Hill interaction model<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Comput. Biol. 18, e1010003 (2022)." href="/articles/s41591-022-01953-6#ref-CR10" id="ref-link-section-d54774234e3126">10</a></sup> (Supplementary Note <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">1</a>). Similar results were obtained by assuming an additive interaction model (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">2</a>). Last, the PE of the combination bnAb over time was predicted based on more conservative protection-by-PT<sub>50</sub> curves and protection-by-PT<sub>80</sub> curves than those shown in Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig11">5</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01953-6#Fig3">3</a>, respectively, assuming the PT<sub>50</sub> or PT<sub>80</sub> value needed for a fixed level of protection is twofold higher in human than in NHP set C (that is, shifting the NHP set C curves to the right by twofold).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec25">Estimation of HIV-1 acquisition dates</h4><p>Point estimates of HIV-1 infection time (calendar date) were calculated by blinded analysts for each participant, using the median of the Bayesian posterior distribution. This was computed by independent combination of the estimated posterior distributions of infection date after conditioning on: (1) diagnostic curves, as described in Grebe et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Grebe, E. et al. Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. BMC Infect. Dis. 19, 894 (2019)." href="/articles/s41591-022-01953-6#ref-CR14" id="ref-link-section-d54774234e3159">14</a></sup> for the infection dating tool method, by a combination of window period distributions (defined in Pilcher et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Pilcher, C. D. et al. A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results. AIDS 33, 1231–1240 (2019)." href="/articles/s41591-022-01953-6#ref-CR46" id="ref-link-section-d54774234e3163">46</a></sup>) of last negative and first positive HIV-1 diagnostic tests; and (2) the distribution of pairwise Hamming distances (as described in Giorgi et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Giorgi, E. E. et al. Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model. BMC Bioinformatics 11, 532 (2010)." href="/articles/s41591-022-01953-6#ref-CR13" id="ref-link-section-d54774234e3167">13</a></sup> for the Poisson Fitter method), calculated from nucleotide sequence data obtained from the first available HIV-positive samples, following the steps listed in Supplementary Note <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">2</a> (i–vii) for sequence-based timing estimates. We also employed Bayesian posterior estimates of infection time by day to assess the probability that the infection occurred in the first 4 weeks after an infusion. These were also used to describe 95% credible regions for the time since infection in the process described in Supplementary Note <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">2</a>.</p><p>Our approach employed Bayesian procedures to combine independent inputs from three data sources: diagnostics timing estimators, <i>gag–pol</i>-based sequence timing estimators and <i>rev–env–nef</i>-based sequence timing estimators. The sequence-based estimates were first fit using the frequentist methodology implemented in Poisson Fitter by employing the steps described below, with the aim of optimizing the estimate of infection time. These Poisson Fitter estimates were then converted to corresponding Bayesian Poisson process regression models to yield probability assessments for incorporation into downstream analyses, maintaining high concordance in both point estimates and uncertainty intervals across the Bayesian and frequentist implementations. When the two sequenced regions yielded distinct time estimates (that is, the 95% posterior credible intervals did not overlap), the <i>gag–pol</i> region was chosen for the final time estimate since it does not encode proteins targeted by the VRC01 bnAb, and therefore the rates of evolution over this region of the viral genome may be impacted to a lesser extent by targeted selection.</p><p>The process of running Poisson Fitter 2.0 included production of separate timing estimates for each curated first time point alignment for the two sequenced regions and then integrating the outputs downstream. Only the first time point sequences were used for the primary analysis, except for cases in which the first time point yielded fewer than five sequences; in such cases, the second available time points were analyzed instead. For each sequenced sample, we created Poisson Fitter estimates and then corresponding Bayesian posterior estimates of time since infection, given (1) <i>gag–pol</i> and (2) <i>rev–env–nef</i> region alignments. The process is described in further detail in Supplementary Note <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM1">2</a>.</p><h3 class="c-article__sub-heading" id="Sec26">Reporting summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01953-6#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>The data underlying the findings of this manuscript are publicly available at the public-facing HVTN website (<a href="https://atlas.scharp.org/cpas/project/HVTN%20Public%20Data/begin.view?">https://atlas.scharp.org/cpas/project/HVTN%20Public%20Data/begin.view?</a>). All individual participant data have been deidentified. The GenBank accession numbers for the HIV-1 Env clones used in the TZM-bl target cell neutralization assay are: HVTN 704/HPTN 085 sequences, ON980814–ON980967; HVTN 703/HPTN 081 sequences, ON890939–ON891092.</p>
            </div></div></section><section data-title="Code availability"><div class="c-article-section" id="code-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="code-availability">Code availability</h2><div class="c-article-section__content" id="code-availability-content">
              
              <p>Code implementation methods described in Gilbert et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Gilbert, P. B., Zhang, Y., Rudnicki, E. &amp; Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. Stat. Med. 38, 4503–4518 (2019)." href="/articles/s41591-022-01953-6#ref-CR15" id="ref-link-section-d54774234e3331">15</a></sup> are publicly available at <a href="http://faculty.washington.edu/peterg/programs.html?">http://faculty.washington.edu/peterg/programs.html?</a> All other code implementing the methods used to generate the figures and tables of this work is available at Github (<a href="https://github.com/HVTN-SDMC/AMP_NeutTiterBiomarker">https://github.com/HVTN-SDMC/AMP_NeutTiterBiomarker</a>). Instructions for installation and use are given in the accompanying README file.</p>
            </div></div></section><section data-title="Change history"><div class="c-article-section" id="change-history-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="change-history">Change history</h2><div class="c-article-section__content" id="change-history-content"><ul class="c-article-change-list"><li class="c-article-change-list__item u-mb-24" id="chg1"><ins datetime="2022-10-03"><h3 class="c-article-change-list__heading u-h3 u-pr-8 u-display-inline">03 October 2022</h3><div class="c-article-change-list__details"><p>In the version of this article initially published, there was a typo in the abstract, where in the text now reading, in part, “Based on this result, we suggest that the goal of sustained PT<sub>80</sub> &gt;200 against 90% of circulating viruses can be achieved...,” the greater than symbol appeared originally as less than. The change has been made in the HTML and PDF version of the article.</p></div></ins></li></ul></div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Plotkin, S. A. Correlates of protection induced by vaccination. <i>Clin. Vaccin. Immunol.</i> <b>17</b>, 1055–1065 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1128/CVI.00131-10" data-track-item_id="10.1128/CVI.00131-10" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1128%2FCVI.00131-10" aria-label="Article reference 1" data-doi="10.1128/CVI.00131-10">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFGitro%3D" aria-label="CAS reference 1">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Correlates%20of%20protection%20induced%20by%20vaccination&amp;journal=Clin.%20Vaccin.%20Immunol.&amp;doi=10.1128%2FCVI.00131-10&amp;volume=17&amp;pages=1055-1065&amp;publication_year=2010&amp;author=Plotkin%2CSA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Bekker, L. G. et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet</i> <b>395</b>, 384–388 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(19)32682-0" data-track-item_id="10.1016/S0140-6736(19)32682-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2819%2932682-0" aria-label="Article reference 2" data-doi="10.1016/S0140-6736(19)32682-0">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20complex%20challenges%20of%20HIV%20vaccine%20development%20require%20renewed%20and%20expanded%20global%20commitment&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2819%2932682-0&amp;volume=395&amp;pages=384-388&amp;publication_year=2020&amp;author=Bekker%2CLG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Plotkin, S. A. &amp; Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. <i>Clin. Infect. Dis.</i> <b>54</b>, 1615–1617 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/cid/cis238" data-track-item_id="10.1093/cid/cis238" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fcid%2Fcis238" aria-label="Article reference 3" data-doi="10.1093/cid/cis238">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Nomenclature%20for%20immune%20correlates%20of%20protection%20after%20vaccination&amp;journal=Clin.%20Infect.%20Dis.&amp;doi=10.1093%2Fcid%2Fcis238&amp;volume=54&amp;pages=1615-1617&amp;publication_year=2012&amp;author=Plotkin%2CSA&amp;author=Gilbert%2CPB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. <i>Cell Host Microbe</i> <b>26</b>, 336–346 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.chom.2019.08.014" data-track-item_id="10.1016/j.chom.2019.08.014" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.chom.2019.08.014" aria-label="Article reference 4" data-doi="10.1016/j.chom.2019.08.014">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslyis77L" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20meta-analysis%20of%20passive%20immunization%20studies%20shows%20that%20serum-neutralizing%20antibody%20titer%20associates%20with%20protection%20against%20SHIV%20challenge&amp;journal=Cell%20Host%20Microbe&amp;doi=10.1016%2Fj.chom.2019.08.014&amp;volume=26&amp;pages=336-346&amp;publication_year=2019&amp;author=Pegu%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Pauthner, M. G. et al. Vaccine-induced protection from homologous Tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers. <i>Immunity</i> <b>50</b>, 241–252 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2018.11.011" data-track-item_id="10.1016/j.immuni.2018.11.011" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2018.11.011" aria-label="Article reference 5" data-doi="10.1016/j.immuni.2018.11.011">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVygtr%2FF" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccine-induced%20protection%20from%20homologous%20Tier%202%20SHIV%20challenge%20in%20nonhuman%20primates%20depends%20on%20serum-neutralizing%20antibody%20titers&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.11.011&amp;volume=50&amp;pages=241-252&amp;publication_year=2019&amp;author=Pauthner%2CMG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. <i>N. Engl. J. Med.</i> <b>384</b>, 1003–1014 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2031738" data-track-item_id="10.1056/NEJMoa2031738" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2031738" aria-label="Article reference 6" data-doi="10.1056/NEJMoa2031738">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXntVWlurw%3D" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Two%20randomized%20trials%20of%20neutralizing%20antibodies%20to%20prevent%20HIV-1%20acquisition&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2031738&amp;volume=384&amp;pages=1003-1014&amp;publication_year=2021&amp;author=Corey%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection. <i>PLoS Pathog.</i> <b>12</b>, e1005520 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.ppat.1005520" data-track-item_id="10.1371/journal.ppat.1005520" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.ppat.1005520" aria-label="Article reference 7" data-doi="10.1371/journal.ppat.1005520">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Optimal%20combinations%20of%20broadly%20neutralizing%20antibodies%20for%20prevention%20and%20treatment%20of%20HIV-1%20Clade%20C%20infection&amp;journal=PLoS%20Pathog.&amp;doi=10.1371%2Fjournal.ppat.1005520&amp;volume=12&amp;publication_year=2016&amp;author=Wagh%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Wagh, K. et al. Potential of conventional &amp; bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C &amp; D infections. <i>PLoS Pathog.</i> <b>14</b>, e1006860 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.ppat.1006860" data-track-item_id="10.1371/journal.ppat.1006860" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.ppat.1006860" aria-label="Article reference 8" data-doi="10.1371/journal.ppat.1006860">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Potential%20of%20conventional%20%26%20bispecific%20broadly%20neutralizing%20antibodies%20for%20prevention%20of%20HIV-1%20subtype%20A%2C%20C%20%26%20D%20infections&amp;journal=PLoS%20Pathog.&amp;doi=10.1371%2Fjournal.ppat.1006860&amp;volume=14&amp;publication_year=2018&amp;author=Wagh%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Reeves, D. B. et al. Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Comput. Biol.</i> <b>16</b>, e1007626 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pcbi.1007626" data-track-item_id="10.1371/journal.pcbi.1007626" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pcbi.1007626" aria-label="Article reference 9" data-doi="10.1371/journal.pcbi.1007626">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXovFSqu7o%3D" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Mathematical%20modeling%20to%20reveal%20breakthrough%20mechanisms%20in%20the%20HIV%20Antibody%20Mediated%20Prevention%20%28AMP%29%20trials&amp;journal=PLoS%20Comput.%20Biol.&amp;doi=10.1371%2Fjournal.pcbi.1007626&amp;volume=16&amp;publication_year=2020&amp;author=Reeves%2CDB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. <i>PLoS Comput. Biol.</i> <b>18</b>, e1010003 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pcbi.1010003" data-track-item_id="10.1371/journal.pcbi.1010003" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pcbi.1010003" aria-label="Article reference 10" data-doi="10.1371/journal.pcbi.1010003">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1CjsrfE" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Optimizing%20clinical%20dosing%20of%20combination%20broadly%20neutralizing%20antibodies%20for%20HIV%20prevention&amp;journal=PLoS%20Comput.%20Biol.&amp;doi=10.1371%2Fjournal.pcbi.1010003&amp;volume=18&amp;publication_year=2022&amp;author=Mayer%2CBT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. <i>J. Acquir Immune Defic. Syndr.</i> <b>83</b>, 434–439 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/QAI.0000000000002272" data-track-item_id="10.1097/QAI.0000000000002272" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2FQAI.0000000000002272" aria-label="Article reference 11" data-doi="10.1097/QAI.0000000000002272">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Brief%20report%3A%20prediction%20of%20serum%20HIV-1%20neutralization%20titers%20after%20passive%20administration%20of%20VRC01&amp;journal=J.%20Acquir%20Immune%20Defic.%20Syndr.&amp;doi=10.1097%2FQAI.0000000000002272&amp;volume=83&amp;pages=434-439&amp;publication_year=2020&amp;author=Huang%2CY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Huang, Y. et al. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Hum. Vaccines Immunother.</i> <a href="https://doi.org/10.1080/21645515.2021.1908030" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1080/21645515.2021.1908030">https://doi.org/10.1080/21645515.2021.1908030</a> (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Giorgi, E. E. et al. Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model. <i>BMC Bioinformatics</i> <b>11</b>, 532 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/1471-2105-11-532" data-track-item_id="10.1186/1471-2105-11-532" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/1471-2105-11-532" aria-label="Article reference 13" data-doi="10.1186/1471-2105-11-532">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Estimating%20time%20since%20infection%20in%20early%20homogeneous%20HIV-1%20samples%20using%20a%20Poisson%20model&amp;journal=BMC%20Bioinformatics&amp;doi=10.1186%2F1471-2105-11-532&amp;volume=11&amp;publication_year=2010&amp;author=Giorgi%2CEE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Grebe, E. et al. Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. <i>BMC Infect. Dis.</i> <b>19</b>, 894 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12879-019-4543-9" data-track-item_id="10.1186/s12879-019-4543-9" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12879-019-4543-9" aria-label="Article reference 14" data-doi="10.1186/s12879-019-4543-9">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Interpreting%20HIV%20diagnostic%20histories%20into%20infection%20time%20estimates%3A%20analytical%20framework%20and%20online%20tool&amp;journal=BMC%20Infect.%20Dis.&amp;doi=10.1186%2Fs12879-019-4543-9&amp;volume=19&amp;publication_year=2019&amp;author=Grebe%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Gilbert, P. B., Zhang, Y., Rudnicki, E. &amp; Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. <i>Stat. Med.</i> <b>38</b>, 4503–4518 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/sim.8310" data-track-item_id="10.1002/sim.8310" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fsim.8310" aria-label="Article reference 15" data-doi="10.1002/sim.8310">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Assessing%20pharmacokinetic%20marker%20correlates%20of%20outcome%2C%20with%20application%20to%20antibody%20prevention%20efficacy%20trials&amp;journal=Stat.%20Med.&amp;doi=10.1002%2Fsim.8310&amp;volume=38&amp;pages=4503-4518&amp;publication_year=2019&amp;author=Gilbert%2CPB&amp;author=Zhang%2CY&amp;author=Rudnicki%2CE&amp;author=Huang%2CY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Karuna, S. T. &amp; Corey, L. Broadly neutralizing antibodies for HIV prevention. <i>Annu. Rev. Med.</i> <b>71</b>, 329–346 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1146/annurev-med-110118-045506" data-track-item_id="10.1146/annurev-med-110118-045506" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1146%2Fannurev-med-110118-045506" aria-label="Article reference 16" data-doi="10.1146/annurev-med-110118-045506">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslWnsrw%3D" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Broadly%20neutralizing%20antibodies%20for%20HIV%20prevention&amp;journal=Annu.%20Rev.%20Med.&amp;doi=10.1146%2Fannurev-med-110118-045506&amp;volume=71&amp;pages=329-346&amp;publication_year=2020&amp;author=Karuna%2CST&amp;author=Corey%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Stephenson, K. E., Wagh, K., Korber, B. &amp; Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. <i>Annu. Rev. Immunol.</i> <b>38</b>, 673–703 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1146/annurev-immunol-080219-023629" data-track-item_id="10.1146/annurev-immunol-080219-023629" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1146%2Fannurev-immunol-080219-023629" aria-label="Article reference 17" data-doi="10.1146/annurev-immunol-080219-023629">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXotVGgtLw%3D" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccines%20and%20broadly%20neutralizing%20antibodies%20for%20HIV-1%20prevention&amp;journal=Annu.%20Rev.%20Immunol.&amp;doi=10.1146%2Fannurev-immunol-080219-023629&amp;volume=38&amp;pages=673-703&amp;publication_year=2020&amp;author=Stephenson%2CKE&amp;author=Wagh%2CK&amp;author=Korber%2CB&amp;author=Barouch%2CDH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nat. Med</i>. <b>28</b>, 1288–1296 (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nat. Med.</i> <b>27</b>, 1718–1724 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-021-01509-0" data-track-item_id="10.1038/s41591-021-01509-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-021-01509-0" aria-label="Article reference 19" data-doi="10.1038/s41591-021-01509-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1WqtrrE" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%20and%20antiviral%20activity%20of%20PGT121%2C%20a%20broadly%20neutralizing%20monoclonal%20antibody%20against%20HIV-1%3A%20a%20randomized%2C%20placebo-controlled%2C%20phase%201%20clinical%20trial&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01509-0&amp;volume=27&amp;pages=1718-1724&amp;publication_year=2021&amp;author=Stephenson%2CKE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults. <i>PLoS Med.</i> <b>15</b>, e1002493 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pmed.1002493" data-track-item_id="10.1371/journal.pmed.1002493" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pmed.1002493" aria-label="Article reference 20" data-doi="10.1371/journal.pmed.1002493">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20pharmacokinetics%20of%20the%20Fc-modified%20HIV-1%20human%20monoclonal%20antibody%20VRC01LS%3A%20a%20Phase%201%20open-label%20clinical%20trial%20in%20healthy%20adults&amp;journal=PLoS%20Med.&amp;doi=10.1371%2Fjournal.pmed.1002493&amp;volume=15&amp;publication_year=2018&amp;author=Gaudinski%2CMR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Cohen, Y. Z. et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study. <i>PLoS ONE</i> <b>14</b>, e0219142 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0219142" data-track-item_id="10.1371/journal.pone.0219142" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0219142" aria-label="Article reference 21" data-doi="10.1371/journal.pone.0219142">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvFamtLvO" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%2C%20and%20immunogenicity%20of%20the%20combination%20of%20the%20broadly%20neutralizing%20anti-HIV-1%20antibodies%203BNC117%20and%2010-1074%20in%20healthy%20adults%3A%20a%20randomized%2C%20phase%201%20study&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0219142&amp;volume=14&amp;publication_year=2019&amp;author=Cohen%2CYZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Amanna, I. J., Carlson, N. E. &amp; Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. <i>N. Engl. J. Med.</i> <b>357</b>, 1903–1915 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa066092" data-track-item_id="10.1056/NEJMoa066092" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa066092" aria-label="Article reference 22" data-doi="10.1056/NEJMoa066092">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXht1ymtbjI" aria-label="CAS reference 22">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Duration%20of%20humoral%20immunity%20to%20common%20viral%20and%20vaccine%20antigens&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa066092&amp;volume=357&amp;pages=1903-1915&amp;publication_year=2007&amp;author=Amanna%2CIJ&amp;author=Carlson%2CNE&amp;author=Slifka%2CMK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> <b>375</b>, 43–50 (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nat. Med.</i> <b>27</b>, 1205–1211 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-021-01377-8" data-track-item_id="10.1038/s41591-021-01377-8" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-021-01377-8" aria-label="Article reference 24" data-doi="10.1038/s41591-021-01377-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtFSktLrP" aria-label="CAS reference 24">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Neutralizing%20antibody%20levels%20are%20highly%20predictive%20of%20immune%20protection%20from%20symptomatic%20SARS-CoV-2%20infection&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01377-8&amp;volume=27&amp;pages=1205-1211&amp;publication_year=2021&amp;author=Khoury%2CDS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. <i>Vaccine</i> <b>39</b>, 4423–4428 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.vaccine.2021.05.063" data-track-item_id="10.1016/j.vaccine.2021.05.063" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.vaccine.2021.05.063" aria-label="Article reference 25" data-doi="10.1016/j.vaccine.2021.05.063">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsV2ltrrK" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Evidence%20for%20antibody%20as%20a%20protective%20correlate%20for%20COVID-19%20vaccines&amp;journal=Vaccine&amp;doi=10.1016%2Fj.vaccine.2021.05.063&amp;volume=39&amp;pages=4423-4428&amp;publication_year=2021&amp;author=Earle%2CKA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Fong, Y. et al. Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. 10.1101/2022.04.06.22272763 Preprint at <a href="https://doi.org/10.1101/2022.04.06.22272763" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1101/2022.04.06.22272763">https://doi.org/10.1101/2022.04.06.22272763</a> (2022).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. <i>N. Engl. J. Med.</i> <b>386</b>, 35–46 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2116298" data-track-item_id="10.1056/NEJMoa2116298" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2116298" aria-label="Article reference 27" data-doi="10.1056/NEJMoa2116298">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhtFalsbk%3D" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20the%20BNT162b2%20Covid-19%20vaccine%20in%20children%205%20to%2011%20years%20of%20age&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2116298&amp;volume=386&amp;pages=35-46&amp;publication_year=2022&amp;author=Walter%2CEB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28"><i>Emergency Use Authorization for Vaccines to Prevent COVID-19</i> (US Food and Drug Administration, 2022); <a href="https://www.fda.gov/media/142749/download" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://www.fda.gov/media/142749/download">https://www.fda.gov/media/142749/download</a></p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Plotkin, S. A. &amp; Gilbert, P. in <i>Plotkin’s Vaccines</i> 7th edn (eds Plotkin, S. A. et al.) 35–40 (Elsevier, 2018).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Astronomo, R. D. et al. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>J. Clin. Invest.</i> <a href="https://doi.org/10.1172/JCI146975" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1172/JCI146975">https://doi.org/10.1172/JCI146975</a> (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Burton, D. R. Amping up HIV antibodies. <i>Science</i> <b>372</b>, 1397–1398 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.abf5376" data-track-item_id="10.1126/science.abf5376" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.abf5376" aria-label="Article reference 31" data-doi="10.1126/science.abf5376">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsVCmsLjJ" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Amping%20up%20HIV%20antibodies&amp;journal=Science&amp;doi=10.1126%2Fscience.abf5376&amp;volume=372&amp;pages=1397-1398&amp;publication_year=2021&amp;author=Burton%2CDR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Carroll, R. J., Ruppert, D., Stefanski, L. A. &amp; Crainiceanu, C. M. <i>Measurement Error in Nonlinear Models</i> (Chapman and Hall/CRC, 2006).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. <i>Biometrics</i> <b>45</b>, 255–268 (1989).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.2307/2532051" data-track-item_id="10.2307/2532051" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.2307%2F2532051" aria-label="Article reference 33" data-doi="10.2307/2532051">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaL1M3kslKrtg%3D%3D" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20concordance%20correlation%20coefficient%20to%20evaluate%20reproducibility&amp;journal=Biometrics&amp;doi=10.2307%2F2532051&amp;volume=45&amp;pages=255-268&amp;publication_year=1989&amp;author=Lin%2CLI">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. <i>Methods Mol. Biol.</i> <b>485</b>, 395–405 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/978-1-59745-170-3_26" data-track-item_id="10.1007/978-1-59745-170-3_26" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/978-1-59745-170-3_26" aria-label="Article reference 34" data-doi="10.1007/978-1-59745-170-3_26">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsV2ksbY%3D" aria-label="CAS reference 34">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Measuring%20HIV%20neutralization%20in%20a%20luciferase%20reporter%20gene%20assay&amp;journal=Methods%20Mol.%20Biol.&amp;doi=10.1007%2F978-1-59745-170-3_26&amp;volume=485&amp;pages=395-405&amp;publication_year=2009&amp;author=Montefiori%2CDC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. <i>J. Virol.</i> <b>79</b>, 10108–10125 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1128/JVI.79.16.10108-10125.2005" data-track-item_id="10.1128/JVI.79.16.10108-10125.2005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1128%2FJVI.79.16.10108-10125.2005" aria-label="Article reference 35" data-doi="10.1128/JVI.79.16.10108-10125.2005">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXntFCrtL8%3D" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Human%20immunodeficiency%20virus%20type%201%20env%20clones%20from%20acute%20and%20early%20subtype%20B%20infections%20for%20standardized%20assessments%20of%20vaccine-elicited%20neutralizing%20antibodies&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.79.16.10108-10125.2005&amp;volume=79&amp;pages=10108-10125&amp;publication_year=2005&amp;author=Li%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. <i>J. Immunol. Methods</i> <b>409</b>, 131–146 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jim.2013.11.022" data-track-item_id="10.1016/j.jim.2013.11.022" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jim.2013.11.022" aria-label="Article reference 36" data-doi="10.1016/j.jim.2013.11.022">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXisVKgug%3D%3D" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Optimization%20and%20validation%20of%20the%20TZM-bl%20assay%20for%20standardized%20assessments%20of%20neutralizing%20antibodies%20against%20HIV-1&amp;journal=J.%20Immunol.%20Methods&amp;doi=10.1016%2Fj.jim.2013.11.022&amp;volume=409&amp;pages=131-146&amp;publication_year=2014&amp;author=Sarzotti-Kelsoe%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. <i>J. Virol.</i> <b>82</b>, 12449–12463 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1128/JVI.01708-08" data-track-item_id="10.1128/JVI.01708-08" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1128%2FJVI.01708-08" aria-label="Article reference 37" data-doi="10.1128/JVI.01708-08">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsVymsL3J" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Initial%20B-cell%20responses%20to%20transmitted%20human%20immunodeficiency%20virus%20type%201%3A%20virion-binding%20immunoglobulin%20M%20%28IgM%29%20and%20IgG%20antibodies%20followed%20by%20plasma%20anti-gp41%20antibodies%20with%20ineffective%20control%20of%20initial%20viremia&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.01708-08&amp;volume=82&amp;pages=12449-12463&amp;publication_year=2008&amp;author=Tomaras%2CGD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. <i>N. Engl. J. Med.</i> <b>366</b>, 1275–1286 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1113425" data-track-item_id="10.1056/NEJMoa1113425" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1113425" aria-label="Article reference 38" data-doi="10.1056/NEJMoa1113425">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XlsVSmtL4%3D" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Immune-correlates%20analysis%20of%20an%20HIV-1%20vaccine%20efficacy%20trial&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1113425&amp;volume=366&amp;pages=1275-1286&amp;publication_year=2012&amp;author=Haynes%2CBF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Mayer, K. H. et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial. <i>PLoS Med.</i> <b>14</b>, e1002435 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pmed.1002435" data-track-item_id="10.1371/journal.pmed.1002435" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pmed.1002435" aria-label="Article reference 39" data-doi="10.1371/journal.pmed.1002435">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%2C%20and%20immunological%20activities%20of%20multiple%20intravenous%20or%20subcutaneous%20doses%20of%20an%20anti-HIV%20monoclonal%20antibody%2C%20VRC01%2C%20administered%20to%20HIV-uninfected%20adults%3A%20results%20of%20a%20phase%201%20randomized%20trial&amp;journal=PLoS%20Med.&amp;doi=10.1371%2Fjournal.pmed.1002435&amp;volume=14&amp;publication_year=2017&amp;author=Mayer%2CKH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Nicely, N. I. et al. Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> <b>2</b>, 713–722 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ebiom.2015.06.016" data-track-item_id="10.1016/j.ebiom.2015.06.016" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ebiom.2015.06.016" aria-label="Article reference 40" data-doi="10.1016/j.ebiom.2015.06.016">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Structural%20analysis%20of%20the%20unmutated%20ancestor%20of%20the%20HIV-1%20envelope%20V2%20region%20antibody%20CH58%20isolated%20from%20an%20RV144%20vaccine%20efficacy%20trial%20vaccinee&amp;journal=EBioMedicine&amp;doi=10.1016%2Fj.ebiom.2015.06.016&amp;volume=2&amp;pages=713-722&amp;publication_year=2015&amp;author=Nicely%2CNI">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Pollara, J. et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. <i>J. Virol.</i> <b>88</b>, 7715–7726 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1128/JVI.00156-14" data-track-item_id="10.1128/JVI.00156-14" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1128%2FJVI.00156-14" aria-label="Article reference 41" data-doi="10.1128/JVI.00156-14">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=HIV-1%20vaccine-induced%20C1%20and%20V2%20Env-specific%20antibodies%20synergize%20for%20increased%20antiviral%20activities&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.00156-14&amp;volume=88&amp;pages=7715-7726&amp;publication_year=2014&amp;author=Pollara%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. <i>Stat. Commun. Infect. Dis.</i> <a href="https://doi.org/10.1515/scid-2016-0001" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1515/scid-2016-0001">https://doi.org/10.1515/scid-2016-0001</a> (2017).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Huang, Y. et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> <b>64</b>, 103203 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ebiom.2020.103203" data-track-item_id="10.1016/j.ebiom.2020.103203" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ebiom.2020.103203" aria-label="Article reference 43" data-doi="10.1016/j.ebiom.2020.103203">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXotlOmurk%3D" aria-label="CAS reference 43">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Pharmacokinetics%20and%20predicted%20neutralisation%20coverage%20of%20VRC01%20in%20HIV-uninfected%20participants%20of%20the%20Antibody%20Mediated%20Prevention%20%28AMP%29%20trials&amp;journal=EBioMedicine&amp;doi=10.1016%2Fj.ebiom.2020.103203&amp;volume=64&amp;publication_year=2021&amp;author=Huang%2CY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Huang, Y. et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> <b>9</b>, 792–800 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1080/19420862.2017.1311435" data-track-item_id="10.1080/19420862.2017.1311435" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1080%2F19420862.2017.1311435" aria-label="Article reference 44" data-doi="10.1080/19420862.2017.1311435">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXos1akt7w%3D" aria-label="CAS reference 44">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Population%20pharmacokinetics%20analysis%20of%20VRC01%2C%20an%20HIV-1%20broadly%20neutralizing%20monoclonal%20antibody%2C%20in%20healthy%20adults&amp;journal=MAbs&amp;doi=10.1080%2F19420862.2017.1311435&amp;volume=9&amp;pages=792-800&amp;publication_year=2017&amp;author=Huang%2CY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Lin, D. Y. On fitting Cox’s proportional hazards models to survey data. <i>Biometrika</i> <b>87</b>, 37–47 (2000).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/biomet/87.1.37" data-track-item_id="10.1093/biomet/87.1.37" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbiomet%2F87.1.37" aria-label="Article reference 45" data-doi="10.1093/biomet/87.1.37">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=On%20fitting%20Cox%E2%80%99s%20proportional%20hazards%20models%20to%20survey%20data&amp;journal=Biometrika&amp;doi=10.1093%2Fbiomet%2F87.1.37&amp;volume=87&amp;pages=37-47&amp;publication_year=2000&amp;author=Lin%2CDY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Pilcher, C. D. et al. A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results. <i>AIDS</i> <b>33</b>, 1231–1240 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/QAD.0000000000002190" data-track-item_id="10.1097/QAD.0000000000002190" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2FQAD.0000000000002190" aria-label="Article reference 46" data-doi="10.1097/QAD.0000000000002190">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20generalizable%20method%20for%20estimating%20duration%20of%20HIV%20infections%20using%20clinical%20testing%20history%20and%20HIV%20test%20results&amp;journal=AIDS&amp;doi=10.1097%2FQAD.0000000000002190&amp;volume=33&amp;pages=1231-1240&amp;publication_year=2019&amp;author=Pilcher%2CCD">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01953-6?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>This work was supported by the NIH through award nos. UM1 AI068614 (D.H.B., L.C. and G.D.T.), UM1 AI068635 (P.B.G. and Y.H.), 4 R37 AI054165-21 (P.B.G.), UM1 AI068618, UM1 AI068619 (M.S.C.), UM1 AI068613, UM1 AI068617, P30 AI027757 (J.I.M.), P30 AI064518 (G.D.T.) and K25 AI155224 (D.B.R.); and by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases and the South African Medical Research Council (L.M.). This work was also supported, in whole or in part, by the Bill &amp; Melinda Gates Foundation (CAVD grant nos. OPP1146996 and INV-036842 (B.K.)). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the author-accepted manuscript version that might arise from this submission. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. We thank the trial participants and staff, study teams and community members of the clinical research sites. We also thank the HVTN Core staff, the Hutchinson Centre Research Institute of South Africa staff, the Statistical Center for HIV/AIDS Research &amp; Prevention, the HVTN Laboratory Center, the DAIDS/NIAID Vaccine Research Program and Pharmaceutical Affairs Branch and Triclinium Clinical Development.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="nAff24"><p class="c-article-author-information__authors-list">Elena E. Giorgi</p><p class="js-present-address">Present address: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA</p></li><li class="c-article-author-information__item" id="nAff25"><p class="c-article-author-information__authors-list">Valerie Bekker</p><p class="js-present-address">Present address: Duke Center for Human Systems Immunology, Duke University Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Durham, NC, USA</p></li><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally: Peter B. Gilbert, Yunda Huang.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">Peter B. Gilbert,&nbsp;Yunda Huang,&nbsp;Allan C. deCamp,&nbsp;Shelly Karuna,&nbsp;Yuanyuan Zhang,&nbsp;Craig A. Magaret,&nbsp;Paul T. Edlefsen,&nbsp;Raabya Rossenkhan,&nbsp;Michal Juraska,&nbsp;Erika Rudnicki,&nbsp;Nidhi Kochar,&nbsp;Ying Huang,&nbsp;Lindsay N. Carpp,&nbsp;Bryan T. Mayer,&nbsp;Daniel B. Reeves,&nbsp;John Hural&nbsp;&amp;&nbsp;Lawrence Corey</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Department of Biostatistics, University of Washington, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">Peter B. Gilbert</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Department of Global Health, University of Washington, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">Yunda Huang&nbsp;&amp;&nbsp;James I. Mullins</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Los Alamos National Laboratory, Los Alamos, NM, USA</p><p class="c-article-author-affiliation__authors-list">Elena E. Giorgi&nbsp;&amp;&nbsp;Bette Korber</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Dan H. Barouch</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA</p><p class="c-article-author-affiliation__authors-list">Dan H. Barouch</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa</p><p class="c-article-author-affiliation__authors-list">Nonhlanhla N. Mkhize,&nbsp;Tandile Hermanus,&nbsp;Prudence Kgagudi,&nbsp;Valerie Bekker,&nbsp;Haajira Kaldine,&nbsp;Rutendo E. Mapengo&nbsp;&amp;&nbsp;Lynn Morris</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa</p><p class="c-article-author-affiliation__authors-list">Nonhlanhla N. Mkhize,&nbsp;Tandile Hermanus,&nbsp;Prudence Kgagudi,&nbsp;Valerie Bekker,&nbsp;Haajira Kaldine,&nbsp;Rutendo E. Mapengo&nbsp;&amp;&nbsp;Lynn Morris</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Department of Surgery, Duke University Medical Center, Durham, NC, USA</p><p class="c-article-author-affiliation__authors-list">Amanda Eaton,&nbsp;Elize Domin,&nbsp;Carley West,&nbsp;Wenhong Feng,&nbsp;Haili Tang&nbsp;&amp;&nbsp;David C. Montefiori</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Duke University Departments of Surgery, Immunology, Molecular Genetics and Micobiology, Duke Center for Human Systems Immunology, Durham, NC, USA</p><p class="c-article-author-affiliation__authors-list">Kelly E. Seaton,&nbsp;Jack Heptinstall,&nbsp;Caroline Brackett,&nbsp;Kelvin Chiong&nbsp;&amp;&nbsp;Georgia D. Tomaras</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Family Health International, Durham, NC, USA</p><p class="c-article-author-affiliation__authors-list">Philip Andrew</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA</p><p class="c-article-author-affiliation__authors-list">Magdalena E. Sobieszczyk</p></li><li id="Aff13"><p class="c-article-author-affiliation__address">Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa</p><p class="c-article-author-affiliation__authors-list">Nigel Garrett&nbsp;&amp;&nbsp;Lynn Morris</p></li><li id="Aff14"><p class="c-article-author-affiliation__address">Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa</p><p class="c-article-author-affiliation__authors-list">Nigel Garrett</p></li><li id="Aff15"><p class="c-article-author-affiliation__address">Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru</p><p class="c-article-author-affiliation__authors-list">Jorge Sanchez</p></li><li id="Aff16"><p class="c-article-author-affiliation__address">Division of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA</p><p class="c-article-author-affiliation__authors-list">Cynthia Gay</p></li><li id="Aff17"><p class="c-article-author-affiliation__address">Botswana-Harvard AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana</p><p class="c-article-author-affiliation__authors-list">Joseph Makhema</p></li><li id="Aff18"><p class="c-article-author-affiliation__address">Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Joseph Makhema</p></li><li id="Aff19"><p class="c-article-author-affiliation__address">Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa</p><p class="c-article-author-affiliation__authors-list">Carolyn Williamson</p></li><li id="Aff20"><p class="c-article-author-affiliation__address">Department of Microbiology, University of Washington, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">James I. Mullins</p></li><li id="Aff21"><p class="c-article-author-affiliation__address">Department of Medicine, University of Washington, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">James I. Mullins&nbsp;&amp;&nbsp;Lawrence Corey</p></li><li id="Aff22"><p class="c-article-author-affiliation__address">Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA</p><p class="c-article-author-affiliation__authors-list">Myron S. Cohen</p></li><li id="Aff23"><p class="c-article-author-affiliation__address">Department of Laboratory Medicine, University of Washington, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">Lawrence Corey</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Peter_B_-Gilbert-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Peter B. Gilbert</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Peter%20B.%20Gilbert" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Peter%20B.%20Gilbert" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Peter%20B.%20Gilbert%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Yunda-Huang-Aff1-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Yunda Huang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Yunda%20Huang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Yunda%20Huang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Yunda%20Huang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Allan_C_-deCamp-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Allan C. deCamp</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Allan%20C.%20deCamp" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Allan%20C.%20deCamp" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Allan%20C.%20deCamp%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Shelly-Karuna-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Shelly Karuna</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Shelly%20Karuna" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Shelly%20Karuna" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Shelly%20Karuna%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Yuanyuan-Zhang-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Yuanyuan Zhang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Yuanyuan%20Zhang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Yuanyuan%20Zhang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Yuanyuan%20Zhang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Craig_A_-Magaret-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Craig A. Magaret</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Craig%20A.%20Magaret" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Craig%20A.%20Magaret" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Craig%20A.%20Magaret%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Elena_E_-Giorgi-Aff4-Aff24"><span class="c-article-authors-search__title u-h3 js-search-name">Elena E. Giorgi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Elena%20E.%20Giorgi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Elena%20E.%20Giorgi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Elena%20E.%20Giorgi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Bette-Korber-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Bette Korber</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Bette%20Korber" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Bette%20Korber" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Bette%20Korber%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Paul_T_-Edlefsen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Paul T. Edlefsen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Paul%20T.%20Edlefsen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Paul%20T.%20Edlefsen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Paul%20T.%20Edlefsen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Raabya-Rossenkhan-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Raabya Rossenkhan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Raabya%20Rossenkhan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Raabya%20Rossenkhan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Raabya%20Rossenkhan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Michal-Juraska-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Michal Juraska</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Michal%20Juraska" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Michal%20Juraska" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Michal%20Juraska%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Erika-Rudnicki-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Erika Rudnicki</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Erika%20Rudnicki" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Erika%20Rudnicki" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Erika%20Rudnicki%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nidhi-Kochar-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Nidhi Kochar</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nidhi%20Kochar" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nidhi%20Kochar" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nidhi%20Kochar%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ying-Huang-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Ying Huang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ying%20Huang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ying%20Huang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ying%20Huang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lindsay_N_-Carpp-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Lindsay N. Carpp</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lindsay%20N.%20Carpp" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lindsay%20N.%20Carpp" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lindsay%20N.%20Carpp%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Dan_H_-Barouch-Aff5-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Dan H. Barouch</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Dan%20H.%20Barouch" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Dan%20H.%20Barouch" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Dan%20H.%20Barouch%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nonhlanhla_N_-Mkhize-Aff7-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Nonhlanhla N. Mkhize</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nonhlanhla%20N.%20Mkhize" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nonhlanhla%20N.%20Mkhize" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nonhlanhla%20N.%20Mkhize%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Tandile-Hermanus-Aff7-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Tandile Hermanus</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Tandile%20Hermanus" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Tandile%20Hermanus" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Tandile%20Hermanus%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Prudence-Kgagudi-Aff7-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Prudence Kgagudi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Prudence%20Kgagudi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Prudence%20Kgagudi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Prudence%20Kgagudi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Valerie-Bekker-Aff7-Aff8-Aff25"><span class="c-article-authors-search__title u-h3 js-search-name">Valerie Bekker</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Valerie%20Bekker" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Valerie%20Bekker" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Valerie%20Bekker%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Haajira-Kaldine-Aff7-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Haajira Kaldine</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Haajira%20Kaldine" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Haajira%20Kaldine" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Haajira%20Kaldine%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rutendo_E_-Mapengo-Aff7-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Rutendo E. Mapengo</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rutendo%20E.%20Mapengo" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rutendo%20E.%20Mapengo" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rutendo%20E.%20Mapengo%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Amanda-Eaton-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Amanda Eaton</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Amanda%20Eaton" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Amanda%20Eaton" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Amanda%20Eaton%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Elize-Domin-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Elize Domin</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Elize%20Domin" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Elize%20Domin" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Elize%20Domin%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Carley-West-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Carley West</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Carley%20West" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Carley%20West" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Carley%20West%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Wenhong-Feng-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Wenhong Feng</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Wenhong%20Feng" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Wenhong%20Feng" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Wenhong%20Feng%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Haili-Tang-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Haili Tang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Haili%20Tang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Haili%20Tang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Haili%20Tang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kelly_E_-Seaton-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Kelly E. Seaton</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kelly%20E.%20Seaton" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kelly%20E.%20Seaton" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kelly%20E.%20Seaton%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jack-Heptinstall-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Jack Heptinstall</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jack%20Heptinstall" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jack%20Heptinstall" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jack%20Heptinstall%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Caroline-Brackett-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Caroline Brackett</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Caroline%20Brackett" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Caroline%20Brackett" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Caroline%20Brackett%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kelvin-Chiong-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Kelvin Chiong</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kelvin%20Chiong" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kelvin%20Chiong" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kelvin%20Chiong%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Georgia_D_-Tomaras-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Georgia D. Tomaras</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Georgia%20D.%20Tomaras" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Georgia%20D.%20Tomaras" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Georgia%20D.%20Tomaras%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Philip-Andrew-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Philip Andrew</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Philip%20Andrew" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Philip%20Andrew" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Philip%20Andrew%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Bryan_T_-Mayer-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Bryan T. Mayer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Bryan%20T.%20Mayer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Bryan%20T.%20Mayer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Bryan%20T.%20Mayer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Daniel_B_-Reeves-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Daniel B. Reeves</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Daniel%20B.%20Reeves" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Daniel%20B.%20Reeves" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Daniel%20B.%20Reeves%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Magdalena_E_-Sobieszczyk-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Magdalena E. Sobieszczyk</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Magdalena%20E.%20Sobieszczyk" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Magdalena%20E.%20Sobieszczyk" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Magdalena%20E.%20Sobieszczyk%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nigel-Garrett-Aff13-Aff14"><span class="c-article-authors-search__title u-h3 js-search-name">Nigel Garrett</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nigel%20Garrett" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nigel%20Garrett" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nigel%20Garrett%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jorge-Sanchez-Aff15"><span class="c-article-authors-search__title u-h3 js-search-name">Jorge Sanchez</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jorge%20Sanchez" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jorge%20Sanchez" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jorge%20Sanchez%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Cynthia-Gay-Aff16"><span class="c-article-authors-search__title u-h3 js-search-name">Cynthia Gay</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Cynthia%20Gay" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Cynthia%20Gay" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Cynthia%20Gay%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Joseph-Makhema-Aff17-Aff18"><span class="c-article-authors-search__title u-h3 js-search-name">Joseph Makhema</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Joseph%20Makhema" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Joseph%20Makhema" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Joseph%20Makhema%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Carolyn-Williamson-Aff19"><span class="c-article-authors-search__title u-h3 js-search-name">Carolyn Williamson</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Carolyn%20Williamson" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Carolyn%20Williamson" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Carolyn%20Williamson%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-James_I_-Mullins-Aff3-Aff20-Aff21"><span class="c-article-authors-search__title u-h3 js-search-name">James I. Mullins</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=James%20I.%20Mullins" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=James%20I.%20Mullins" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22James%20I.%20Mullins%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-John-Hural-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">John Hural</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=John%20Hural" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=John%20Hural" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22John%20Hural%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Myron_S_-Cohen-Aff22"><span class="c-article-authors-search__title u-h3 js-search-name">Myron S. Cohen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Myron%20S.%20Cohen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Myron%20S.%20Cohen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Myron%20S.%20Cohen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lawrence-Corey-Aff1-Aff21-Aff23"><span class="c-article-authors-search__title u-h3 js-search-name">Lawrence Corey</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lawrence%20Corey" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lawrence%20Corey" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lawrence%20Corey%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-David_C_-Montefiori-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">David C. Montefiori</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=David%20C.%20Montefiori" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=David%20C.%20Montefiori" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22David%20C.%20Montefiori%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lynn-Morris-Aff7-Aff8-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Lynn Morris</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lynn%20Morris" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lynn%20Morris" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lynn%20Morris%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>P.B.G. and Yunda Huang contributed equally to this work. D.C.M. and L.M. also contributed equally to this work. P.B.G., Yunda Huang, A,C,d,C., S.K., M.S.C., L.C., D.C.M. and L.M. conceived the study. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K., Ying Huang, N.N.M., T.H., P.K., V.B., H.K., R.M., A.E., E.D., C.W., W.F., H.T., K.E.S., J.H., C.B., K.C., G.D.T., C.W., J.I.M., D.C.M. and L.M. developed the methodology used in the study. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K. and Y.H. developed the software/code used in the study. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K., Ying Huang, N.N.M., T.H., P.K., V.B., H.K., R.M., A.E., E.D., C.W., W.F., H.T., K.E.S., J.H., C.B., K.C., G.D.T., C.W., J.I.M., D.C.M. and L.M. contributed to validation. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K., Ying Huang, D,C,M. and L.M. performed analyses. P.B.G., S.K., N.N.M., T.H., P.K., V.B., H.K., R.M., A.E., E.D., C.W., W.F., H.T., K.E.S., J.H., C.B., K.C., G.D.T., P.A., B.T.M., D.B.R., M.E.S., N.G., J.S., C.G., J.M., C.W., J.H., M.S.C., J.I.M., L.C., D.C.M. and L.M. conducted research and/or performed experiments. P.B.G., S.K., B.K., D.H.B., G.D.T., P.A., M.E.S., N.G., J.S., C.G., J.M., C.W., J.I.M., J.H., L.C., D.C.M. and L.M. provided study materials, laboratory samples, computing resources or other analysis tools. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K. and Ying Huang curated data. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.G., B.K., P.T.E., R.R., M.J., E.R., N.K., Ying Huang and L.N.C. contributed to visualization/data presentation. P.B.G., Yunda Huang, B.K., P.T.E., G.D.T., M.S.C., L.C., D.C.M. and L.M. supervised effort on this work. P.B.G., Yunda Huang, S.K., G.D.T., J.I.M., J.H., M.S.C., L.C., D.C.M. and L.M. worked on project administration. P.B.G., Yunda Huang, B.K., D.B.R., J.I.M., M.S.C., L.C., G.D.T. and L.M. acquired funding. P.B.G. wrote the original draft. Yunda Huang, S.K., L.N.C., D.C.M. and L.M. also contributed to writing. All coauthors reviewed and edited the manuscript and provided approval of the final version.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:pgilbert@fredhutch.org">Peter B. Gilbert</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3>
                <p>The authors declare no competing interests.</p>
              
            </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
              
              
                <h3 class="c-article__sub-heading" id="FPar3">Peer review information</h3>
                <p><i>Nature Medicine</i> thanks Giuseppe Pantaleo and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Alison Farrell and Saheli Sadanand, in collaboration with the <i>Nature Medicine</i> team.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec28-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec28">Extended data</h2><div class="c-article-section__content" id="Sec28-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 estimated protection curves (" href="/articles/s41591-022-01953-6/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig7_ESM.jpg">Extended Data Fig. 1 Estimated protection curves (calculated from logistic regression) by day-of-challenge predicted serum ID80 titer (PT80) against the challenge SHIV, shown by bnAb class and by challenge SHIV, in subsets of N = 274 non-human primates (NHPs) that received a single bnAb and underwent SHIV challenge<sup></sup></a><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336–346 (2019)." href="/articles/s41591-022-01953-6#ref-CR4" id="ref-link-section-d54774234e3379">4</a>.</h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Day-of-challenge PT80 was calculated as day-of-challenge bnAb concentration divided by IC80 against the challenge SHIV, where PT80 values &lt; 2 were set to 1. Only neutralization titer data obtained by the TZM-bl target cell assay were included. The bnAb and SHIV challenge description of each subset is shown in the lower right legend. <b>a)</b> Only CD4 binding site-targeting bnAbs, separated by challenge SHIV; <b>b)</b> All bnAbs excluding MPER-targeting bnAbs, separated by challenge SHIV. The figure shows that the estimated protection curve for SF162P3 challenge is an outlier.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 estimated serum vrc01 concent" href="/articles/s41591-022-01953-6/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig8_ESM.jpg">Extended Data Fig. 2 Estimated serum VRC01 concentration (filled black dot) at the estimated time of infection (median of the Bayesian posterior distribution of infection time) since last infusion in all primary endpoint HIV-1 cases, by randomization arm in each trial.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>(a)</b> HVTN 704/HPTN 085 (n = 36 cases in Control, n = 31 cases in the 10 mg/kg arm and n = 25 cases in the 30 mg/kg arm) with an additional 3 cases not shown in the 30 mg/kg panel due to estimated infection time &gt; 10 weeks since last infusion, and 7 and 1 case(s) not shown in the Control and 10 mg/kg panels, respectively, due to estimated infection time ≤ 0 or not being available. <b>(b)</b> HVTN 703/HPTN 081 (n = 27 cases in Control, n = 28 cases in the 10 mg/kg arm and n = 17 cases in the 30 mg/kg arm) with an additional 2 and 2 cases not shown in the Control and 30 mg/kg panels, respectively, due to estimated infection time ≤ 0 or not being available. For each VRC01-recipient case, vertical error bars represent the 90% prediction interval around the estimated serum VRC01 concentration at the estimated infection time (center of the error bars), accounting for variabilities in both the estimation of the infection time and the estimation of concentration are displayed for each VRC01-recipient case. The former uncertainty is incorporated via resampling infection time from the Bayesian posterior distribution of infection time and the latter is incorporated via variabilities estimated based on the final popPK model for the daily grid concentrations at each given estimated infection time (see Methods). The solid black line represents the median and the shaded area represents bands covered by the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the estimated concentrations over time within each dose group using the median body weight of participants in the case-control cohort, accounting for between-individual variabilities estimated based on the final popPK model.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 predicted serum id80 titer (p" href="/articles/s41591-022-01953-6/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig9_ESM.jpg">Extended Data Fig. 3 Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Solid line: median. Shaded area: 95% prediction interval. Predictions made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, using observed serum concentration data<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022)." href="/articles/s41591-022-01953-6#ref-CR18" id="ref-link-section-d54774234e3445">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718–1724 (2021)." href="/articles/s41591-022-01953-6#ref-CR19" id="ref-link-section-d54774234e3448">19</a></sup>. The viruses circulating in each trial are: <b>(a)</b> the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; <b>(b)</b> the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT80 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT80 titers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Comput. Biol. 18, e1010003 (2022)." href="/articles/s41591-022-01953-6#ref-CR10" id="ref-link-section-d54774234e3458">10</a></sup>.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 agreement between predicted v" href="/articles/s41591-022-01953-6/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig10_ESM.jpg">Extended Data Fig. 4 Agreement between predicted vs experimental serum neutralization ID50 titer.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Sera from samples from the last visit (and for a subset from the last two last visits) prior to the first positive HIV-1 RNA PCR test were assayed against autologous isolates from 64 VRC01 recipients who acquired HIV-1 infection (cases) (90 isolates, 164 titers). Predicted serum ID50 titer (PT50) values are plotted against the experimental ID50 for each sample and each isolate [Lin’s concordance correlation coefficient<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45, 255–268 (1989)." href="/articles/s41591-022-01953-6#ref-CR33" id="ref-link-section-d54774234e3484">33</a></sup> = 0.92 (95% CI 0.80 to 0.97)]. PT50 was calculated as popPK model-predicted concentration divided by IC50. Thirty-two of 164 experimental ID50 titers were below the limit of detection when the PT50 was greater than 10 (range 10.2 to 36.3). Zero of 164 experimental ID50 titers was at or above the limit of detection when the PT50 was less than 10. Dashed horizontal and vertical lines at a value of 10 show the experimental ID50 limit of detection; concordance of predicted vs. experimental values above vs. below 10 was 132 of 164 (80.5%).</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 estimated prevention efficacy" href="/articles/s41591-022-01953-6/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig11_ESM.jpg">Extended Data Fig. 5 Estimated prevention efficacy (PE) by predicted serum ID50 titer (PT50) to the autologous acquired virus in the AMP trials and in non-human primate (NHP) studies.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a)</b> Estimated PE by PT50 to the acquired virus in AMP (black line), compared to the protection curve in three different sets of NHP (blue, mustard, and green lines). <b>b)</b> PT50 associated with 50% PE, 75% PE, and 90% PE, for the AMP trials and for each of the three sets of NHP. Set A: N = 274 NHPs that received a single bnAb followed by SHIV challenge, bnAb titer data from all neutralization assays<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336–346 (2019)." href="/articles/s41591-022-01953-6#ref-CR4" id="ref-link-section-d54774234e3516">4</a></sup>; Set B: only the NHPs in Set A that received a CD4 binding site-targeting bnAb, excluding all that were challenged with SF162P3, and only including bnAb titer data from the TZM-bl target cell assay; and Set C: all NHPs in Set A, but excluding those that received an MPER-targeting bnAb and excluding all that were challenged with SF162P3, and only including bnAb titer data from the TZM-bl target cell assay.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 distributions of predicted se" href="/articles/s41591-022-01953-6/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig12_ESM.jpg">Extended Data Fig. 6 Distributions of predicted serum ID50 titers (PT50s) against viruses acquired by placebo recipients, within each virus neutralization IC50 sensitivity category.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Distributions of predicted serum ID50 titers (PT50s) against viruses acquired by placebo recipients, within each virus neutralization IC50 sensitivity category. Approach 2 of Huang et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. J. Acquir Immune Defic. Syndr. 83, 434–439 (2020)." href="/articles/s41591-022-01953-6#ref-CR11" id="ref-link-section-d54774234e3542">11</a></sup> was used to calculate PT50 against a given virus by dividing the population PK model-predicted VRC01 serum concentration by the IC80 of the VRC01 drug product against the virus. The distributions are for PT50s of the 82 non-cases in the case-control cohort calculated at each day over the 80-week follow-up against each of the viruses acquired by placebo recipients. On the y-axis, each filled black dot is a point estimate of prevention efficacy against viruses in the specified sensitivity category and the vertical lines are 95% confidence interval estimates as previously reported<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021)." href="/articles/s41591-022-01953-6#ref-CR6" id="ref-link-section-d54774234e3546">6</a></sup>. The downward arrowhead indicates a value below the y-axis lower limit. On the x-axis, each filled black dot is the median PT50 against viruses acquired by placebo recipients, within each virus neutralization IC50 sensitivity category; the horizontal rectangles extend through the interquartile range and on each side of the boxplot is a kernel density estimation of the distribution shape of the PT50.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 predicted serum id50 titers (" href="/articles/s41591-022-01953-6/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig13_ESM.jpg">Extended Data Fig. 7 Predicted serum ID50 titers (PT50s) to autologous acquired viruses at HIV-1 acquisition among VRC01 arm cases, and to placebo-recipient acquired viruses among VRC01 arm non-cases.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>(a)</b> Violin plots for VRC01-recipient cases vs. non-cases, where Approach 2 of Huang et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. J. Acquir Immune Defic. Syndr. 83, 434–439 (2020)." href="/articles/s41591-022-01953-6#ref-CR11" id="ref-link-section-d54774234e3574">11</a></sup> was used to calculate PT50 at a given time point against a given virus. For each VRC01-recipient case, PT50 at the estimated date of HIV-1 acquisition (red dots) was calculated as the estimated VRC01 concentration at acquisition divided by the VRC01 drug product IC50 against the autologous virus. For each of the 82 sampled VRC01-recipient non-cases, PT50 at each day of follow-up against each placebo-recipient acquired virus was calculated as the estimated VRC01 concentration divided by the VRC01 drug product IC50 against the virus (blue dots). The lower bound, horizontal line, and upper bound of the vertical rectangle boxplots show the 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentiles, respectively. On each side of the boxplot is a kernel density estimation of the distribution shape of the PT50. <b>(b)</b> By VRC01 dose arm and across dose arms pooled: geometric mean PT50 at HIV-1 acquisition in VRC01-recipient cases against the autologous acquired virus, geometric mean PT50 in VRC01-recipient non-cases (their individual-specific medians over follow-up) to placebo-recipient acquired viruses, and their ratio. Error bars represent 95% confidence intervals.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig14"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 (a, b) neutralization coverag" href="/articles/s41591-022-01953-6/figures/14" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig14_ESM.jpg">Extended Data Fig. 8 (A, B) Neutralization coverage (defined by PT50 &gt; 600) (averaged to viruses) and (C, D) geometric mean predicted serum ID50 (PT50) titer against viruses circulating in each of the AMP trials for the bnAb regimen PGT121LS + PGDM1400LS + VRC07-523LS 20 + 20 + 20 mg/kg delivered intravenously every 16 weeks and evaluated in study cohorts of the same sizes as the AMP trials.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>In (A, B), the tables below each plot provide the neutralization coverage averaged to viruses and averaged over the given time frame. A virus exposure was considered covered by 1-active, 2-active, or 3-active bnAbs if the coverage threshold (PT50 &gt; 600) is achieved by at least 1, at least 2, or all 3 bnAbs. All predictions were made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, based on modeling of observed serum concentration data of PGT121 and PGDM1400<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022)." href="/articles/s41591-022-01953-6#ref-CR18" id="ref-link-section-d54774234e3609">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718–1724 (2021)." href="/articles/s41591-022-01953-6#ref-CR19" id="ref-link-section-d54774234e3612">19</a></sup>. For each bnAb regimen, geometric mean PT50 at each time-point was calculated as the geometric mean of predicted serum concentration across bnAb recipients at each time-point during steady state (simulated based on population PK modeling of each bnAb as described in Methods) divided by the geometric mean of bnAb drug product IC50 across viruses circulating in the designated AMP trial, that is <b>(a, c)</b> the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; <b>(b, d)</b> the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT50 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT50 titers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Comput. Biol. 18, e1010003 (2022)." href="/articles/s41591-022-01953-6#ref-CR10" id="ref-link-section-d54774234e3622">10</a></sup>.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig15"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 predicted serum id50 titer (p" href="/articles/s41591-022-01953-6/figures/15" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig15_ESM.jpg">Extended Data Fig. 9 Predicted serum ID50 titer (PT50)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 16 weeks and evaluated in study cohorts of the same sizes as the AMP trials.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Solid line: median. Shaded area: 95% prediction interval. Predictions made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, using observed serum concentration data<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288–1296 (2022)." href="/articles/s41591-022-01953-6#ref-CR18" id="ref-link-section-d54774234e3648">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718–1724 (2021)." href="/articles/s41591-022-01953-6#ref-CR19" id="ref-link-section-d54774234e3651">19</a></sup>. The viruses circulating in each trial are: <b>(a)</b> the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; <b>(b)</b> the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT50 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT50 titers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Comput. Biol. 18, e1010003 (2022)." href="/articles/s41591-022-01953-6#ref-CR10" id="ref-link-section-d54774234e3661">10</a></sup>.</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec29-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec29">Supplementary information</h2><div class="c-article-section__content" id="Sec29-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Notes 1 and 2, Tables 1–3 and Figs. 1 and 2.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Neutralization%20titer%20biomarker%20for%20antibody-mediated%20prevention%20of%20HIV-1%20acquisition&amp;author=Peter%20B.%20Gilbert%20et%20al&amp;contentID=10.1038%2Fs41591-022-01953-6&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2022-08-22&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-022-01953-6" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-022-01953-6" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Gilbert, P.B., Huang, Y., deCamp, A.C. <i>et al.</i> Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.
                    <i>Nat Med</i> <b>28</b>, 1924–1932 (2022). https://doi.org/10.1038/s41591-022-01953-6</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01953-6?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-11-16">16 November 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-07-14">14 July 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-08-22">22 August 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-09">September 2022</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-022-01953-6</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/antibodies" data-track="click" data-track-action="view subject" data-track-label="link">Antibodies</a></li><li class="c-article-subject-list__subject"><a href="/subjects/hiv-infections" data-track="click" data-track-action="view subject" data-track-label="link">HIV infections</a></li><li class="c-article-subject-list__subject"><a href="/subjects/predictive-markers" data-track="click" data-track-action="view subject" data-track-label="link">Predictive markers</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Immune-mediated strategies to solving the HIV reservoir problem" href="https://doi.org/10.1038/s41577-025-01136-7">
                                        Immune-mediated strategies to solving the HIV reservoir problem
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Deanna A. Kulpa</li><li>Mirko Paiardini</li><li>Guido Silvestri</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Immunology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Antibody prophylaxis may mask subclinical SIV infections in macaques" href="https://doi.org/10.1038/s41586-024-08500-y">
                                        Antibody prophylaxis may mask subclinical SIV infections in macaques
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Christopher A. Gonelli</li><li>Hannah A. D. King</li><li>Mario Roederer</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV" href="https://doi.org/10.1186/s12865-025-00687-7">
                                        Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Tariro D. Chawana</li><li>Stephen R. Walsh</li><li>Yunda Huang</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>BMC Immunology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits" href="https://doi.org/10.1038/s41467-024-47492-1">
                                        CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Annemart Koornneef</li><li>Kanika Vanshylla</li><li>Frank Wegmann</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Communications</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa" href="https://doi.org/10.1038/s41467-024-54580-9">
                                        Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Maria P. Lemos</li><li>Rena D. Astronomo</li><li>M. Juliana McElrath</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Communications</i> (2024)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01953-6.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: 409.45px;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec10" class="c-reading-companion__section-item"><a href="#Sec10" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec11" class="c-reading-companion__section-item"><a href="#Sec11" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-code-availability" class="c-reading-companion__section-item"><a href="#code-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Code availability">Code availability</a></li><li id="rc-sec-change-history" class="c-reading-companion__section-item"><a href="#change-history" data-track="click" data-track-action="section anchor" data-track-label="link:Change history">Change history</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-peer-review" class="c-reading-companion__section-item"><a href="#peer-review" data-track="click" data-track-action="section anchor" data-track-label="link:Peer review">Peer review</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec28" class="c-reading-companion__section-item"><a href="#Sec28" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec29" class="c-reading-companion__section-item"><a href="#Sec29" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-022-01953-6;doi=10.1038/s41591-022-01953-6;subjmeta=1291,1901,2152,2153,2423,250,255,308,53,631,692;kwrd=Antibodies,HIV+infections,Predictive+markers">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-237841886&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01953-6%26doi%3D10.1038/s41591-022-01953-6%26subjmeta%3D1291,1901,2152,2153,2423,250,255,308,53,631,692%26kwrd%3DAntibodies,HIV+infections,Predictive+markers">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-237841886&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01953-6%26doi%3D10.1038/s41591-022-01953-6%26subjmeta%3D1291,1901,2152,2153,2423,250,255,308,53,631,692%26kwrd%3DAntibodies,HIV+infections,Predictive+markers"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: Visual representation of how two independent pieces of information (serum bnAb concentration at a given time point and neutralization sensitivity of a target virus to the bnAb (IC<sub>80</sub>)) are used to calculate the PT<sub>80</sub> biomarker.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Agreement between predicted versus experimental serum neutralization ID<sub>80</sub> titer.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Estimated PE by PT<sub>80</sub> to the autologous acquired virus in AMP trials and in NHP studies.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: Distributions of VRC01 serum PT<sub>80</sub> against viruses acquired by placebo recipients, within each virus neutralization IC<sub>80</sub> sensitivity category.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Fig. 5: PT<sub>80</sub> values to autologous acquired viruses at HIV-1 acquisition among VRC01 arm cases, and to placebo recipient-acquired viruses among VRC01 arm noncases.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig5_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig5_HTML.png" alt="figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Fig. 6: Neutralization coverage, geometric mean PT<sub>80</sub> and PT<sub>80</sub>-predicted prevention efficacy over time against viruses circulating in each of the AMP trials for the bnAb regimen, delivered IV every 16 weeks and evaluated in study cohorts of the same size as in the AMP trials.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig6_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig6_HTML.png" alt="figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 1 Estimated protection curves (calculated from logistic regression) by day-of-challenge predicted serum ID80 titer (PT80) against the challenge SHIV, shown by bnAb class and by challenge SHIV, in subsets of N = 274 non-human primates (NHPs) that received a single bnAb and underwent SHIV challenge<sup></sup></b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 2 Estimated serum VRC01 concentration (filled black dot) at the estimated time of infection (median of the Bayesian posterior distribution of infection time) since last infusion in all primary endpoint HIV-1 cases, by randomization arm in each trial.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 3 Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 4 Agreement between predicted vs experimental serum neutralization ID50 titer.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 5 Estimated prevention efficacy (PE) by predicted serum ID50 titer (PT50) to the autologous acquired virus in the AMP trials and in non-human primate (NHP) studies.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 6 Distributions of predicted serum ID50 titers (PT50s) against viruses acquired by placebo recipients, within each virus neutralization IC50 sensitivity category.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 7 Predicted serum ID50 titers (PT50s) to autologous acquired viruses at HIV-1 acquisition among VRC01 arm cases, and to placebo-recipient acquired viruses among VRC01 arm non-cases.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig14">Extended Data Fig. 8 (A, B) Neutralization coverage (defined by PT50 &gt; 600) (averaged to viruses) and (C, D) geometric mean predicted serum ID50 (PT50) titer against viruses circulating in each of the AMP trials for the bnAb regimen PGT121LS + PGDM1400LS + VRC07-523LS 20 + 20 + 20 mg/kg delivered intravenously every 16 weeks and evaluated in study cohorts of the same sizes as the AMP trials.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig14_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig14_ESM.jpg" alt="extended data figure 14" aria-describedby="rc-Fig14"></picture><p class="c-reading-companion__figure-links"><a href="#Fig14" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/14" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig15">Extended Data Fig. 9 Predicted serum ID50 titer (PT50)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 16 weeks and evaluated in study cohorts of the same sizes as the AMP trials.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig15_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01953-6/MediaObjects/41591_2022_1953_Fig15_ESM.jpg" alt="extended data figure 15" aria-describedby="rc-Fig15"></picture><p class="c-reading-companion__figure-links"><a href="#Fig15" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01953-6/figures/15" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Plotkin, S. A. Correlates of protection induced by vaccination. <i>Clin. Vaccin. Immunol.</i> <b>17</b>, 1055–1065 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1128%2FCVI.00131-10" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1128/CVI.00131-10" data-track-item_id="10.1128/CVI.00131-10">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFGitro%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Correlates%20of%20protection%20induced%20by%20vaccination&amp;journal=Clin.%20Vaccin.%20Immunol.&amp;doi=10.1128%2FCVI.00131-10&amp;volume=17&amp;pages=1055-1065&amp;publication_year=2010&amp;author=Plotkin%2CSA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Bekker, L. G. et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet</i> <b>395</b>, 384–388 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2819%2932682-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(19)32682-0" data-track-item_id="10.1016/S0140-6736(19)32682-0">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20complex%20challenges%20of%20HIV%20vaccine%20development%20require%20renewed%20and%20expanded%20global%20commitment&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2819%2932682-0&amp;volume=395&amp;pages=384-388&amp;publication_year=2020&amp;author=Bekker%2CLG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Plotkin, S. A. &amp; Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. <i>Clin. Infect. Dis.</i> <b>54</b>, 1615–1617 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fcid%2Fcis238" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/cid/cis238" data-track-item_id="10.1093/cid/cis238">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Nomenclature%20for%20immune%20correlates%20of%20protection%20after%20vaccination&amp;journal=Clin.%20Infect.%20Dis.&amp;doi=10.1093%2Fcid%2Fcis238&amp;volume=54&amp;pages=1615-1617&amp;publication_year=2012&amp;author=Plotkin%2CSA&amp;author=Gilbert%2CPB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. <i>Cell Host Microbe</i> <b>26</b>, 336–346 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.chom.2019.08.014" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.chom.2019.08.014" data-track-item_id="10.1016/j.chom.2019.08.014">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslyis77L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20meta-analysis%20of%20passive%20immunization%20studies%20shows%20that%20serum-neutralizing%20antibody%20titer%20associates%20with%20protection%20against%20SHIV%20challenge&amp;journal=Cell%20Host%20Microbe&amp;doi=10.1016%2Fj.chom.2019.08.014&amp;volume=26&amp;pages=336-346&amp;publication_year=2019&amp;author=Pegu%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Pauthner, M. G. et al. Vaccine-induced protection from homologous Tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers. <i>Immunity</i> <b>50</b>, 241–252 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2018.11.011" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2018.11.011" data-track-item_id="10.1016/j.immuni.2018.11.011">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVygtr%2FF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccine-induced%20protection%20from%20homologous%20Tier%202%20SHIV%20challenge%20in%20nonhuman%20primates%20depends%20on%20serum-neutralizing%20antibody%20titers&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.11.011&amp;volume=50&amp;pages=241-252&amp;publication_year=2019&amp;author=Pauthner%2CMG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. <i>N. Engl. J. Med.</i> <b>384</b>, 1003–1014 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa2031738" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa2031738" data-track-item_id="10.1056/NEJMoa2031738">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXntVWlurw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Two%20randomized%20trials%20of%20neutralizing%20antibodies%20to%20prevent%20HIV-1%20acquisition&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2031738&amp;volume=384&amp;pages=1003-1014&amp;publication_year=2021&amp;author=Corey%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection. <i>PLoS Pathog.</i> <b>12</b>, e1005520 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.ppat.1005520" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.ppat.1005520" data-track-item_id="10.1371/journal.ppat.1005520">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Optimal%20combinations%20of%20broadly%20neutralizing%20antibodies%20for%20prevention%20and%20treatment%20of%20HIV-1%20Clade%20C%20infection&amp;journal=PLoS%20Pathog.&amp;doi=10.1371%2Fjournal.ppat.1005520&amp;volume=12&amp;publication_year=2016&amp;author=Wagh%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Wagh, K. et al. Potential of conventional &amp; bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C &amp; D infections. <i>PLoS Pathog.</i> <b>14</b>, e1006860 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.ppat.1006860" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.ppat.1006860" data-track-item_id="10.1371/journal.ppat.1006860">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Potential%20of%20conventional%20%26%20bispecific%20broadly%20neutralizing%20antibodies%20for%20prevention%20of%20HIV-1%20subtype%20A%2C%20C%20%26%20D%20infections&amp;journal=PLoS%20Pathog.&amp;doi=10.1371%2Fjournal.ppat.1006860&amp;volume=14&amp;publication_year=2018&amp;author=Wagh%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Reeves, D. B. et al. Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Comput. Biol.</i> <b>16</b>, e1007626 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pcbi.1007626" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pcbi.1007626" data-track-item_id="10.1371/journal.pcbi.1007626">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXovFSqu7o%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mathematical%20modeling%20to%20reveal%20breakthrough%20mechanisms%20in%20the%20HIV%20Antibody%20Mediated%20Prevention%20%28AMP%29%20trials&amp;journal=PLoS%20Comput.%20Biol.&amp;doi=10.1371%2Fjournal.pcbi.1007626&amp;volume=16&amp;publication_year=2020&amp;author=Reeves%2CDB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. <i>PLoS Comput. Biol.</i> <b>18</b>, e1010003 (2022).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pcbi.1010003" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pcbi.1010003" data-track-item_id="10.1371/journal.pcbi.1010003">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1CjsrfE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Optimizing%20clinical%20dosing%20of%20combination%20broadly%20neutralizing%20antibodies%20for%20HIV%20prevention&amp;journal=PLoS%20Comput.%20Biol.&amp;doi=10.1371%2Fjournal.pcbi.1010003&amp;volume=18&amp;publication_year=2022&amp;author=Mayer%2CBT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. <i>J. Acquir Immune Defic. Syndr.</i> <b>83</b>, 434–439 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2FQAI.0000000000002272" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/QAI.0000000000002272" data-track-item_id="10.1097/QAI.0000000000002272">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Brief%20report%3A%20prediction%20of%20serum%20HIV-1%20neutralization%20titers%20after%20passive%20administration%20of%20VRC01&amp;journal=J.%20Acquir%20Immune%20Defic.%20Syndr.&amp;doi=10.1097%2FQAI.0000000000002272&amp;volume=83&amp;pages=434-439&amp;publication_year=2020&amp;author=Huang%2CY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Huang, Y. et al. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Hum. Vaccines Immunother.</i> <a href="https://doi.org/10.1080/21645515.2021.1908030" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1080/21645515.2021.1908030">https://doi.org/10.1080/21645515.2021.1908030</a> (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Giorgi, E. E. et al. Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model. <i>BMC Bioinformatics</i> <b>11</b>, 532 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/1471-2105-11-532" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/1471-2105-11-532" data-track-item_id="10.1186/1471-2105-11-532">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Estimating%20time%20since%20infection%20in%20early%20homogeneous%20HIV-1%20samples%20using%20a%20Poisson%20model&amp;journal=BMC%20Bioinformatics&amp;doi=10.1186%2F1471-2105-11-532&amp;volume=11&amp;publication_year=2010&amp;author=Giorgi%2CEE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Grebe, E. et al. Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. <i>BMC Infect. Dis.</i> <b>19</b>, 894 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s12879-019-4543-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s12879-019-4543-9" data-track-item_id="10.1186/s12879-019-4543-9">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Interpreting%20HIV%20diagnostic%20histories%20into%20infection%20time%20estimates%3A%20analytical%20framework%20and%20online%20tool&amp;journal=BMC%20Infect.%20Dis.&amp;doi=10.1186%2Fs12879-019-4543-9&amp;volume=19&amp;publication_year=2019&amp;author=Grebe%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Gilbert, P. B., Zhang, Y., Rudnicki, E. &amp; Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. <i>Stat. Med.</i> <b>38</b>, 4503–4518 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fsim.8310" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/sim.8310" data-track-item_id="10.1002/sim.8310">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Assessing%20pharmacokinetic%20marker%20correlates%20of%20outcome%2C%20with%20application%20to%20antibody%20prevention%20efficacy%20trials&amp;journal=Stat.%20Med.&amp;doi=10.1002%2Fsim.8310&amp;volume=38&amp;pages=4503-4518&amp;publication_year=2019&amp;author=Gilbert%2CPB&amp;author=Zhang%2CY&amp;author=Rudnicki%2CE&amp;author=Huang%2CY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Karuna, S. T. &amp; Corey, L. Broadly neutralizing antibodies for HIV prevention. <i>Annu. Rev. Med.</i> <b>71</b>, 329–346 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1146%2Fannurev-med-110118-045506" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1146/annurev-med-110118-045506" data-track-item_id="10.1146/annurev-med-110118-045506">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslWnsrw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Broadly%20neutralizing%20antibodies%20for%20HIV%20prevention&amp;journal=Annu.%20Rev.%20Med.&amp;doi=10.1146%2Fannurev-med-110118-045506&amp;volume=71&amp;pages=329-346&amp;publication_year=2020&amp;author=Karuna%2CST&amp;author=Corey%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Stephenson, K. E., Wagh, K., Korber, B. &amp; Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. <i>Annu. Rev. Immunol.</i> <b>38</b>, 673–703 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1146%2Fannurev-immunol-080219-023629" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1146/annurev-immunol-080219-023629" data-track-item_id="10.1146/annurev-immunol-080219-023629">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXotVGgtLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Vaccines%20and%20broadly%20neutralizing%20antibodies%20for%20HIV-1%20prevention&amp;journal=Annu.%20Rev.%20Immunol.&amp;doi=10.1146%2Fannurev-immunol-080219-023629&amp;volume=38&amp;pages=673-703&amp;publication_year=2020&amp;author=Stephenson%2CKE&amp;author=Wagh%2CK&amp;author=Korber%2CB&amp;author=Barouch%2CDH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nat. Med</i>. <b>28</b>, 1288–1296 (2022).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nat. Med.</i> <b>27</b>, 1718–1724 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-021-01509-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-021-01509-0" data-track-item_id="10.1038/s41591-021-01509-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1WqtrrE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%20and%20antiviral%20activity%20of%20PGT121%2C%20a%20broadly%20neutralizing%20monoclonal%20antibody%20against%20HIV-1%3A%20a%20randomized%2C%20placebo-controlled%2C%20phase%201%20clinical%20trial&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01509-0&amp;volume=27&amp;pages=1718-1724&amp;publication_year=2021&amp;author=Stephenson%2CKE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults. <i>PLoS Med.</i> <b>15</b>, e1002493 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pmed.1002493" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pmed.1002493" data-track-item_id="10.1371/journal.pmed.1002493">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20pharmacokinetics%20of%20the%20Fc-modified%20HIV-1%20human%20monoclonal%20antibody%20VRC01LS%3A%20a%20Phase%201%20open-label%20clinical%20trial%20in%20healthy%20adults&amp;journal=PLoS%20Med.&amp;doi=10.1371%2Fjournal.pmed.1002493&amp;volume=15&amp;publication_year=2018&amp;author=Gaudinski%2CMR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Cohen, Y. Z. et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study. <i>PLoS ONE</i> <b>14</b>, e0219142 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0219142" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0219142" data-track-item_id="10.1371/journal.pone.0219142">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvFamtLvO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%2C%20and%20immunogenicity%20of%20the%20combination%20of%20the%20broadly%20neutralizing%20anti-HIV-1%20antibodies%203BNC117%20and%2010-1074%20in%20healthy%20adults%3A%20a%20randomized%2C%20phase%201%20study&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0219142&amp;volume=14&amp;publication_year=2019&amp;author=Cohen%2CYZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Amanna, I. J., Carlson, N. E. &amp; Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. <i>N. Engl. J. Med.</i> <b>357</b>, 1903–1915 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa066092" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa066092" data-track-item_id="10.1056/NEJMoa066092">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXht1ymtbjI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Duration%20of%20humoral%20immunity%20to%20common%20viral%20and%20vaccine%20antigens&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa066092&amp;volume=357&amp;pages=1903-1915&amp;publication_year=2007&amp;author=Amanna%2CIJ&amp;author=Carlson%2CNE&amp;author=Slifka%2CMK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> <b>375</b>, 43–50 (2022).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nat. Med.</i> <b>27</b>, 1205–1211 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-021-01377-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-021-01377-8" data-track-item_id="10.1038/s41591-021-01377-8">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtFSktLrP" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Neutralizing%20antibody%20levels%20are%20highly%20predictive%20of%20immune%20protection%20from%20symptomatic%20SARS-CoV-2%20infection&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01377-8&amp;volume=27&amp;pages=1205-1211&amp;publication_year=2021&amp;author=Khoury%2CDS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. <i>Vaccine</i> <b>39</b>, 4423–4428 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.vaccine.2021.05.063" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.vaccine.2021.05.063" data-track-item_id="10.1016/j.vaccine.2021.05.063">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsV2ltrrK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Evidence%20for%20antibody%20as%20a%20protective%20correlate%20for%20COVID-19%20vaccines&amp;journal=Vaccine&amp;doi=10.1016%2Fj.vaccine.2021.05.063&amp;volume=39&amp;pages=4423-4428&amp;publication_year=2021&amp;author=Earle%2CKA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Fong, Y. et al. Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. 10.1101/2022.04.06.22272763 Preprint at <a href="https://doi.org/10.1101/2022.04.06.22272763" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1101/2022.04.06.22272763">https://doi.org/10.1101/2022.04.06.22272763</a> (2022).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. <i>N. Engl. J. Med.</i> <b>386</b>, 35–46 (2022).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa2116298" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa2116298" data-track-item_id="10.1056/NEJMoa2116298">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhtFalsbk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20the%20BNT162b2%20Covid-19%20vaccine%20in%20children%205%20to%2011%20years%20of%20age&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2116298&amp;volume=386&amp;pages=35-46&amp;publication_year=2022&amp;author=Walter%2CEB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28"><i>Emergency Use Authorization for Vaccines to Prevent COVID-19</i> (US Food and Drug Administration, 2022); <a href="https://www.fda.gov/media/142749/download" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://www.fda.gov/media/142749/download">https://www.fda.gov/media/142749/download</a></p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Plotkin, S. A. &amp; Gilbert, P. in <i>Plotkin’s Vaccines</i> 7th edn (eds Plotkin, S. A. et al.) 35–40 (Elsevier, 2018).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Astronomo, R. D. et al. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>J. Clin. Invest.</i> <a href="https://doi.org/10.1172/JCI146975" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1172/JCI146975">https://doi.org/10.1172/JCI146975</a> (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Burton, D. R. Amping up HIV antibodies. <i>Science</i> <b>372</b>, 1397–1398 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.abf5376" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.abf5376" data-track-item_id="10.1126/science.abf5376">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsVCmsLjJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Amping%20up%20HIV%20antibodies&amp;journal=Science&amp;doi=10.1126%2Fscience.abf5376&amp;volume=372&amp;pages=1397-1398&amp;publication_year=2021&amp;author=Burton%2CDR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Carroll, R. J., Ruppert, D., Stefanski, L. A. &amp; Crainiceanu, C. M. <i>Measurement Error in Nonlinear Models</i> (Chapman and Hall/CRC, 2006).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. <i>Biometrics</i> <b>45</b>, 255–268 (1989).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.2307%2F2532051" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.2307/2532051" data-track-item_id="10.2307/2532051">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaL1M3kslKrtg%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20concordance%20correlation%20coefficient%20to%20evaluate%20reproducibility&amp;journal=Biometrics&amp;doi=10.2307%2F2532051&amp;volume=45&amp;pages=255-268&amp;publication_year=1989&amp;author=Lin%2CLI" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. <i>Methods Mol. Biol.</i> <b>485</b>, 395–405 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/978-1-59745-170-3_26" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/978-1-59745-170-3_26" data-track-item_id="10.1007/978-1-59745-170-3_26">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsV2ksbY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Measuring%20HIV%20neutralization%20in%20a%20luciferase%20reporter%20gene%20assay&amp;journal=Methods%20Mol.%20Biol.&amp;doi=10.1007%2F978-1-59745-170-3_26&amp;volume=485&amp;pages=395-405&amp;publication_year=2009&amp;author=Montefiori%2CDC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. <i>J. Virol.</i> <b>79</b>, 10108–10125 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1128%2FJVI.79.16.10108-10125.2005" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1128/JVI.79.16.10108-10125.2005" data-track-item_id="10.1128/JVI.79.16.10108-10125.2005">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXntFCrtL8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Human%20immunodeficiency%20virus%20type%201%20env%20clones%20from%20acute%20and%20early%20subtype%20B%20infections%20for%20standardized%20assessments%20of%20vaccine-elicited%20neutralizing%20antibodies&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.79.16.10108-10125.2005&amp;volume=79&amp;pages=10108-10125&amp;publication_year=2005&amp;author=Li%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. <i>J. Immunol. Methods</i> <b>409</b>, 131–146 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jim.2013.11.022" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jim.2013.11.022" data-track-item_id="10.1016/j.jim.2013.11.022">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXisVKgug%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Optimization%20and%20validation%20of%20the%20TZM-bl%20assay%20for%20standardized%20assessments%20of%20neutralizing%20antibodies%20against%20HIV-1&amp;journal=J.%20Immunol.%20Methods&amp;doi=10.1016%2Fj.jim.2013.11.022&amp;volume=409&amp;pages=131-146&amp;publication_year=2014&amp;author=Sarzotti-Kelsoe%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. <i>J. Virol.</i> <b>82</b>, 12449–12463 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1128%2FJVI.01708-08" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1128/JVI.01708-08" data-track-item_id="10.1128/JVI.01708-08">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsVymsL3J" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Initial%20B-cell%20responses%20to%20transmitted%20human%20immunodeficiency%20virus%20type%201%3A%20virion-binding%20immunoglobulin%20M%20%28IgM%29%20and%20IgG%20antibodies%20followed%20by%20plasma%20anti-gp41%20antibodies%20with%20ineffective%20control%20of%20initial%20viremia&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.01708-08&amp;volume=82&amp;pages=12449-12463&amp;publication_year=2008&amp;author=Tomaras%2CGD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. <i>N. Engl. J. Med.</i> <b>366</b>, 1275–1286 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1113425" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1113425" data-track-item_id="10.1056/NEJMoa1113425">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XlsVSmtL4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immune-correlates%20analysis%20of%20an%20HIV-1%20vaccine%20efficacy%20trial&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1113425&amp;volume=366&amp;pages=1275-1286&amp;publication_year=2012&amp;author=Haynes%2CBF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Mayer, K. H. et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial. <i>PLoS Med.</i> <b>14</b>, e1002435 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pmed.1002435" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pmed.1002435" data-track-item_id="10.1371/journal.pmed.1002435">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%2C%20and%20immunological%20activities%20of%20multiple%20intravenous%20or%20subcutaneous%20doses%20of%20an%20anti-HIV%20monoclonal%20antibody%2C%20VRC01%2C%20administered%20to%20HIV-uninfected%20adults%3A%20results%20of%20a%20phase%201%20randomized%20trial&amp;journal=PLoS%20Med.&amp;doi=10.1371%2Fjournal.pmed.1002435&amp;volume=14&amp;publication_year=2017&amp;author=Mayer%2CKH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Nicely, N. I. et al. Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> <b>2</b>, 713–722 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ebiom.2015.06.016" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ebiom.2015.06.016" data-track-item_id="10.1016/j.ebiom.2015.06.016">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Structural%20analysis%20of%20the%20unmutated%20ancestor%20of%20the%20HIV-1%20envelope%20V2%20region%20antibody%20CH58%20isolated%20from%20an%20RV144%20vaccine%20efficacy%20trial%20vaccinee&amp;journal=EBioMedicine&amp;doi=10.1016%2Fj.ebiom.2015.06.016&amp;volume=2&amp;pages=713-722&amp;publication_year=2015&amp;author=Nicely%2CNI" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Pollara, J. et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. <i>J. Virol.</i> <b>88</b>, 7715–7726 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1128%2FJVI.00156-14" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1128/JVI.00156-14" data-track-item_id="10.1128/JVI.00156-14">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=HIV-1%20vaccine-induced%20C1%20and%20V2%20Env-specific%20antibodies%20synergize%20for%20increased%20antiviral%20activities&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.00156-14&amp;volume=88&amp;pages=7715-7726&amp;publication_year=2014&amp;author=Pollara%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. <i>Stat. Commun. Infect. Dis.</i> <a href="https://doi.org/10.1515/scid-2016-0001" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1515/scid-2016-0001">https://doi.org/10.1515/scid-2016-0001</a> (2017).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Huang, Y. et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> <b>64</b>, 103203 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ebiom.2020.103203" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ebiom.2020.103203" data-track-item_id="10.1016/j.ebiom.2020.103203">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXotlOmurk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pharmacokinetics%20and%20predicted%20neutralisation%20coverage%20of%20VRC01%20in%20HIV-uninfected%20participants%20of%20the%20Antibody%20Mediated%20Prevention%20%28AMP%29%20trials&amp;journal=EBioMedicine&amp;doi=10.1016%2Fj.ebiom.2020.103203&amp;volume=64&amp;publication_year=2021&amp;author=Huang%2CY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Huang, Y. et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> <b>9</b>, 792–800 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1080%2F19420862.2017.1311435" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1080/19420862.2017.1311435" data-track-item_id="10.1080/19420862.2017.1311435">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXos1akt7w%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Population%20pharmacokinetics%20analysis%20of%20VRC01%2C%20an%20HIV-1%20broadly%20neutralizing%20monoclonal%20antibody%2C%20in%20healthy%20adults&amp;journal=MAbs&amp;doi=10.1080%2F19420862.2017.1311435&amp;volume=9&amp;pages=792-800&amp;publication_year=2017&amp;author=Huang%2CY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Lin, D. Y. On fitting Cox’s proportional hazards models to survey data. <i>Biometrika</i> <b>87</b>, 37–47 (2000).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbiomet%2F87.1.37" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/biomet/87.1.37" data-track-item_id="10.1093/biomet/87.1.37">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=On%20fitting%20Cox%E2%80%99s%20proportional%20hazards%20models%20to%20survey%20data&amp;journal=Biometrika&amp;doi=10.1093%2Fbiomet%2F87.1.37&amp;volume=87&amp;pages=37-47&amp;publication_year=2000&amp;author=Lin%2CDY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Pilcher, C. D. et al. A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results. <i>AIDS</i> <b>33</b>, 1231–1240 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2FQAD.0000000000002190" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/QAD.0000000000002190" data-track-item_id="10.1097/QAD.0000000000002190">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20generalizable%20method%20for%20estimating%20duration%20of%20HIV%20infections%20using%20clinical%20testing%20history%20and%20HIV%20test%20results&amp;journal=AIDS&amp;doi=10.1097%2FQAD.0000000000002190&amp;volume=33&amp;pages=1231-1240&amp;publication_year=2019&amp;author=Pilcher%2CCD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif " data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Flagship">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing" src="/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg" width="250" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing</em> newsletter — what matters in science, free to your inbox daily.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/briefing" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Flagship">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="MainBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="MainBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:nature_briefing_daily" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get the most important science stories of the day, free in your inbox.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="https://www.nature.com/briefing/signup/?brieferEntryPoint=MainBriefingBanner">Sign up for Nature Briefing
            </a>
        </div>

    </div>

</div>






<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-022-01953-6&amp;format=js&amp;last_modified=2022-10-03" async=""></script>

<inb-bzvweskmkxqm></inb-bzvweskmkxqm><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>